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Blastocystis is a ubiquitous enteric parasite found in the intestinal tract of humans and a 
wide range of animals. Accumulating evidence over the last decade suggests association 
of Blastocystis with gastrointestinal disorders. Despite new knowledge of Blastocystis 
cell biology, genetic diversity, life cycle and epidemiology; several key questions 
concerning its clinical relevance remain unanswered. Numerous clinical and 
epidemiological studies either implicated or exonerate the parasite as a cause of intestinal 
disease. Clinical and experimental studies have associated Blastocystis with intestinal 
inflammation and it has been shown that Blastocystis has potential to modulate host 
immune response. Blastocystis is also considered an opportunistic pathogen and high 
prevalence is reported in immunocompromised HIV patients. However, nothing is known 
about the parasitic virulence factors and early events following host-parasite interactions. 
A large number of asymptomatic carriers and frequent reports of treatment failure also 
cast doubts over pathogenic potential of Blastocystis. Subtype-dependent variations in 
Blastocystis pathobiology have been proposed to be the primary reasons for these 
controversies, but direct experimental evidence is lacking. 
The aim of this study was to investigate the pathogenic potential of Blastocystis, by 
studying the interactions of zoonotic Blastocystis isolates belonging to subtype-4 and 
subtype-7 with human intestinal epithelial cell line Caco-2. This study reports that a 
pathogenic strain of Blastocystis evades antiparasitic host nitric oxide response by 
suppression of epithelial iNOS, making intestinal environment more conducive to its 
colonization. Following immune evasion, Blastocystis cysteine proteases rearrange F-
 xix 
actin and tight junction distribution, decrease transepithelial resistance, and increases 
epithelial permeability in Caco-2 monolayers. A strain-to-strain and not subtype-
dependent variation in Blastocystis virulence was observed. Only one of the four isolates 
tested in this study suppressed Caco-2 iNOS and compromised epithelial barrier function. 
In addition, it was demonstrated that effects of Blastocystis on transepithelial electrical 
resistance and epithelial permeability were significantly abrogated by inhibition of 
epithelial Rho kinase. 
Additionally high-throughput drug susceptibility assays were developed for Blatocystis.  
Antibiotic susceptibility studies on these assays suggested that pathogenic strain of the 
parasite is resistant to metronidazole, the treatment of choice against Blastocystis 
infections. A subtype-dependent variation in susceptibility to a range of antimicrobial 
agents was also observed, suggesting that although subtyping of Blastocystis might not be 
useful in identification of virulent strains, but it does help in predicting treatment 
outcomes. 
Lastly, epithelial barrier dysfunction induced by pathogenic and metronidazole-resistant 
Blastocystis was significantly inhibited by inhibition of epithelial Rho kinase and HMG 
CoA reductase by Fasudil and Simvastatin respectively. Both these agents are clinically 
useful and could provide alternative or adjunctive treatment options against antibiotic 
resistant Blastocystis infections. These findings will certainly help to understand 
pathobiology of a poorly studied parasite whose public health importance is increasingly 
recognized. Our findings also suggest novel treatment options against antibiotic resistant 
and potentially virulent Blastocystis strains. 
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1.1 INTRODUCTION  
Blastocystis is a unicellular protistan parasite belonging to the stramenopile group 
(Arisue et al., 2002). It is an anaerobe found to parasitize a wide range of hosts 
(Boreham and Stenzel, 1993; Iguchi et al., 2007; Singh et al., 1996; Tan, 2008). 
Blastocystis resides in the intestinal tract of its hosts and it is one of the most 
common parasites reported in humans. It’s prevalence ranges between 30 - 50% of 
the population in developing countries (Stenzel and Boreham, 1996). Symptomatic 
infections caused by the parasite are called blastocystosis  (Tan, 2008). The most 
common symptoms are diarrhea, vomiting, abdominal cramps, bloating and 
flatulence (Boorom et al., 2008; Stensvold et al., 2009b). 
The pathogenic potential of the parasite is controversial. Controversies concerning 
its pathogenecity are primarily due to asymptomatic Blastocystis carriage (Stensvold 
et al., 2009b), limitations of common diagnostic tools (Suresh and Smith, 2004) and 
non-responsiveness of Blastocystis infections to conventional treatment strategies 
(Moghaddam et al., 2005; Stensvold et al., 2008). Dearth of controlled experimental 
studies and conflicting case reports are largely to blame for the underestimation of 
this organism’s pathogenecity.  
Blastocystis was first described by Alexeieff in the early 1900’s (Alexeieff, 1911). The 
organism was named Blastocystis hominis (Brumpt, 1912). Early reports described it 
as a harmless intestinal yeast, but later on a number of studies suggested its 
association with human diseases (Zierdt, 1991). About a century after the discovery 
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of the parasite the pathogenic mechanisms of the parasite are still unknown. Several 
clinical and epidemiological studies implicate the parasite as a human pathogen but 
others exonerate it as an etiology of human disease (Tan et al., 2010). In recent 
years significant progress has been made with regards to the morphology and 
genetic diversity of Blastocystis, but most controversies concerning the life cycle, 
molecular biology and pathogenecity of the organism remain unresolved (Tan, 
2008; Tan et al., 2010). 
1.2 CLASSIFICATION 
There are several controversies surrounding the taxonomic classification of 
Blastocystis. In the early years of its discovery, Blastocystis was described as a 
fungus or a yeast (Alexeieff, 1911; O'Connor, 1919), cyst of another protozoa 
(Bensen, 1909) or even a degenerating cell (Swellengrebel, 1917). Based on several 
morphological features such as the presence of a smooth and rough endoplasmic 
reticulum, a Golgi complex, a mitochondria like organelle and one or more nuclei 
(Zierdt et al., 1967), Blastocystis was later identified as a protist (Zierdt et al., 1967). 
Certain physiological features, such as the inability to grow on fungal medium, the 
ineffectiveness of anti-fungal agents and the susceptibility to common antiprotozoal 
drugs also suggested its similarity to other protists. Blastocystis was later classified 
as a sporozoan and finally as a sarcodine (Zierdt, 1991). 
Analysis of Blastocystis partial small-subunit RNA (ssrRNA) suggested that it is not 
monophyletic with sarcodine, sporozoan or even yeast and fungi (Johnson et al., 
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1989). Later, a complete ssrRNA analysis suggested that the parasite should be 
classified within the Stramenopiles (Heterokonata) (Silberman et al., 1996). 
Molecular phylogenetic analysis also showed that Blastocystis is closely related to a 
Stramenopile, Proteromonas lacerate (Arisue et al., 2002). Further analysis of 
Blastocystis ssrRNA, cytosolic-type 70-kDA heat shock protein, translation 
elongation factor 2, and the non-catalytic ‘B’ subunit of vacuolar ATPase confirmed 
that it is indeed a Stramenopile (Arisue et al., 2002). Flagella with mastigonemes is a 
common characteristic of Stramenopiles but, since Blastocystis lacks a flagella, it was 
placed under a new class called Class Blastocystea in the Subphylum Opalinata, 
Infrakingdom Heterokonta, Subkingdom Chromobiota, and Kingdom Chromista 
(Cavalier-Smith, 1998). Elongation factor- 1α (EF- 1α) sequencing for phylogenetic 
analysis also showed that Blastocystis is not a fungus and suggested that it diverged 
before Trypanosoma, Euglena, Dictyostelium and other eukaryotes.  
Past studies frequently classified Blastocystis species according to their host origin. 
For example, rat isolates were reported as Blastocystis ratti while human isolates 
were called Blastocystis hominis. This outdated classification created confusion 
regarding the cell biology, host specificity as well as pathogenecity of the parasite. 
On the contrary, several reports in the last decade suggested cross-infectivity of 
Blastoycstis between humans and animals (Iguchi et al., 2007; Noël et al., 2005; Yan 
et al., 2007). 
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1.3 GENETIC DIVERSITY 
The parasite can be found in a wide range of hosts including primates, rodent, birds, 
insects, pigs, reptiles and amphibians (Boreham and Stenzel, 1993). Irrespective of 
the host of origin, most of these strains were also found in humans (Noël et al., 2005; 
Tan, 2004). Pulsed-field gel electrophoresis for karyotyping was used in the past for 
speciation of Blastocystis isolates recovered from rats (Chen et al., 1997), reptiles 
(Teow et al., 1991), tortoise  and rhino iguana (Singh et al., 1996) as well as humans 
(Upcroft et al., 1989). Extensive intra-species diversity of karyotypes was observed, 
suggesting that karyotyping might not be the best method of speciation in 
Blastocystis (Yoshikawa et al., 2004a). As a result, the method of assigning different 
specie names to isolates of Blastocystis based on their host specificity and 
morphology was dropped (Stensvold et al., 2007b). 
One study did ssrRNA sequence analysis of 16 Blastocystis isolates recovered from 
humans and other common hosts (Arisue et al., 2002). This method of phylogenetic 
analysis revealed that Blastocystis could be divided into seven distinct genetic 
groups (Arisue et al., 2002). Later studies also suggested the presence of these 
distinct genotypes in a whole range of non-human hosts, endorsing the zoonotic 
potential of Blastocystis (Noël et al., 2005; Yoshikawa et al., 2004a). Furthermore, 
another report tested 78 different isolates of Blastocystis based on ssrRNA sequence 
analysis. Findings of this study suggested that most of the isolates tested can be 
grouped into seven clades, referred as group I to VII (Noël et al., 2005). 
Interestingly, Blastocystis isolates from human sources were positioned in six of 
 6 
these seven groups. The study proposed that group I (subtype 1) consisted of 
zoonotic isolates of mammalian origin, group II (subtype 2) isolates were of primate 
origin, group III (subtype 3) were of human origin, group IV (subtype-4) were 
rodent, group V (subtype 5) comprised of pigs and cattle isolates and group VI 
(subtype 6) and VII (subtype-7) isolates comprised of zoonotic isolates of avian 
origin (Noël et al., 2005). Finally in 2007 a consensus on Blastocystis classification 
was reached (Stensvold et al., 2007b). Based on published small-subunit ribosomal 
RNA gene analyses (Noël et al., 2005) , it was proposed Blastocystis isolates should 
be designated as Blastocystis sp. and assigned to one of nine subtypes (Stensvold et 
al., 2007b) . 
In a large-scale epidemiological study, Stensvold et al. correlated subtype 2, 4, 7 and 
9 infections with intestinal symptoms (Stensvold et al., 2009b). Hussein et al. also 
proposed a subtype dependent variation in Blastocystis induced morbidity and 
mortality in infected rats (Hussein et al., 2008b). Subtype-dependent variability in 
detection of Blastocystis by conventional diagnostic techniques (Stensvold et al., 
2007a) was also reported recently. These studies highlighted the clinical importance 
of subtyping in Blastocystis infections.  
With a few exceptions, subtype distribution in humans do not vary much 
geographically (Tan et al., 2010; Yoshikawa et al., 2004b). An investigation of 
Blastocystis subtype distribution on isolates recovered from humans in Bangladesh, 
Germany, Japan, Pakistan, and Thailand suggested that apart from Thailand, subtype 
3 is the most frequently isolated subtype from humans, followed by either subtype 1 
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or 6 (Yoshikawa et al., 2004b). Subtype 1 was the most common subtype in the Thai 
population (Yoshikawa et al., 2004a). Some surveys also report other Blastocystis 
subtypes in humans, such as subtypes 2, 4, 6, 7, 8, and 9 in decreasing frequencies 
(Stensvold et al., 2009a). More often than not, an individual harbors only one 
Blastocystis subtype at a time, but mixed infections with multiple subtypes have also 
been reported (Meloni et al., 2011).
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1.4 CELL BIOLOGY 
1.4.1 Blastocystis phenotypes 
 Blastocystis exists in at least four different morphological forms (Tan, 2008). These 
includes, vacuolar, granular, amoeboid (Dunn et al., 1989) and cyst (Tan, 2008). 
There is limited information available on the physiological relevance of these forms. 
Mechanisms involved in transition of the parasite from one form to other are not 
known either.  
1.4.1 (a) Vacuolar form 
The vacuolar form is also referred to as vacuolated or central body form. It is the 
most commonly reported form of Blastocystis (Tan, 2008). It is spherical with a 
characteristic large central vacuole and a thin peripheral rim of cytoplasm (Figs. 1.1, 
1.2)(Zierdt, 1973). In electron micrographs the peripheral cytoplasm appears to 
contain cellular organelles like nucleus, mitochondria-like organelle, endoplasmic-
reticulum and Golgi bodies (Zierdt, 1973). The size of this form ranges between 2-
200 μm in diameter (Zierdt, 1991). The number of nuclei varies and it may possess 
on average 4 nuclei per cell (Zierdt, 1973). Another characteristic of the vacuolar 
form is the presence of a surface coat of varying thickness (Cassidy et al., 1994). The 
physiological role of the surface coat is not known but it is suspected to either trap 
bacteria for nutrition or protect the cell against osmotic shock (Zaman et al., 1997; 
Zaman et al., 1999). The surface coat appears to be thicker in parasite freshly 
isolated from stools, but it reduces with prolonged in-vitro culturing (Cassidy et al., 
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1994). The plasma membrane of the vacuolar form also possesses pits that are 
suspected to play a role in endocytosis (Stenzel et al., 1989). 
 
1.4.1 (b) Cyst form 
Blastocystis cysts are much smaller than the vacuolar form (Fig. 1.1). The size ranges 
between 2-5 μm in diameter (Moe et al., 1996). Similar to the vacuolar form, a thin 
surface coat is also observed in the cyst form (Moe et al., 1996). It can survive up to 
19 days in water at normal temperature, up to 1 month at 25°C (Moe et al., 1996) 
and as long as 2 months at 4°C (Yoshikawa et al., 2004c).  Due to their survivability 
in harsh conditions, they are suspected to play a significant role in fecal-oral 
transmission of the parasite (Yoshikawa et al., 2004c). The transmissibility of the 
cyst has been observed in both avian (Tanizaki et al., 2005) and rodent (Yoshikawa 
et al., 2004c) experimental models. A report of Blastocystis cysts also suggests its 
resistance to common antiprotozoal agent metronidazole (Zaman and Zaki, 1996). 
1.4.1 (c) Granular form 
This form is similar to the vacuolar form. The only differentiating characteristic is 
the presence of multiple granules, especially within the central vacuole (Fig 1.1). 
Their diameter ranges between 3-80 μm. The granules might appear as myelin-like 
inclusions, droplets of lipid, tiny vesicles or crystalline granules (Dunn et al., 1989). 
Granular forms are more readily visible in non-axenized or old cultures. The 
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physiological role of this form is not clear, but it is suggested they play a role in 
parasite programmed cell death (Tan, 2004). 
1.4.1 (d) Amoeboid form 
This is the most infrequently observed Blastocystis form. Although reports are 
conflicting (Dunn et al., 1989; McClure et al., 1980), amoeboid forms have been 
reported in antibiotic treated and old cultures (Zierdt, 1973) of Blastocystis. They 
were also observed in stool samples (Zierdt, 1973). The size is considerably smaller, 
between 2-7 μm (Fig 1.1) (Tan, 2008). One report suggests the presence of extended 
pseudopodia (Dunn et al., 1989). Tan et al. observed a central vacuole, a Golgi body 
and mitochondria within the cytoplasmic extensions of pseudopods (Tan et al., 
2001). Unlike amoeba, pseudopods in Blastocystis are not responsible for 
locomotion. They might play a role in phagocytosis since ingested bacteria have 
been observed within Blastocystis vacuoles (Boreham and Stenzel, 1993). 
 11 
     
Figure 1.1 Phase contrast micrographs representing four morphological forms 
of Blastocystis  
A) Vacuolar (V) and Multivacuolar (MV) forms 
B) Granular form (G) 
C) Cyst (arrow) 
D) Amoeboid form (arrow) 
* Adapted from Chen et al. 1999
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1.4.2 Organelles  
Typical eukaryotic cell organelles such as Golgi apparatus and endoplasmic 
reticulum and vacuoles have been observed in Blastocystis (Zierdt et al., 1967). Two 
of these organelles, the central vacuole and the mitochondria-like organelle are of 
particular interest to researchers. 
1.4.2 (a) Central Vacuole 
This is the most obvious cellular organelle found in the vacuolar form of Blastocystis 
(Tan, 2008). The exact function of the central vacuole in Blastoycstis is not known 
but it appears to act as a storage organelle (Figs. 1.1, 1.2) (Puthia et al., 2008a; Tan, 
2008). One report also suspects that it participates in the parasite’s schizogony-like 
reproduction (Suresh et al., 1994). A few studies also suggest its role as a depository 
for apoptotic bodies during Blastocystis programmed cell death (Tan and 
Nasirudeen, 2005; Yin et al., 2010b). It is also reported to store carbohydrates and 
lipids necessary for the parasite growth (Yoshikawa and Hayakawa, 1996). Recently, 
the Blastocystis central vacuole was found to contain cysteine proteases (Fig 1.2) 
(Puthia et al., 2008a). Cysteine proteases are the predominant proteases found in 
the parasite. These proteases play a crucial role in the parasites virulence and cell 
survival (Mirza and Tan, 2009; Puthia et al., 2005; Sio et al., 2006; Wu et al., 2010). 
1.4.2 (b) Mitochondria-like organelle 
This organelle of Blastocystis is of particular interest due to its peculiar nature. 
Although Blastocystis is a strict anaerobe, it has mitochondrion-like organelles 
(MLO) with cristae, a transmembrane potential and DNA (Nasirudeen and Tan, 
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2004; Zierdt et al., 1988). Lack of several key mitochondrial pathways suggests that 
these organelles might be hydrogenosomes, an anaerobic organelles related to 
mitochondria (van der Giezen et al., 2005). One study generated 12,767 expressed 
sequence tags (ESTs) from Blastocystis and identified 115 clusters encoding putative 
mitochondrial and hydrogenosomal proteins (Stechmann et al., 2008). Among these 
protiens is the typical hydrogenosomal protein iron-only [FeFe] hydrogenase 
localizing to the organelles. The MLO also has mitochondrial characteristics, 
including amino acid metabolism pathways, incomplete tricarboxylic acid cycle, 
iron-sulfur cluster biogenesis, and mitochondrial genome (Fig. 1.3) (Stechmann et 
al., 2008). The study concluded that the Blastocystis MLO has metabolic properties 
of aerobic and anaerobic mitochondria and of hydrogenosomes and that it is similar 
to a recently described organelle in ciliate Nyctotherus ovalis (Boxma et al., 2005). 
These findings blur the distinction between mitochondria, hydrogenosomes 
(Stechmann et al., 2008). 
Genomic analysis of the parasite revealed that the mitochondria-like organelle of 
Blastocystis contains a 29, 270 bp circular DNA and sequences for oxidative 
phosphorylation complex 1 subunits, but lacks complexes III, IV and V (Wawrzyniak 
et al., 2008). Furthermore studies also described that mitochondrial enzymes, 
(NADH:ubiquinone oxidoreductase subunit 7 (NAD7) and beta-succinyl-CoA 
synthase (beta-SCS) as well as hydrogenosomal enzymes (pyruvate ferredoxin 
oxido-reductase (PFOR) and iron hydrogenase) were found in this organelle (Fig. 
1.3) (Lantsman et al., 2008; Wawrzyniak et al., 2008). 
Oxygen sensitive electron acceptors PFOR and PNO are of particular interest in 
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clinical microbiology of anaerobic organisms. Their activity determines the 
susceptibility and resistance of anaerobic organisms against common antiprotozoal 
agents such as nitazoxanide and nitroimidazoles (Upcroft and Upcroft, 2001). 
Mitochondrial membrane bound PFOR/PNO are needed for the activation of 
nitroimidazoles into their active forms (Upcroft and Upcroft, 2001). PFOR/PNO are 
key mediators of anaerobic respiration and crucial for the survival of anaerobes 
(Stechmann et al., 2008). Nitazoxanides directly target PFOR/PNO to kill the 
organism (Gargala, 2008).  
Interestingly, as observed in its mammalian counterpart, the mitochondria-like 
organelle of Blastocystis is also involved in the parasite programmed cell death (Yin 




Figure 1.2. Micrographs illustrating the localization of Blastocystis cysteine 
proteases in central vacuole. Representative fluorescence, light, and merged 
micrographs show the activities and localization of cysteine proteases in live 
parasites. Parasites were incubated in a cysteine protease substrate, Arg-Arg-4-
methoxy-2-naphtylamide. Fuorescence was exhibited by All parasites (arrowhead, 
first column on the left), at  higher-magnification (second column) \ fluorescence 
was observed only at the parasite central vacuole (arrow). Parasites treated with 
the cysteine inhibitor iodoacetamide exhibited diminished fluorescence (third 
column) while parasites without cysteine protease substrate showed no 
fluorescence (fourth column). 
 




Figure 1.3 Proposed pathway of metabolism in the mitochondria like 
organelle MLO of Blastocystis.  
 
(1) Malic enzyme, (2) PNO, (3) ASCT, (4) STK, (5) -ketoglutarate dehydrogenase, (6) 
isocitrate dehydrogenase, (7) aconitase, (8) fumarate hydratase, (9) malate 
dehydrogenase, (10) PEPCK, (11) pyruvate kinase, (12) lactate dehydrogenase.  
 
Proposed end products of the pathway are in bold. Reactions shown within the box 
occur in the MLO. 
 
Adapted from Lantsman et al. 2008  
 17 
 
1.5 LIFE CYCLE 
Several life cycles have been proposed for Blastocystis and most of them are based 
on microscopic analysis. Alexeieff explained the first amongst them in 1911 
(Alexeieff, 1911). He proposed that the parasite undergoes autogamy and binary 
fission. Later the role of plasmotomy and schizogony was also suggested (Singh et 
al., 1995; Zierdt, 1973). A recent classification by Tan et al. suggests that the 
infection is initiated by ingestion of cysts (Tan, 2004). The cysts after reaching 
intestine transform into the vacuolar form and undergo binary fission. Following 
reproduction, the vacuolar forms encyst again and are passed out in the feces (Tan, 
2004).  
Molecular typing of the parasite in recent years has led to a revision of the above-
mentioned life cycle. Apart from humans, several animal hosts have been described 
for Blastocystis including, rats, pigs, birds, reptiles and even insects. Blastocystis 
commonly exhibits zoonoses and to complete its life cycle through the fecal-oral 
route, the parasite appears to involve one of more host species (Tan, 2008). Due to 
genetic diversity and some degree of host specificity, it can be hypothesized that 
different strains of Blastocystis might follow variant life cycles, but more work is 
required in this area. 
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Figure. 1.4. Proposed life cycle for Blastocystis suggesting the existence of 
zoonotic genotypes (subtypes 1 to 7) with various host specificities. Subtype 1 
is cross infective among mammalian and avian isolates; subtypes 2, 3, 4, and 5 
comprise primate/pig, human, cattle/pig, and rodent isolates, respectively; and 
subtypes 6 and 7 include avian isolates. The proposed scheme suggests that humans 
are potentially infected by seven or more species of Blastocystis and that certain 
animals represent reservoirs for transmission to humans. 
Adapted from Tan et al. 2008 
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1.6 CLINICAL PRESENTATION 
Blastocystosis is the common terminology used for symptomatic human infections 
caused by the parasite. Several intestinal and non-intestinal symptoms are 
associated with Blastocystis infections. 
1.6.1 Intestinal symptoms 
Blastocystosis frequently presents with diarrhea and abdominal pain (Tan, 2008; 
Tan et al., 2010), along with other nonspecific gastrointestinal symptoms including 
nausea, vomiting, constipation, dysentery, flatulence, bloating, anorexia and weight 
loss (Stensvold et al., 2009b; Tan et al., 2010). Symptoms range from mild chronic 
diarrhea to acute enteritis (Tan, 2008; Tan et al., 2010). 
There is some evidence associating parasite density with severity of clinical 
symptoms caused by Blastocystis (Kaya et al., 2007; Moghaddam et al., 2005).  
Greater than five parasites per high-power field (× 400) for wet mounts or oil 
immersion (× 1000) in permanent stained smears are associated with higher 
frequency of acute intestinal symptoms (Kaya et al., 2007; Moghaddam et al., 2005). 
Recent studies however focus on association of subtypes with human pathology, 
without any information on infection density (Eroglu et al., 2009; Stensvold et al., 
2009b). Since that data is limited to rule out the association of parasite density with 
intestinal symptoms, future studies might benefit by investigating Blastocystis-
induced intestinal pathology, focusing on parasite density along with subtype-
association. 
1.6.2 Extraintestinal Symptoms 
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A correlation between Blastocystis and cutaneous lesions, particularly urticaria, has 
been reported (Hameed et al., 2011; Katsarou-Katsari et al., 2008; Vogelberg et al., 
2010). Multiple case studies suggest a causal link between acute or chronic urticaria 
and Blastocystis. There are reports on association between delayed-pressure 
urticaria, angioedema, and palmoplantar pruritus with Blastocystis as well 
(Armentia et al., 1993; Tan, 2008; Vogelberg et al., 2010). Resolution of cutaneous 
symptoms after chemotherapeutic treatment observed in these studies, re-enforce 
the role of Blastocystis with skin disorders (Armentia et al., 1993; Pasqui et al., 
2004).
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1.7 LABORATORY DIAGNOSIS 
1.7.1 Stool Samples 
Due to multiple morphological forms of the parasite as well as inter-subtype 
variations Blastocystis is one of the most difficult organisms to identify in stool 
samples. A recent survey comparing several European diagnostic laboratories 
reported a wide discrepancy in reporting of Blastocystis-positive stool samples 
(Utzinger et al., 2010). The formol ether concentration technique (FECT) is 
commonly used to detect parasite ova and cysts. Due to poor sensitivity of FECT 
however, it is not recommended for laboratory identification of Blastocystis (Rene et 
al., 2009; Stensvold et al., 2007a). The reason for the lower sensitivity might be 
inability of FECT to isolate subtype 3 of Blastocystis (Rene et al., 2009; Stensvold et 
al., 2007a), a very common subtype in humans. Using only FECT to isolate 
Blastocystis might contribute to the underestimation of the parasite burden in 
epidemiologic studies (Tan et al., 2010). Recent studies also suggest that 20-30% of 
stool samples of infected individuals only contain cysts form of Blastocystis (Rene et 
al., 2009; Suresh and Smith, 2004). Due to a considerably smaller size and stark 
morphological differences from the vacuolar form, diagnostic staff should be trained 
to identify cyst stages of Blastocystis. Trichrome-stained fecal smears or short-term 
xenic in-vitro culture (XIVC) exhibits superior sensitivity in identification of the 
parasite. However, XIVC should also be used with caution. Due to difference in 
generation time between Blastocystis strains (Zierdt and Swan, 1981), slower-
growing subtypes and mixed infections of slower- and faster-growing subtypes may 
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be missed by this technique. For accurate identification of subtypes and precise 
estimation of mixed infections, genotyping of Blastocystis by PCR methods is 
preferable (Stensvold et al., 2006), and should ideally be performed directly on stool 
samples. Another consideration for better diagnosis of Blastocystis infections is to 
take multiple stool samples over a period of time since the parasite shedding by 
humans is irregular (Suresh and Smith, 2004). 
Emerging data suggests association of certain Blastocystis subtypes with human 
diseases and antibiotic susceptibility (Stensvold et al., 2009b; Stensvold et al., 2010). 
For effective clinical management; information concerning Blastocystis subtype 
might be useful. This could either be accomplished by sequence analysis of 
Blastocystis specific PCR products or use of PCR primers that are specific for 
different parasite subtypes (Yoshikawa et al., 1998). 
1.7.2 Serology 
There are reports of the usefulness of serological techniques in identification of 
Blastocystis infections. Few studies involving enzyme-linked immunosorbent assay 
(ELISA) for Blastocystis correlate antibody titers with symptoms (Hussain et al., 
1997; Mahmoud and Saleh, 2003). Since these techniques are quantitative and 
identify parasites rapidly with high sensitivity and specificity, they could be 
powerful tools for diagnosis of the parasite (Tan et al., 2010). Development of such 
assays however should take into consideration the genetic diversity of Blastocystis. 
A panel of antibodies highly specific for individual subtypes would be useful for 
diagnosis of Blastocystis (Tan et al., 2010).
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1.8 BLASTOCYSTIS AND IRRITABLE BOWEL 
SYNDROME 
The association of Blastocystis infections with irritable bowel syndrome (IBS) has 
been suggested by several studies (Boorom et al., 2008; Stark et al., 2007; Stensvold 
et al., 2009b). IBS is a functional disorder of gastrointestinal tract presenting with 
abdominal pain and altered bowel habits. Compared to healthy controls, a higher 
incidence of Blastocystis in IBS patients is reported in several studies (Boorom et al., 
2008; Stark et al., 2007; Stensvold et al., 2009b). Recently, Stensvold et al. suggested 
an association of specific Blastocystis subtypes with IBS (Stensvold et al., 2009b).  It 
is proposed that persistent exposure of Blastocystis antigens during chronic 
infections induces low-grade inflammation in the intestine leading to IBS (Tan et al., 
2010). It is also quite possible that an altered luminal environment during IBS is 
favorable to Blastocystis growth. Studies exhibiting resumption of IBS symptoms 
after treatment of Blastocystis infections would help to resolve this controversy (Tan 
et al., 2010). A better understanding of the molecular mechanisms employed by 
Blastocystis antigens inducing host inflammation would further clarify the situation. 
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1.9 OPPORTUNISM 
Blastocystis is considered an opportunistic organism. Several surveys report a 
higher incidence of Blastocystis in immunocompromised individuals 
1.9.1 Blastocystis in AIDS and HIV patients 
HIV infected individuals have a higher incidence of Blastocystis infections.  A serious 
outcome of such infections is disseminated disease, not frequently observed in 
healthy individuals (Kurniawan et al., 2009; Stensvold et al., 2009a). Blastocystis 
was the most commonly isolated protozoan parasite from HIV/AIDS patients in one 
study (Tan et al., 2009). Subtype 3 appears to be the most opportunistic of 
Blastocystis subtypes since it is the most frequently isolated subtype found in HIV 
infected as well as cancer patients (Tan et al., 2009). 
1.9.2 Blastocystis in cancer patients 
One study found Blastocystis to be the  most common parasite in stools of cancer 
patients (Taşova et al., 2000). Common symptoms of Blastocystis infection in cancer 
patients are abdominal pain, diarrhea and flatulence (Taşova et al., 2000). In one 
report, carcinoma-induced intestinal obstruction facilitated overt growth of 
Blastocystis (Horiki et al., 1999). A recent study also described growth of the 
parasite in abdominal fluid following bowel perforation by adenocarcinoma (Patino 




1.9.3 Blastocystis infections in minors 
Children are highly susceptible to Blastocystis infections (Londoño et al., 2009). 
Increased incidences of Blastocystis infections were reported in immunocompetent 
(Londoño et al., 2009) as well as immunocompromised (Noureldin et al., 1999) 
children. Children on corticosteroid therapy for nephrotic syndrome were also 




Since pathogenesis of the parasite is controversial, antibiotics are seldom prescribed 
for Blastocystis infections. The mild nature of the disease and self-limitation of 
symptoms also make clinicians skeptical about prescription of chemotherapy 
against the parasite (Stensvold et al., 2010). Several drug trials and clinical studies 
suggest the efficacy of metronidazole against Blastocystis (Stensvold et al., 2010), 
but frequent reports of treatment failure make antiparasitic therapy against it even 
more controversial (Tan et al., 2010). Chronic infections in which all other etiologies 
have been excluded, metronidazole is the treatment of choice (Table 1.1) (Tan et al., 
2010). Several factors might influence treatment outcomes, including infection 
density, acquisition of mutations, resistance of certain developmental stages to 
metronidazole and, most importantly, subtype or strain-to-strain variation in drug 
susceptibility (Tan et al., 2010). In fact, in-vitro studies have suggested a varying 
response of different Blastocystis isolates to metronidazole (Zaman and Zaki, 1996; 
Zierdt et al., 1983).  
The most commonly prescribed alternatives to metronidazole for Blastocystis 
infections are co-trimoxazole and paramomycin (Table 1.1) (Stensvold et al., 2010). 
Unfortunately, resistance to these drugs has also been reported in the parasite 
(Stensvold et al., 2010). There is a pressing need to identify alternative treatment 
option of Blastocystis infections.  
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Major roadblocks in development of new treatments against the parasite are the 
absence of efficient drug resistance and susceptibility screening tools. A lack of 
knowledge concerning molecular mechanisms of Blastocystis antibiotic resistance as 
well as pathogenesis further complicates the situation. Since Blastocystis infections 
are predominantly reported in developing countries, interest and resources 
required to develop anti-Blastocystis treatment options are also limited. 
 
Table 1.1 Treatment options and regimens for blastocystosis 
 
 Adult Pediatric 
Metronidazole 750 mg tid for 10 d 15 mg/kg/d for 7 d 
 500 mg tid for 10 d 20-30 mg/kg/d for 10 d 
 1.5-g single dose/d for 10 d  
TMP-SMX 320 mg TMP and 1600 mg SMX daily in 
two equal doses for 7 d 
6 mg/kg TMP and 30 mg/kg SMX  
daily in two equal doses for 7 d 
Nitazoxanide 500 mg bid for 3 d 100 mg bid for 3 d (1-3 y) 
  200 mg bid for 3 d (4-11 y) 
bid—twice a day; tid—three times a day; TMP-SMX—trimethoprim-
sulfamethoxazole  





Several studies find no significant association between Blastocystis carriage and 
gastrointestinal symptoms (Tan, 2008). Most of these reports however compare 
distribution of the parasite between symptomatic and asymptomatic groups (Tan, 
2008). Most of these studies also assume that pathobiology of Blastocystis infections 
is homogenous while ignoring the genetic and phenotypic heterogeneity of the 
parasite (Tan et al., 2010) and may not truly reflect the pathogenic potential of 
Blastocystis. Placebo-controlled treatment trials on patients infected with 
Blastocystis alone should be more representative of the parasite pathogenic 
potential (Nigro et al., 2003; Tan et al., 2010). Only two such studies were done, both 
concluding that chemotherapy successfully resolves clinical symptoms along with 
eradication of the parasite (Nigro et al., 2003; Rossignol et al., 2005). In one study, 
metronidazole eradicated the parasite in 80% of the patients, while it resolved 
symptoms in 88% (Nigro et al., 2003). In another study, treatment with 
nitazoxanide also provided comparable results (Rossignol et al., 2005). However, 
symptoms persisted in infections where Blastocystis was not eradicated due to 
possible resistance or reduced susceptibility to the antibiotic (Rossignol et al., 
2005). These studies provide compelling evidence for the parasite’s pathogenic 
potential but the clinical outcomes could be influenced by other factors, such as use 
of broad-spectrum antibiotics. Resolution of symptoms by administration of these 
chemotherapeutic agents might be attributed to clearance of some unidentified 
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intestinal pathogen (Tan et al., 2010). 
 
1.11.2 Animal infection models 
An acceptable infection model for Blastocystis is not established yet (Tan et al., 
2010). A lack of an appropriate animal model is an important obstacle in estimation 
of the Blastocystis pathogenic potential. Surveys suggest that mice do not harbor 
Blastocystis and they are not suitable models to study the parasite pathobiology 
(Eida et al., 2008; Moe et al., 1997). Interestingly, Blastocystis is commonly found in 
rats and chicken. Therefore, in recent years, researchers focused on these animals as 
possible models for the parasite infections (Iguchi et al., 2007). A variation was 
observed in the infectivity of rodent subtype-4 and avian subtype 6 isolates (Iguchi 
et al., 2007). Interestingly, subtype 3, the most common human subtype, could not 
infect either animals (Iguchi et al., 2007). Surprisingly, subtype-7 isolates from 
humans only infected birds suggesting that the parasite exhibits certain degree of 
host specificity (Iguchi et al., 2007). Another study concluded that Blastocystis 
infections increase intestinal epithelial permeability (Hussein et al., 2008b). In this 
study, rats were infected with Blastocystis isolates recovered from symptomatic and 
asymptomatic humans. Moderate to severe rat pathology was observed in rats 
infected with isolates from symptomatic humans, whereas rats exposed to isolates 
from asymptomatic individuals only exhibited mild pathology. This report 
concluded that subtype 1 isolates were pathogenic and induced mortality in 25% of 
the infected rats. Subtype 3 and 4 isolates however, exhibited variable pathogenic 
potential (Hussein et al., 2008b). Up-regulation of proinflammatory cytokine 
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interferon-γ, tumor necrosis factor-α and interleukin (IL)-12 was observed in rats 
infected with Blastocystis, although the local tissue pathology was moderate (Iguchi 
et al., 2009). These results, while encouraging, point out a few problems in using 
rodent and avian infection models.  
Humans harbor a broad range of Blastocystis subtypes. Due to possible host 
specificity, rodents only carry subtype-4 in the wild, while birds harbor subtype 6 
and 7 (Tan, 2008). This limits the usefulness of these models for other clinically 
significant Blastocystis subtypes. The often observed absence of pathology in animal 
models might represent resistance of these hosts against effective colonization by 
specific Blastocystis subtypes, rather than avirulence (Stensvold et al., 2009a; Tan et 
al., 2010).  
1.11.3 In-vitro, host-pathogen interaction models. 
Due to the lack of suitable animal models, in-vitro host-pathogen interaction models 
are useful alternatives to study Blastocystis-induced host pathology (Puthia et al., 
2008b; Puthia et al., 2006). Recently, studies using such systems revealed that 
Blastocystis compromises the epithelial barrier function (Puthia et al., 2006) in rat 
intestinal cells. Blastocystis ST-4 induced caspase-dependent and contact-
independent apoptosis in the rat intestinal epithelial cell line IEC-6 (Puthia et al., 
2008b). In the same study, Blastocystis infections increased the epithelial 
permeability and decreased the transepithelial resistance (Puthia et al., 2008b). The 
breach in the epithelial barrier was accompanied by alterations of the actin-
cytoskeleton. Since these findings are limited to rat epithelium, it will be interesting 
to see how human epithelium responds to Blastocystis infections. It will also be 
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interesting to study how Blastocystis affects the tight junction complex, the primary 
gate-keeper of the epithelial barrier (Epple et al., 2009). Knowledge of molecular 
mechanisms employed by the parasite to alter intestinal barrier function will also be 
useful in identifying new treatment options for Blastocystis infections. 
As stated earlier, Blastocystis modulates the host immune system. An in-vitro study 
reported that Blastocystis cysteine proteases up-regulate interleukin-8 (IL-8) 
production in a human colonic cell line by activation of NF-κB (Puthia et al., 2008b). 
Another study also suggested that Blastocystis infections cause an up-regulation of 



















Figure. 1.5. Proposed model for Blastocystis pathogenesis at the cellular level. 
Blastocystis infection may result in a variety of pathologic outcomes such as 
secretory IgA degradation, barrier function compromise via alterations to tight 
junctions, host cell apoptosis, and induction of the proinflammatory cytokines 
interleukin (IL)-8, IL-12, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α. IgA 
degradation and barrier disruption may promote the growth and invasion of other 
luminal pathogens. Parasite cysteine proteases have been shown to mediate most of 
these features.  
IgA, immunoglobulin A; MLC, myosin light-chain kinase; MLC-p, phosphorylated 
MLC; NF-κB, nuclear factor-κB; PAR-2, protease activated receptor type 2; RhoA, 
Rho-GTPase family member A; ROCK, Rho-associated kinase; ZO-1, zona occludens- 
Adapted from Tan et al 2010 
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1.12 OBJECTIVES OF THE PRESENT STUDY 
Despite recent advances in our understanding of the parasite, several pertinent 
questions concerning the clinical significance of Blastocystis remain unanswered. 
Asymptomatic carriage (Stensvold et al., 2009b), as well as eradication of infections 
(Stensvold et al., 2010) have troubled both scientists and clinicians alike (Tan et al., 
2010). Lack of an appropriate infection model is the major limitation in addressing 
these controversies. The aim of this study is to address clinically relevant questions 
concerning Blastocystis infections in light of recent developments in the areas of 
Blastocystis cell biology, genotyping, epidemiology, antibiotic susceptibility and 
host-pathogen interaction modeling. Using in-vitro approaches, the study will 
identify for the first time a metronidazole-resistant strain of Blastocystis capable of 
evading host immunity, and causing intestinal epithelial pathology. Based on these 
observations we will also address clinical controversies concerning the parasite 
pathogenic potential and evaluate alternative and adjunctive treatment options 
against Blastocystis infections. Several studies in recent years suggest that 
asymptomatic carriage (Stensvold et al., 2009b) as well as inconsistent outcomes of 
antiparasitic treatment (Stensvold et al., 2010) might be due to subtype-dependent 
variations in Blastocystis pathobiology, but direct evidence of these variation are 
lacking. Therefore, this study will also evaluate the relevance of subtyping in 
predicting the severity as well as treatment outcomes of Blastocystis infections. 
Very little is known about Blastocystis virulence factors. Cysteine proteases are 
suggested to be potential virulence factors of the parasite (Puthia et al., 2008a; 
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Puthia et al., 2005; Tan et al., 2010). As we have discussed in the previous Chapter, 
they play a significant role in activation of host epithelial NF-κB and up-regulation of 
pro-inflammatory cytokine IL-8 (Puthia et al., 2008a) as well as degradation of 
human secretory IgAs (Puthia et al., 2005). This study will provide further evidence 
on the importance of cysteine proteases in the parasite pathobiology. A comparison 
of the activity of these proteases between parasite isolates of two clinically relevant 
zoonotic subtypes ST-4 and ST-7 will also be studied. We will also study differences 
between the cell size and generation times of these subtypes. This information will 
provide the stepping stone for more detailed analysis of parasite pathogenecity, 
immune evasion and antibiotic resistance in this study.  
Chronic carriage, both symptomatic and asymptomatic, is a common observation in 
Blastocystis infections (Boorom et al., 2008; Gupta and Parsi, 2006; Kaneda et al., 
2000; Pasqui et al., 2004; Vogelberg et al., 2010). The tug of war between host 
antimicrobial defense and microbial immune evasion mechanisms determine the 
effective colonization of gut lumen by non-invasive pathogens. Since Blastocystis is 
an opportunistic pathogen (Kurniawan et al., 2009; Tan et al., 2009), competence of 
the host immune response plays an important role in the ability of the parasite to 
colonize human gut. In this study, we will explore the susceptibility of ST-4 and ST-7 
isolates to nitrosative stress, a possible host anti-Blastocystis defense mechanism. 
Furthermore, using differentiated and polarized Caco-2 epithelial cells as a host-
pathogen interaction model, we will also study the suppression of the host 
nitrosative defense response by Blastocystis. 
 35 
Due to a lack of appropriate infection models, Blastocystis pathogenic mechanisms 
are difficult to decipher. We will use the Caco-2 host-epithelial interaction model to 
study the role of Blastocystis cysteine proteases in the modulation of the epithelial 
cytoskeleton and tight junctions. We will also study whether these alteration lead to 
an increase in epithelial permeability, exposing subepithelial tissue to luminal 
contents. Moreover, we will identify epithelial pathways modulated by Blastocystis 
leading to epithelial barrier compromise. Although several studies, including this 
one, elaborate on the pthogenecity of Blastocystis, but asymtpomatic carriage of the 
parasite continues to cast doubts over its pathogenic potential. Using the Caco-2 
model, we will also study a strain-to-strain variation between pathogenecity of 
Blastocystis ST-4 and ST-7 isolates. Identification of virulent and avirulent strains of 
the parasite might provide an explanation for inconsistencies in the clinical outcome 
of Blastocystis infections. 
Another controversy concerning the pathogenic potential of Blastocystis is 
treatment failure. It is often argued that, since anti-Blastocystis treatment does not 
lead to resolution of intestinal symptoms, Blastocystis might not be the etiological 
agent and the symptoms might be caused by some undiagnosed pathogen. Giardia 
intestinalis was recognized as a clinically significant organism only after it became 
possible to effectively eliminate it from the gut (Markell, 1995). Although antibiotic 
resistance is suspected by some as a reason for treatment failure in Blastocystis 
infections (Stensvold et al., 2008), a lack of adequate drug susceptibility assays 
limits our understanding in this area. In this study we will develop high-throughput 
drug susceptibility assays for Blastocystis to study antibiotic susceptibility and 
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resistance in isolates of Blastocystis ST-4 and ST-7. The assays will be useful in 
evaluating the susceptibility of Blastocystis strains to a panel of drugs, compounds 
and host-derived anti-microbial molecules. Importantly, this method will allow us to 
identify metronidazole-resistant strains of Blastocystis. 
Pathogenic strains of Blastocystis that are resistant to antibiotics pose a significant 
threat. We will utilize the knowledge acquired by this study regarding the 
pathogenic pathway of a metronidazole-resistant isolate of Blastocystis to evaluate 
the therapeutic potential of a few novel treatment options. In particular, we will 
study the inhibition of host HMG-CoA-reductase and Rho Kinase by Simvastatin and 
Fasudil, respectively, as possible alternative or adjunctive treatment options against 
drug resistant intestinal infections. 
Hence, the specific objectives of this study are: 
1. To characterize biological differences between two clinically relevant 
zoonotic Blastocystis subtypes by: 
a. Studying the differences in cysteine protease activity, generation time 
and cell size between ST-4 and ST-7 isolates of Blastocystis. 
b. Developing high throughput in-vitro drug susceptibility assays for 
Blastocystis in order to identify metronidazole resistant isolates and 
study variations in susceptibility of ST-4 and ST-7 isolates of the 
parasite to antiparasitic agents. 
2. To investigate host defense and pathological responses to Blastocystis by: 
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a. Studying the inhibition of epithelial nitric oxide production by 
Blastocystis as a survival and immune evasion mechanism. 
b. Studying the effect of Blastocystis cysteine proteases on intestinal 
epithelial permeability and transepithelial resistance. 
3. To characterize the signaling pathways involved in host cell pathobiology 
and to exploit this knowledge for the development of novel treatment 
strategies by: 
a. Identifying molecular pathways modulated by Blastocystis to induce 
tight junction and cytoskeletal rearrangements leading to epithelial 
barrier dysfunction. 
b. Studying the protective effect (therapeutic potential) of epithelial Rho 
kinase and HMG CoA reductase inhibition by Fasudil and Simvastatin, 
respectively, against epithelial barrier dysfunction induced by 








INTER- AND INTRA-SUBTYPE VARIATION IN 
BLASTOCYSTIS BASIC BIOLOGY, CYSTEINE 




We began this study by characterization of some basic biological properties of 
Blastocystis strains we intend to use in later studies. This information will help in 
analysis of the pathogenic potential of the parasite and will be useful in evaluation of 
antibiotic resistance and alternate treatment options. This chapter will identify 
variations in generation times and cell size between Blastocystis subype-7 and 
subtype-4 isolates, but the primary focus of this Chapter would be cysteine protease 
activity of different Blastocystis isolates. This basic information will provide the 
stepping-stone towards development of in-vitro assays for more detailed 
characterization of parasite pathogenic mechanisms. Difference in pathogenic 
potential of varying Blastocystis strains is suspected in several clinical and animal 
infection studies. A subtype dependent variation in susceptibility of Blastoycystis to 
antibiotics though, is yet to be investigated. This Chapter will also explore whether 
subtype-dependent differences extend beyond basic biology of Blastocystis strains 
to antibiotic susceptibility and resistance.  
Interest in cystiene proteases has increased considerably in recent years. Proteases 
cleave peptide bonds of proteins and peptides. The activity of the cystiene proteases 
depend on the nucleophilic nature of the cysteine side chains and directly attack the 
peptide bond to form a transient covalent enzyme-substrate intermediate (Klemba 
and Goldberg, 2002). Cysteine proteases are known to have cytopathic effect and 
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there are several reports of their function as virulence factors of protozoan 
parasites (Sajid and McKerrow, 2002). 
Enteric parasites such as Giardia intestinalis and Entamoeba histolytica possess 
cysteine proteases that disrupt epithelial integrity and modulate host immune 
responses (Buret, 2007; Leber, 1999; Moncada et al., 2005; Panaro et al., 2007; Que 
et al., 2003; Zhang et al., 2000). Pathogenic strains of E. histolytica were shown to 
have quantitatively higher cysteine protease activity than non-pathogenic strains, 
whereas for G. intestinalis, isolates from symptomatic patients exhibited more 
proteolytic bands in substrate gels than an isolate from an asymptomatic carrier 
(Guimarães et al., 2003). Qualitative differences in cysteine protease profiles have 
also been reported between pathogenic and non-pathogenic strains of E. histolytica 
(Davis et al., 2007; Hirata et al., 2007; Reed et al., 1989) and G. intestinalis (DuBois et 
al., 2006; Guimarães et al., 2003). 
 Blastocystis cysteine proteases are implicated as the virulence factors of the 
parasite in recent years. They are known to modulate host immunity by at least two 
mechanisms. They cleave human secretory immunoglobulin A (Puthia et al., 2005) 
and activate NF-κB resulting in the up-regulation of interleukin 8 cytokine 
transcription and secretion by intestinal epithelial cells (Puthia et al., 2008a). There 
is little evidence however, of a variation in cystiene proteases activity of virulent 
and avirulent strains of Blastocystis as observed in other pathogens. 
In this Chapter, we measured the time-dependent variation in cysteine protease 
activity of Blastocystis isolates belonging to two subtypes, 4 and 7, and compared 
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their peak protease activity. In addition, cell size and protease activity variations in 
relation to culture age were also investigated. Our results indicate the presence of 
inter- and intra-subtype differences in Blastocystis cysteine protease activity. Our 
data also suggest a positive correlation between cell size and protease activity. 
Identification of antibiotic-resistant subtypes of the parasite and development of 
new therapeutic options to counter antimicrobial resistance requires a high-
throughput screening tool. Conventional drug susceptibility assays for Blastocystis 
(Dunn and Boreham, 1991; Vdovenko and Williams, 2000; Yakoob et al., 2004; 
Zierdt et al., 1983) are unsuitable for high-throughput drug screening (HTS). These 
tests are laborious, time-consuming, expensive, prone to bias and potentially 
hazardous. Incidence of Blastocystis is higher in developing countries (Tan et al., 
2010) and the cost and availability of sophisticated equipment are also limitations 
for such screenings. In this study, two high-throughput viability assays were 
evaluated and applied for drug susceptibility microassays for Blastocystis. Resazurin 
(7-hydroxy-3H-phenoxazin-3-one 10-oxide) is the active compound of, Alamar blue 
(O'Brien et al., 2000). This assay measures intrinsic metabolic activity of the cell, 
which reduces resazurin and changes its color as an indicator of the number of 
viable cells present in a test sample (McBride et al., 2005). It is commonly used for 
drug susceptibility analysis of eukaryotic (Glass et al., 1991; McBride et al., 2005; 
O'Brien et al., 2000; Perrot et al., 2003) and prokaryotic (Leonard et al., 2008) 
organisms. Simmilar to resazurin, the tetrazolium salt 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) is reduced by cytoplasmic redox 
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enzymes and mitochondrial to colored formazan compound with a direct correlation 
with cell proliferation. Tetrazolium compounds have been utilized widely for 
viability evaluation of both prokaryotic (De Logu et al., 2003) and eukaryotic 
(Bénéré et al., 2007) organisms. 
Metronidazole (Mz) is considered first-line therapy for Blastocystis infections. 
Therapeutic intervention though is equivocal primarily due to large number of 
asymptomatic carriers and reports of treatment failure (Armentia et al., 1993; 
Haresh et al., 1999; Moghaddam et al., 2005; Ozyurt et al., 2008; Stensvold et al., 
2010). The variation in treatment response suggests the presence of metronidazole-
resistant (Mzr) strains of Blastocystis but there are currently no in-vitro or in-vivo 
reports to support this hypothesis. Despite these controversies, in recent years 
interest in the parasite has increased. Giardia intestinalis was recognized as a 
clinically significant organism only after it became possible to effectively eliminate it 
from the gut (Markell, 1995). To understand the role of Blastocystis as a human 
pathogen, there is an urgent need to identify standardized and effective treatment 
options for various Blastocystis subtypes. 
In the current study, resazurin and XTT redox-based assays were optimized. They 
were found to be appropriate to study viability of Blastocystis. Blastocystis subtype-4 
and subtype-7 isolates are most commonly found in rats and birds, respectively 
(Tan, 2008). Both colonize the human intestine, and studies report both subtypes as 
clinically significant (Stensvold et al., 2009b). We utilized the optimized assays to 
determine the susceptibility of these isolates to a range of conventional and 
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experimental chemotherapeutic agents. We found subtype-dependent variations in 
Blastocystis susceptibility to a panel of antiprotozoal agents and identified Mz- and 
emetine (EM)-resistant subtypes of the parasite. Importantly, several new and 
potentially effective treatment options for Mzr Blastocystis infections were 
identified.
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2.2 MATERIALS AND METHODS 
2.2.1 Parasite culture 
Four axenised isolates of Blastocystis were used in this study. Isolates WR-1 and S-1 
belonging to subtype-4 were isolated during an animal survey of Wistar and 
Sprague Dawley rats (Chen et al., 1997). Isolates B and E belonging to subtype-7 
were isolated from symptomatic patients at the Singapore General Hospital. All 
isolates are classified according to a recently described classification scheme 
(Stensvold et al., 2007b; Wong et al., 2008). The isolates were cultured as described 
previously (Sio et al., 2006) with some modifications. In brief, parasites were 
maintained in 10 ml of pre-reduced Iscove’s modified Dulbecco’s medium (IMDM) 
containing 10% horse serum in anaerobic jars at 37°C. Parasites were sub-cultured 
alternately at 72 and 96 h and 72-h-old cultures were used for the time course 
experiments. This phenotypes is advantageous for MZ resistance assessment since 
Blastocystis cysts are naturally resistant to the drug (Zaman and Zaki, 1996), and 
might complicate our study. Cultures were harvested from log-phase in-vitro 
cultures for viability studies in 96-well plates. 
2.2.2 Culture on a 96-well platform for highthroughput screening 
In order to establish and validate the assays for Blastocystis cytotoxicity assessment, 
the culture conditions were optimized for 96-well plates. Subtype-7 parasites 
(isolate B) were used during optimization. Unless otherwise stated, parasite 
numbers between 103 and 106 cells were incubated in Blastocystis culture medium 
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in a final volume of 200 µl/well. The plates were then incubated at 37°C under 
anaerobic conditions for 24 h unless otherwise stated.  
2.2.3 Preparation of lysate 
For azocasein assays, 4 × 106 parasites were harvested from the culture in each of 
the five different time points (0, 24, 48, 72 and 96 h) and washed twice in 
phosphate-buffered saline (PBS) (pH 7.4). Lysates were prepared by three freeze-
thaw cycles in liquid nitrogen and 37°C water and stored at −80°C. 
2.2.4 Azocasein assay for cysteine protease activity 
Parasite protease activity was determined by azocasein assay as described 
previously (Sio et al., 2006). Briefly, parasite lysates were co-incubated with 2 mM 
dithiothreitol (DTT) (Sigma) at 37°C for 10 min to activate protease activity. 
Azocasein, 100 μl of 5 mg/ml, (Sigma) solution was prepared in PBS (pH 7.4) and 
incubated with 100 μl parasite lysate for 1 h at 37°C. The reaction was stopped by 
adding 300 μl of 10% trichloroacetic acid and samples were incubated on ice for 
30 min. Undigested azocasein assay was removed by centrifugation (5,000 × g for 
5 min) and the resultant supernatant was transferred to a clean tube containing 
500 μl of 525 mM NaOH. Absorbance was measured with a spectrophotometer at 
442 nM (Tecan Magellan). PBS and lysates boiled at 90°C for 15 min to inactivate 
proteases were used as negative controls and 100 μl trypsin (2.5 mg/ml) was used 
as a positive control. 
2.2.5 Flow-cytometeric cell count and cell size analysis 
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Parasite culture cell size distribution was obtained by comparing forward scatter 
profiles of individual cultures with forward scatter peaks generated using polyvinyl 
beads of five different known diameters (3 , 6 , 8 , 10  and 15 μm), using a 488 nm 
laser Epic Altra flow-cytometer (Beckman Coulter). At each of the five different time 
points (0, 24, 48, 72 and 96 h) parasite pellets were re-suspended and cell counts 
and diameters were measured using appropriate dilutions. The generation time of 
each of the four isolates was also calculated as described previously (Zierdt and 
Swan, 1981) using the formula: 
GT = t/nb = t/3.3 log(b/B), where 
B = number of Blastocystis cells at start of time period t 
b = number of Blastocystis cells at the end of time period t 
t = time period 
n = number of generations 
log = logarithm to base 1- (common log) 
GT = generation time 
2.2.6 Redox assays 
After incubation, the cultures were incubated with resazurin or XTT dyes for 
additional 3 h and 5 h for quantitative and semiquantitative evaluation, respectively. 
Unless otherwise stated, a 5% final dilution of the resazurin dye solution (Sigma) 
was used for resazurin assays, whereas XTT (Sigma) was used at a final 
concentration of 50 µg/ml. After incubation, fluorescence readings of resazurin were 
taken at 550-nm excitation and 570-nm emission wavelengths. XTT measurements 
were made at an absorbance wavelength of 450 nm. Tecan Infinite M200 reader was 
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used for both fluorimetric and colorimetric measurements. Color change in each 
well was visually observed and recorded after 5 h for semiquantitative evaluation. 
2.2.7 Preparation of reference chemotherapeutic agents 
Compounds purchased from Sigma are Mz, ornidazole (Oz), ronidazole (Rz), 
furazolidone (FUR), mefloquine (MQ), quinacrine (QC), quinine (QN), chloroquine 
(CQ), emetine (EM), doxycycline (DOX), trimethoprim sulfate-sulfamethoxazole 
(TMP-SMZ), paromomycin (PAR), ampicillin (AMP), pyrimethamine (PYR), and 
iodoacetamide (IA). Nitazoxanide (NTZ) was purchased from Romark Laboratory 
and Tinidazole (Tz) was purchased from AK Scientifics. C-17 is an experimental, 
chemically synthesized, 2-position 5-nitroimidazole (NI) compound (66). Stock 
solutions of each compound were prepared fresh in dimethyl sulfoxide (DMSO) 
before testing in. For determination of drug susceptibility, stock solutions were 
diluted in prereduced Blastocystis culture media and transferred to 96-well plates. 
Total 0.5 x 106 cells/well were incubated for 24 h with varying dilutions of the drugs 
between 0 and 100 µg/ml. Final concentration of DMSO was kept constant at 0.5%. 
2.2.8 Confocal Microscopy 
Parasites confocal micrographs were taken to confirm that changes in Blastocystis 
redox activity under antibiotic tension observed in redox assays was associated with 
morphological features of cell death. Metronidazole-susceptible (Mzs) ST-4 (isolate 
WR-1) and Mzr ST-7 (isolate E) were treated for 24 h with a 12.5-µg/ml 
concentration of FUR and Mz. After exposure to drug, parasites were washed and 
resuspended in annexin V binding buffer (BioVision). Annexin V and propidium 
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iodide (PI) (BioVision) were then added to the cell suspension. Olympus Fluoview 
FV1000 (Japan) equipped with a dual filter set for fluorescein isothiocyanate (FITC) 
and rhodamine was used for confocal imaging of the parasite cell suspensions. 
Images were captured using Olympus Fluoview version 1.6b. 
2.2.9 Statistical evaluation and validation.  
Smaller pilot screenings are used before using a particular assay for full scale HTS, 
to predict its usefulness for applications on a large-scale. Z-factor predicts the 
robustness of an assay for HTS. It takes into account mean and standard deviation of 
positive and negative controls of pilot screening (Wawrzyniak et al., 2008). Z-factor 
of both the assays for Blastocystis drug screening was calculated using the following 
equation.  
Z’-factor = 1 – [(3σc+ + 3σc-) / |μc+ - μc-|] 
Where, c+ = positive control (0.5% DMSO); c- = negative control (6.25 μg/ml FUR); σ 
= standard deviation and μ = mean. 
Assays with a Z’-factor score within the range of 0.5-1 are considered excellent for 
HTS (Wawrzyniak et al., 2008). 
Comparison of data sets with large differences between means should be made 
using co-efficient of variation (Cv) instead of standard deviation (σ). It represents 
the σ in the context of mean (μ). It is another test used to determine the robustness 
of HTS assays. We calculated Cv of both the assays by the following formula 
(Kurniawan et al., 2009). 
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Cv = σ / μ 
Where, Cv = coefficient of variation; σ = standard deviation of positive control (5 X 
105 parasites in 200 μl culture media + 0.5% DMSO); and μ = mean of positive 
control (5 X 105 parasites in 200 μl culture media + 0.5% DMSO).  
Assays with Cv < 1 are considered low-variance and fit for HTS (Li et al., 2009). 
Final assay validation step was the screening of antiprotozoal activity to titrations of 
FUR against all 4 isolates of Blastocystis, repeated twice in triplicates. The results 
were compared statistically for reproducibility. 
The ANOVA test was used to determine statistical significance. Differences with p-




2.3.1 Time dependent variations in parasite protease activity 
Lysates of Blastocystis isolates exhibited significant protease activity with the 
azocasein substrate (Fig. 2.1). Protease activity was measured in azocasein units, 
defined as the amount of enzyme producing an increase of 0.01 OD units per hour. 
We have previously reported that the protease activity of Blastocystis isolate B, 
changes with culture age (Sio et al., 2006) but only two time points were 
investigated. In the current study it was observed that the protease activity of 
4 × 106 cells of both ST-7 and rodent isolates fluctuate over time with a peak at 
either 24-h post-incubation for isolates B, WR-1 and S-1 or 48-h post-incubation for 
isolate E, indicating that there is a variation in protease activity of parasite at 
different culture ages (Figs. 2.1 and 2.2). 
2.3.2 Intra- and inter-subtype variation in peak protease activity 
A difference between peak protease activities among Blastocystis isolates was 
observed (Fig. 2.1). Isolates B, E, S-1 and WR-1 showed peak protease activity of 
30.41 ± 3.65, 37.54 ± 1.77, 17.35 ± 1.4 and 16.62 ± 0.8 azocasein units, respectively. 
These values were significantly higher than the negative controls, with isolate E the 
highest and WR-1 the lowest. The average peak protease activity of ST-7 isolates 
was approximately twofold higher than the rodent isolates. A significant (p-
value = 0.034) intra-subtype difference in peak protease activity was observed for 
the ST-7 isolates. A subtle difference in peak protease activity between rodent 
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isolates was also observed but it was not significant (p-value = 0.18). 
When iodoacetamide was added to inhibit the cysteine proteases, abolishment of 
protease activity of each sample (p-value < 0.01) was observed. Mean baseline 
protease activity after iodoacetamide inhibition was found to be 6.59 ± 0.35 and 
5.07 ± 0.3 azocasein units for subtype-7 and subtype-4, respectively (Fig. 2.2). 
2.3.3 Time-dependent variations in parasite culture morphology 
Distinct cell size distributions were observed for each isolate with broadly similar 
patterns between isolates of the same subtype (Fig. 2.3). Subtype-7 cells (Fig. 2.3a,b) 
were distinctly larger than subtype-4 cells (Fig. 2.3 c,d). Change in cell size 
distribution was also determined over time for each isolate. All isolates displayed 
highest proportion of larger cells at 24 h while cell size distribution tended towards 
smaller cells from 48 h to 96 h. Another interesting observation is that for each 
isolate, time-dependent fluctuation in cell size profile were observed in replicate 
experiments performed more than a month apart, indicating that these fluctuations 
are consistent for all four isolates assayed. 
2.3.4 Parasite generation times 
From the growth curves of each isolate (results not shown), generation times were 
calculated. Isolate B and E had generation times of 50.25 ± 1.89 and 83.83 ± 8.96 h, 
respectively, while WR-1 and S-1 had doubling times of 31.35 ± 0.49 and 
21.44 ± 5.7 h, respectively (Table 2.1). 
2.3.5 Association between protease activity and cell size 
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A correlation between protease activity of a particular isolate with its cell size 
distribution was observed. Cultures of subtype-4 isolates have more cells in the 
lower cell size ranges (Fig. 2.3c–d) and have significantly lower protease activity 
compared to subtype-7 isolates (Fig. 2.3a–b) which have more cells in higher cell 
size ranges. Furthermore, from the time course assay, it was evident that the peak 
protease activity of all isolates correlated with culture ages containing the highest 
proportion of large cells. An exception was the protease activity of isolate E, which 
peaked 24 h after the parasite culture attained its peak cell size profile. 
2.3.6 Blastocystis exhibits cell density-dependent fluorimetric and 
colorimetric reactions with Resazurin and XTT.  
For semiquantitative analysis, changes in color were observed by naked eye after 5 
h of incubation of resazurin and XTT with Blastocystis sp. subtype-7 in 200 µl 
parasite culture medium. Varying shades of resazurin dye, from blue to pink, 
developed with increasing cell number per well. Similarly, shades ranging from 
yellow to deep orange developed with XTT with increasing cell density. Minimums 
105 parasites/well were required for visual evidence of color change for both dyes. 
Color change was more obvious in the resazurin dye than with XTT.  
Fluorescence and absorbance measurements were taken after 3 h of incubation, for 
quantitative analysis of resazurin and XTT dyes respectively. Negligible changes in 
measurements were observed between the blank medium control and up to 104 
parasites/well (Fig. 2.4), but a linear increase in fluorimetric, as well as colorimetric, 
measurements was noted from 104 parasites to 106 parasites/well (Fig. 2.4). The R2 
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values for resazurin and XTT dyes were 0.995 and 0.983, respectively (Fig. 2.4; see 
Table 2.2). A cell count of 5 x 105 parasites/well lies within the linear range of cell 
density versus dye reduction for both assays (Fig. 2.4) and provides visible color 
changes in a short time. This count was chosen as the optimal cell density for further 
experiments. 
2.3.7 200-µl/well volumes was required for optimal metabolic activity of the 
parasite.  
Cells should be at their optimal metabolic activity for viability assays. An increase in 
metabolic activity of Acanthamoeba with a reduction of the culture volume from 200 
to 100 µl/well was reported in a recent study (McBride et al., 2005). In the current 
study, a drop in Blastocystis metabolic activity was observed with a decrease in 
volume per well (Fig. 2.5). Blastocystis, is an anaerobic organism (Tan, 2008), and it 
should have higher metabolic activity in high well volumes as compareed to 
Acanthamoeba, an aerobic protozoan (McBride et al., 2005). Therefore, a 200-
µl/well volume was used in the rest of the experiments (Table 2.3 and Fig. 2.5). 
2.3.8 Exponential growth of Blastocystis in microcultures. 
When incubated under optimal microplate growth conditions, Blastocystis sp. 
subtype-7 exhibited an increasing degradation of resazurin over time, suggesting 
that total redox activity of the culture has increased (Fig. 2.6).This increase could be 
a result of increasing parasite metabolic activity or numbers. Parasite redox activity 
of the cultures peaked at 24 h, followed by a drop, suggesting a decrease in culture 
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growth or metabolism due to overcrowding. The 24-h time point was chosen for 
drug susceptibility assays (Table 2.6). Optimized parameters for assays are 
summarized in Table 2.3. 
2.3.9 Suitability of Resazurin and XTT for HTS of Blastocystis drug 
susceptibility. Both resazurin and XTT assays met HTS quality control parameters, 
i.e., a Z' factor of >0.5 (Zhang et al., 1999) and a Cv of <10% (Li et al., 2009) (Table 
2.2) and exhibited statistical reproducibility for dose-dependent activity assays of 
FUR against Blastocystis (Fig. 2.7). 
2.3.10 Blastocystis exhibits subtype-dependent variation in susceptibility and 
resistance to Mz. Using the optimized resazurin assay, the 50% inhibitory 
concentrations (IC50s) of Mz against subtype-4 and subtype-7 isolates of Blastocystis 
were calculated. Mz inhibited 50% of growth of subtype-4 isolates WR-1 and S-1 at 
concentrations of 5.5 ± 2.89 µg/ml and 1.9 ± 1.32 µg/ml, respectively (Table 2.4; 
Fig.2.7 and 2.8). These values were within the range of previously reported values of 
Mz susceptibility for Blastocystis (Dunn and Boreham, 1991; Zierdt et al., 1983). The 
IC50 of Mz against isolate B (subtype-7) was 32.5 ± 3.4 µg/ml. This value is 
significantly higher than the IC50 of subtype-4 isolates (P < 0.01) and exceeds the 
average fecal Mz concentration of 9.5 µg/ml (Krook et al., 1981). Isolate E of 
subtype-7 exhibited minimal susceptibility to Mz (Table 2.4 and Fig. 2.7), even at 
concentrations as high as 100 µg/ml. These results suggest that isolates B and E of 
subtype-7 are Mzr strains of Blastocystis. The XTT assay further confirmed these 
strains to be Mzr (Table 2.4). 
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2.3.11 An Mzs isolate of Blastocystis exhibits typical morphological features of 
cell death after exposure to Mz, as opposed to an Mzr isolate. Our findings, 
based on resazurin and XTT assays, indicate suppression of parasite redox activity 
under drug tension. Concomitantly, to determine whether Blastocystis undergoes 
morphological changes after drug exposure, parasites were stained with propidium 
iodide and annexin V-FITC. Both PI and annexin V stain only dying parasites (Wu et 
al., 2010). PI binds to the parasite nuclear material (Wu et al., 2010). Annexin V 
binds with high affinity to phosphatidylserine (PS). PS is located at the cytosolic face 
of the cell membrane and has access to annexin V only when it becomes exposed at 
cell death (Wu et al., 2010). Healthy parasites are impermeable to both PI and 
annexin V (Wu et al., 2010). Mzs ST-4 (isolate WR-1) exhibited nuclear incorporation 
of PI and annexin V binding after 24 h of exposure to a 12.5-µg/ml concentration of 
Mz, suggesting a breach in the parasite cell membrane (Fig. 2.9A). No changes were 
observed in Mzr ST-7 (isolate E) after Mz treatment (Fig. 2.9B). MZs and Mzr isolates 
exhibited cell death morphology after treatment with a 12.5-µg/ml concentration of 
FUR (Fig. 2.9A and B), whereas neither of the isolates incorporated PI or annexin V 
after treatment with the DMSO control (Fig. 2.9A and B). These findings suggest that 
after treatment with Mz, morphological alterations typical of dying cells were 
observed in the Mzs isolate, while the Mzr isolate remained unaffected. 
2.3.12 Mzr isolates of Blastocystis exhibit cross-resistance with a 1-position-
substituted 5-NI. Tz, a compound closely related to Mz due to the presence of its 
side chain at position 1 of the imidazole ring (Fig. 2.8), was effective in killing both 
Mzr and Mzs isolates. Interestingly, Mzs subtype-4 isolates WR-1 and S exhibited 
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IC50s (0.51 ± 0.02 and 0.3 ± 0.1 µg/ml, respectively) of Tz lower than those of Mzr 
subtype-7 isolates B and E (5.13 ± 0.16 and 9.33 ± 0.45 µg/ml, respectively) (P < 
0.01) (Table 2.5). Even within subtype-7, the IC50 of Tz for Mzr isolate E was 
significantly higher than that for isolate B (Table 2.5). These findings in Blastocystis 
suggest a cross-resistance pattern similar to those exhibited by other parasites 
(Boreham, 1988; Crowell et al., 2003). Oz, another closely related 5-NI (Fig. 2.8), 
despite having a position 1 side chain, was found to be equally effective against both 
Mzr and Mzs isolates (Table 2.5). Interestingly, Mzr subtype-7 isolates exhibited 
significantly higher susceptibility to the position 2 side chain 5-NIs Rz and C-17 (Fig. 
2.8) than to position 1 5-NI. No significant subtype-dependent variation in 
Blastocystis susceptibility to position 2 5-NIs was observed. 
2.3.13 Blastocystis exhibits subtype-dependent variations in susceptibility to 
NTZ, MQ, and QC. NTZ, a well-documented pyruvate-ferredoxin oxidoreductase 
(PFOR) inhibitor (Orozco, 2009), was found to be more effective against Mzr strains 
of the parasite in this study (Table 2.6). Subtype-7 isolates were significantly more 
sensitive to NTZ than subtype-4 isolates (P < 0.01). Similarly, the anti-malarial MQ 
and a closely related drug, QC, were also found to be significantly more effective 
against subtype-7 isolates than subtype-4 (Table 2.6).  
2.3.14 No subtype-dependent variations in FUR and QN susceptibility. Both Mzr 
and Mzs isolates exhibited sensitivity to FUR and QN (Table 2.6), two well-known 
antiprotozoal agents.  
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2.3.15 Higher susceptibility of Blastocystis spp. to a TMP/SMZ ratio of 1:2 than 
to one of 1:5. SMZ and TMP are administered in two different ratios for protozoan 
infections. TMP/SMZ ratios of 1:5 and 1:2 were tested for Blastocystis inhibition. All 
isolates exhibited susceptibility to both combinations, but all four isolates were 
significantly more sensitive (P < 0.01) to a TMP/SMZ ratio of 1:2 than to one of 1:5 
(Table 2.6).  
2.3.16 Nonsusceptibility of Blastocystis to broad-spectrum antibiotics. PAR, 
PYR, CQ, DOX, and AMP were found to be ineffective against all four isolates of the 
parasite. 
2.3.17 Cysteine protease inhibition causes parasite death. The significance of 
cysteine proteases in Blastocystis pathobiology is well reported (Mirza and Tan, 
2009; Puthia et al., 2008a; Tan et al., 2010; Wu et al., 2010). In this study, Inhibition 
of cysteine protease activity of the parasite by IA resulted in complete inhibition of 
all four isolates with similar IC50s (Table 2.6), suggesting the importance of cysteine 





























































Fig. 2.1 Peak protease activity of Blastocystis isolates E, B, WR-1 and S-1 
determined by azocasein assays. There is a significant inter-subtype difference 
between mean peak protease activities of subtype-7 and subtype-4 (p-value < 0.01) 
and a significant intra-subtype difference between the peak protease activity of 
isolates E and B of subtype-7 (p-value < 0.05). Values are averages of two 
independent experiments. Trypsin was used as a positive control. PBS showed 
activity that was significantly lower (p-value < 0.01) when compared to protease 




Fig. 2.2 Protease activity fluctuations of Blastocystis isolates E, B, WR-1 and S-1 
over time. Protease activity of isolates B, WR-1and S-1 peaked at 24 h while E 
peaked at 48 h. Peak protease activity of each isolate was significantly higher (p-
value < 0.05) than the preceding time point and falls significantly (p-value < 0.05) at 
the succeeding time point. An exception is isolate WR-1, of which peak protease 
activity at 24-h time point is not significantly higher than the preceding time point 
(p-value < 0.08). Note that cysteine protease inhibitor iodoacetamide (IA) abolished 
protease activity of the isolates at all time points. Each point represents averages 
values of two independent experiments. ST-7, Blastocystis spp. subtype-7 (isolates E 
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Fig. 2.3 Variations in cell size distribution of Blastocystis isolates B, E, WR-1 
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and S-1 over time by flow cytometry. At 24-h post-incubation, cell size 
distribution within cultures of all four isolates tended towards higher cell size 
ranges compared to other time points (a–d), with cultures of isolates belonging to 
same subtype showing similar size distribution profiles over time. ST-7 isolates B 
and E (a, b) comprise larger percentages of cells in higher cell size ranges compared 
to ST-4 isolates S-1 and WR-1 (c, d). Line graph representations (a 2, b 2, c 2, d 2) of 
histograms (a 1, b 1, c 1, d 1) clearly illustrate variations in size distributions over 
time, with 24-h cultures (arrow) comprising the largest cells. Except for isolate E, all 
other isolates show a correlation between cultures comprising the largest cells (*) 






Fig 2.4 Correlation between the number of subtype-7 parasites and relative 
fluorescence units (RFU) (A) and relative absorbance units (RAU) (B) after 24 h 
of incubation and 3 h of development with resazurin and XTT, respectively. Each 
point represents an average of 6 values derived from two independent sets of 
experiments. The error bars represent standard errors. 
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Fig 2.5 Correlation of total volume per well and dye concentration with 
relative fluorescence units (RFU) (A) and relative absorbance units (RAU) (B) 
for resazurin (res) and XTT dyes, respectively. Higher volumes per well and dye 
concentrations resulted in higher sensitivity of resazurin and XTT, denoted by 
higher RFU and RAU readings, respectively. Each point represents a mean of 6 




Fig 2.6 Blastocystis subtype-7 exhibits a time-dependent increase in redox 
activity when cultured in a 96-well plate under the resazurin assay conditions 
described in this study. The starting parasite density was 0.5 x 106 cells in 200 µl of 
IMDM supplemented with 10% horse serum and 0.5% DMSO. The redox activity of 
the culture peaked at 24 h, followed by a steady decline. A drug contact duration of 
24 h was chosen based on these results. Each point represents a mean of 6 values 
derived from two independent experiments, with each experiment conducted in 




FIG. 2.7. Graph representing percent inhibition of Blastocystis subtype-4 and 7 
cultures by Mz using the resazurin assay. The IC50s of Mz against subtype-4 
isolates were found to be significantly lower than those of subtype-7 isolates (P < 
0.01). Mz induced 50% inhibition of subtype-7 isolate B cultures at a concentration 
(conc.) of 32.5 ± 3.4 µg/ml, whereas isolate E cultures exhibited only minimal 
inhibition even at concentrations as high as 100 µg/ml. Each point represents a 
mean of six readings derived from two independent experiments. The error bars 
represent standard errors. 
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FIG. 2.9. Confocal micrographs of Blastocystis stained with propidium iodide 
(arrow) and annexin V-FITC. (A) Mzs ST-4 (WR-1) exhibited nuclear incorporation 
of PI and annexin V-FITC binding after 24 h of exposure to 12.5 µg/ml Mz. (B) Mzr 
ST-7 (isolate E) did not exhibit these classical signs of cell death after Mz treatment. 
Both Mzs and Mzr isolates exhibited PI incorporation and annexin V-FITC binding 
after 24-h treatment with 12.5 µg/ml FUR, while no changes were observed in 
healthy parasites incubated with DMSO. Bars, 5 µm.
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Table 2.1 Generation times of isolates belonging to subtype-7 and subtype-4 in 
comparison with characteristics of cell size and peak protease activity 
 























       
Subtype-
7 
E 83.825 ± 
8.96 
24 48 37.54 ± 1.77 
 
6.59 ± 0.35 
 B 50.255 ± 
1.89 





WR-1 31.38 ± 
0.439 
24 24 16.62 ± 0.8 5.07 ± 0.3 
 S-1 21.44 ± 5.68 24 24 17.35 ± 1.4  
# Time point after incubation of parasites in fresh culture media, at which cultures 
comprise highest % of large cells (h) 
* Time point after incubation of parasites in fresh culture media, at which cultures 
exhibit peak protease activity  
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TABLE 2.2. Statistical evaluation of the quality of resazurin and XTT assaysa 
Assay Z' factor Cv (%)b Linearity (R2)c 
 
Resazurin 0.9 ± 0.02 7.6 ± 0.35 0.995 
XTT 0.89 ± 0.1 2.4 ± 0.54 0.983 
 
a Ideal HTS parameters are a Z' factor of >0.5 (74) and a Cv of <10% (30). 
b Cv %, coefficient of variance of cell controls. 
c Linearity of the dye reduction-versus-parasites/well curve. 
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 TABLE 2.3. Optimized parameters for resazurin and XTT assays 
Parameter Value 
 
Dye concn  
    Resazurin 5% 
    XTT 50 µg/ml 
Growth medium IMDM + 10% HSa + 0.5% DMSO 
Volume/well 200 µl 
Temperature 37°C 
Culture conditions Anaerobic 
Contact time with dye (h)  
    Semiquantitative/visual 5 
    Quantitative 3 
Excitation/emission (nm) 
 
    Resazurin 550/580 
    XTT 450 
Optimal cell density (parasites/well) 0.5 x 106 
 
a HS, heat-inactivated horse serum. 
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TABLE 2.4. IC50 values of Blastocystis susceptibility to Mz 
Viability assay 






B E WR-1 S 
 
Resazurin 32.5 ± 3.4 (189.8) NSa 5.5 ± 2.89 (32.16) 0.75 ± 0.04 (4.38) 
XTT 29 ± 3.4 (169.36) NS 1.76 ± 0.39 (10.27) 1.1 ± 0.08 (6.4) 
 
a NS, not susceptible to drug concentrations of 100 µg/ml. 
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TABLE 2.5. IC50 values of Blastocystis for 5-NIs by resazurin assay 
Drug 






B E WR-1 S 
 
1-Position 5-NIsa     
    Mzd 32.5 ± 3.4 
(189.8) 
NSc 5.5 ± 2.89 
(32.16) 
0.75 ± 0.04 
(4.38) 
    Tzd 5.13 ± 0.16 
(20.52) 
9.33 ± 0.45 
(37.32) 
0.51 ± 0.02 
(2.04) 
0.3 ± 0.1 
 (1.2) 
    Oze 1.42 ± 0.02 
(6.44) 
1.23 ± 0.15 
(5.58) 
1.1 ± 0.3  
(4.9) 
1.15 ± 0.05 
(5.22) 
2-Position 5-NIsb     
    Rze 0.52 ± 0.02  
(2.6) 
0.31 ± 0.08 
(1.55) 
0.32 ± 0.1  
(1.6) 
0.37 ± 0.08 
(1.85) 
    C-17f 0.63 ± 0.1  
(1.56) 
0.36 ± 0.13 
(0.89) 
0.42 ± 0.08 
(1.04) 
0.5 ± 0.05 
(1.24) 
 
a Side chain at position 1 of the imidazole ring of 5-NI. 
b Side chain at position 2 of the imidazole ring of 5-NI. 
c NS, not susceptible to drug concentrations of 100 µg/ml. 
d FDA-approved antimicrobial agent. 
e Veterinary antiparasitic agent. 
f Experimental antiparasitic agent effective against Trichomonas and Giardia. 
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TABLE 2.6. IC-50 values of antiprotozoal agents effective against Blastocystis 
isolates using the resazurin assay 
Drug 
IC50 [µg/ml (µM)] 
 
Subtype-7 (Mzr) isolates 
 
Subtype-4 (Mzs) isolates 
 
B E WR-1 S 
 
NTZb 0.62 ± 0.07 
(2.01) 
1.14 ± 0.49 
(3.7) 
4.15 ± 0.41 
(13.48) 
8 ± 4.7 (26) 
FURb 0.65 ± 0.05 
(2.88) 
1.06 ± 0.4 (4.7) 0.49 ± 0.01 
(2.17) 
0.475 ± 0.05 
(2.1) 
MQb 1.49 ± 0.83 
(3.93) 
1.85 ± 0.88 
(4.88) 
4.7 ± 0.35 (12.4) 5.1 ± 0.58 
(13.46) 
QCb 2.8 ± 0.56 (7) 1.9 ± 0.2 (4.75) 5.1 ± 0.47 
(12.75) 
4.9 ± 0.53 
(12.25) 
QNb 5.1 ± 1.1 (15.7) 4.3 ± 2.4 
(13.24) 
3.2 ± 0.52 (9.8) 5.4 ± 1.4 
(16.63) 
EMc 1.03 ± 0.4 
(2.13) 





4.7 ± 0.5 5.3 ± 0.62 3.2 ± 0.8 4.3 ± 0.48 
TMP:SMZ 
1:5b 
22 ± 3.2 18.5 ± 1.3 24.5 ± 2.4 19 ± 0.46 
IAd 0.34 ± 0.05 
(1.83) 
0.2 ± 0.03 
(1.08) 
0.33 ± 0.06 
(1.78) 
0.26 ± 0.02 
(1.4) 
 
a N/S, not susceptible to 100-µg/ml concentration of the drug. 
b FDA-approved antimicrobial agent. 
c Antiparasitic agent with adverse side effects; not currently used in clinical practice. 
d Carcinogenic cysteine protease inhibitor; not clinically useful.
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2.4 DISCUSSION 
2.4.1 Inter- and intra-subtype variations in Blastocystis basic biology 
Observations made from recent studies using in-vivo rodent models as well as 
clinical reports of Blastocystis infections suggest that a variation in virulence might 
exist between different genotypes of Blastocystis (Hussein et al., 2008b; Kaneda et 
al., 2001). Blastocystis cysteine proteases have been reported in in-vitro studies to 
cleave human secretory IgA (Puthia et al., 2005) as well as induce pro-inflammatory 
cytokine IL-8 production (Puthia et al., 2008a) suggesting that these are potential 
virulence factors, however nothing is known about relative protease activity 
between Blastocystis subtypes and within isolates of the same subtype. In this study, 
we report for the first time that there is a quantitative difference between cysteine 
proteases activity of isolates belonging to two different subtypes. We also observed 
that in addition to an inter-subtype variation, a quantitative intra-subtype protease 
activity difference also exists between isolate B and E of subtype-7. 
Extensive size variations have been reported in Blastocystis laboratory cultures 
(Dunn et al., 1989) and stool specimens (MacPherson and MacQueen, 1994). The 
significance of this variation is unknown. Cell size variations within yeast microbial 
cultures may arise from asymmetrical division of daughter cells and is a natural 
phenomenon, which becomes pronounced in the presence of stress (Rupes, 2002). 
As soon as the insulting agent is removed, order is restored leading to a reduction of 
cell size variations. Cell size homeostasis mechanisms that coordinate between cell 
growth and division are responsible for the maintenance of this order (Jorgensen 
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and Tyers, 2004). Studies on yeast suggest that nutrient deficiency increase cell size 
variations in a given colony. New daughter cells in such cultures grow more than 
mother cells to acquire the “critical size” before division, hence prolonging the cell 
cycle (Rupes, 2002). Cytometric analysis of Blastocystis cultures in our study 
suggests that ST-7 isolate cultures exhibit more pronounced asymmetrical cell 
division compared to rodent isolate cultures. ST-7 isolates also have significantly 
prolonged generation time. In light of our understanding of cell size homeostasis in 
other organisms, a simple explanation for extensive cell size distribution in 
Blastocystis cultures could be that current in-vitro growth conditions are not 
optimal for the ST-7 isolates. ST-7 subtypes may grow optimally at 40°C instead of 
37°C, as is the case for the ST-7 protozoan flagellate Histomonas meleagridis (van 
der Heijden and Landman, 2008). However, when in-vitro time course experiments 
were repeated after more than 30 days and including multiple subculture cycles 
between the replicate experiments, an almost exact pattern of fluctuation over time 
in cell size distribution was observed for each isolate, suggesting that these 
fluctuations are stable over time. Hence, an extensive analysis of the Blastocystis cell 
cycle is needed to better understand the functional roles of Blastocystis size 
variation. 
Cysteine proteases play a crucial role in the cell cycle progression of eukaryotic cells 
(Concha et al., 2005) including protozoans (Gantt et al., 1998; Sharma et al., 1996; 
Ward et al., 1997). Day-to-day variation in protease activity was reported for E. 
histolytica (Reed et al., 1989) and culture age-dependent variation in total protease 
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activity was also previously observed for Blastocystis isolate B (Sio et al., 2006). In 
this study we observed protease activity variations in cultures of isolates E, WR-1 
and S-1. Inhibition of cysteine protease activity by iodoacetamide revealed that this 
variation is predominantly due to fluctuations in cysteine proteases. Interestingly 
this fluctuation coincides with age-dependent variation in culture cell size 
distribution. Cysteine protease activity and cell size distribution of Blastocystis 
isolates peak simultaneously at 24-h post-incubation. The only exception was isolate 
E for which cysteine proteases activity peaked at 48 h but cell size distribution 
peaked at 24 h. This suggests that, unlike the other isolates, the production of 
cellular proteases is not tightly coupled to the attainment of maximum cell size, and 
may be associated with the longer generation time of this isolate, which in turn 
might have influenced the rate at which proteases accumulate in the cell. Biological 
properties of different Blastocystis isolates change over time. This poses a particular 
difficulty for comparative studies. Based on the current findings we will use only 24 
h old cultures of all four isolates in the following experiments, since the size of all 
the isolates and cysteine proteases activity of all but one isolate (isolatet E) peak at 
this time point. 
Pathogenic strains of E. histolytica show higher cysteine protease activity per cell 
compared to non-pathogenic strains (Reed et al., 1989). We observed that the larger 
ST-7 Blastocystis isolates showed almost twice as much cysteine protease activity 
compared to smaller rodent isolates. Interestingly rodent and not ST-7 subtypes are 
considered as potentially pathogenic variants of the parasite. In-vitro (Puthia et al., 
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2005; Puthia et al., 2008b) and in-vivo experimental models (Hussein et al., 2008b) 
as well as epidemiological studies (Kaneda et al., 2001) associate subtype-4 (rodent 
isolates) with gastrointestinal symptoms. A possibility for this apparent discrepancy 
could be qualitative differences between cysteine proteases of the two subtypes. 
Interestingly, a G. intestinalis isolate from a symptomatic patient was shown to have 
lower cysteine protease activity than isolates from asymptomatic carriers (Coradi 
and Guimarães, 2006). It has been reported that G. intestinalis and E. histolytica 
possess qualitative inter-strain variations in cysteine protease activity and that 
these variations contribute to differences in pathogenicity (Davis et al., 2007; 
DuBois et al., 2006; Guimarães et al., 2003; Hirata et al., 2007). For Blastocystis, 
rodent isolates may express specific cysteine proteases which are potentially 
injurious to the gastrointestinal epithelium. Future studies should include a 
qualitative analysis of cysteine proteases of pathogenic and non-pathogenic 
Blastocystis subtypes. 
2.4.2 Inter- and intra-subtype variation Blastocystis susceptibility to 
antimicrobial agents 
We found both resazurin and XTT assays to be suitable for high-throughput analysis 
of drug susceptibility in Blastocystis isolates. The HTS parameters (a Z' factor of >0.5 
and a Cv of <10%) provide a highly conservative estimate of the sensitivity of an 
assay (Li et al., 2009; Zhang et al., 1999). The high Z' factor value, low Cv, and 
reproducibility of both resazurin and XTT assays suggest that they are robust and 
suitable for HTS. The option of semiquantitative visual evaluation of color gives 
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these assays the flexibility to be applied in the field without the need for 
sophisticated equipment. The suppression of metabolic activity observed in these 
redox assays was also found to be associated with morphological signs of cell death 
(Wu et al., 2010), i.e., nuclear incorporation of PI and annexin V binding to the cell 
membrane, further validating these assays in determining drug susceptibilities. 
Considering the large number of variant Blastocystis isolates and the predominance 
of the parasite in developing countries (Tan et al., 2010) with limited research 
funding, these assays will be particularly useful due to their low cost and high yield. 
In addition to the use of resazurin in assessment of Blastocystis susceptibility to 
antibiotics, in the next Chapter it will also be used to compare the susceptibility of 
Blastocystis isolates to potential host antimicrobial defense mechanisms. 
Subtype-7 isolates were shown to be resistant to Mz and cross-resistant to Tz, the 1-
position-substituted 5-NI of choice to treat a wide variety of anaerobic organisms 
(Bassily S, 1987; Harder, 2002). This is consistent with previous reports of cross-
resistance between the two drugs in Trichomonas (Crowell et al., 2003; Löfmark et 
al., 2010) and Giardia (Boreham, 1988). In these organisms, resistance is proposed 
to be due to downregulation of the enzymes PFOR (Upcroft and Upcroft, 2001) and 
thioredoxin oxidoreductase (Leitsch et al., 2010), which in conjunction with the 
electron acceptor ferredoxin are believed to activate the 5-NI prodrugs to the toxic 
radical states inside the parasite (Leitsch et al., 2010; Upcroft and Upcroft, 2001). 
However, this mechanism of activation has not been shown for Blastocystis, although 
PFOR and other oxidoreductase enzymes are present in the organism (Wawrzyniak 
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et al., 2008). The subtype-4 isolates showed no convincing uniformity in 
susceptibility to Mz and Tz, indicating that new, unknown mechanisms of activation 
and/or resistance may be involved.  
All isolates were similarly susceptible to another 1-position 5-NI, Oz. Compared to 
Mz, the drug has significantly higher efficacy against Mzr isolates of Blastocystis (P < 
0.01), as observed in other parasites (Chintana et al., 1986; Upcroft et al., 1999) and 
also reported for Blastocystis previously (Dunn and Boreham, 1991). However, its 
superior efficacy against Mzs isolates is not as obvious, again suggesting new, 
unknown mechanisms of activation and/or resistance to 1-position 5-NIs in the 
parasite. Oz is frequently used to treat amoebiasis in India (Güven, 2003). Although 
the IC50s of Oz against all four isolates tested here (4.9 to 6.44 µM) were higher than 
the MIC of the drug against Entamoeba (0.25 µM) (Chintana et al., 1986), its 
effectiveness against both Mzr and Mzs isolates suggests the drug would be a useful 
alternative to Mz to treat Blastocystis infections.  
Similarly to Oz, 2-position 5-NIs, the commercially available poultry drug Rz and the 
experimental drug C-17, were uniformly effective against the isolates of both 
subtypes tested. These 2-position 5-NIs exhibited significantly higher efficacy 
against Mzr isolates than 1-position 5-NIs (P < 0.01), as observed in Giardia and 
Trichomonas (Upcroft et al., 2006). Again, the improved efficacy of 2-position 5-NIs 
against Mzs subtype-4 isolates is not as obvious, suggesting a different mechanism of 
action in Blastocystis than in other organisms (Upcroft et al., 2006). The IC90 of C-17 
against Giardia was recently reported to be 0.5 µM (Dunn et al., 2010), whereas 
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against Trichomonas it exhibited a MIC of 6.3 µM (Upcroft et al., 2006). In this study, 
the IC50 of C-17 against Blastocystis ranged from 0.89 to 1.54 µM, suggesting the 
potential of the drug as a broad-spectrum antiprotozoal agent against Mzr parasites. 
Two-position 5-NIs may prove to be effective alternatives to treat Blastocystis 
infections in cases of Mz treatment failure.  
The susceptibility of the Mzr subtype-7 isolates to NTZ and the reduced 
susceptibility to the Mzs subtype-4 isolates are also evidence for different 
mechanisms of action of NTZ in Blastocystis than in Giardia and Trichomonas, where 
cross-resistance between Mz and NTZ is apparent (Adagu et al., 2002). These data 
suggest that Mz treatment failures in blastocystosis may well respond to NTZ, as in 
the case of Cryptosporidium parvum infections. C. parvum infections do not respond 
well to Mz (Gargala, 2008), and NTZ is the treatment of choice, with in-vitro IC50s of 
<10 µg/ml (Theodos et al., 1998), similar to the IC50s of the drug against both Mzr 
and Mzs isolates of Blastocystis in this study. Recent in-vitro (Vdovenko and 
Williams, 2000) and clinical data (Stensvold et al., 2010) also suggest the usefulness 
of the drug in Blastocystis infections.  
Another alternative to treat Mzr Blastocystis isolates is FUR, which was equally 
effective against all isolates in this study. FUR is a nitrofuran commonly used to treat 
giardiasis (Quiros-Buelna, 1989). It is activated inside the cell by NADH oxidase and 
generates toxic products that interfere with DNA processes in the parasite (Brown 
et al., 1996). The IC50s of FUR against both Mzr and Mzs isolates of Blastocystis were 
found to be similar to that against Giardia (2 µM) (Bénéré et al., 2007).  
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The prophylactic antimalarial MQ and a closely related drug, QC, were also found to 
be more effective against Mzr subtype-7 isolates than Mzs subtype-4 isolates. These 
findings are surprising because in Giardia, cross-resistance against QC has been 
observed between Mzr (Brasseur and Favennec, 1995) and Tzr (Upcroft et al., 1996) 
strains, suggesting a different mode of action of the drug in Blastocystis. The exact 
mechanisms of action of these drugs against luminal parasites are not known, 
although they have been suggested to act on protozoan cell membranes (Upcroft J, 
1996). The activity of QC against Blastocystis has been reported previously (Dunn 
and Boreham, 1991; Vdovenko and Williams, 2000), but the current study is the first 
to report the potential usefulness of MQ as an anti-Blastocystis drug.  
EM is an effective antiamoebic agent with unpleasant side effects. It targets 
ribosomes and limits protein synthesis (Orozco, 2009). The in-vitro activity of EM 
against Blastocystis has been evaluated in two previous studies. While both studies 
suggested its effectiveness against Blastocystis, Zierdt et al. reported strain-to-strain 
variation in the susceptibility of the parasite to the drug (Zierdt et al., 1983). The 
multidrug resistance (MDR) phenotype of Entamoeba histolytica exhibits resistance 
to a wide range of drugs, including EM, while responding to Mz (Orozco, 2009), but 
no such MDR phenotypes have been reported in Blastocystis spp. Our study 
describes the existence of EM resistance in Mzs isolates of Blastocystis, suggesting 
that MDR phenotypes might be present in the parasite. Clinically, however, EM has 
limited use because of its severe side effects (Marino et al., 1990; Sugie et al., 1984).  
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TMP and SMZ are often prescribed in combination at a 1:5 ratio as an alternative to 
Mz in Blastocystis infections. Clinical studies suggest that this drug combination 
successfully eradicates Blastocystis infections in 95% to 100% of cases (Stensvold et 
al., 2008; Stensvold et al., 2009b). There are no reports of the effectiveness of a 1:2 
combination against Blastocystis. Our findings suggest the superiority of a 1:2 
combination over a 1:5 combination with no subtype-dependent variation in 
susceptibility. We suggest that the 1:2 combination is likely to be more effective than 
the 1:5 combination in treatment of clinical infections of Blastocystis.  
Cysteine proteases play an important role in the cell cycle and pathophysiology of 
protozoan parasites. Blastocystis cysteine proteases have been reported to cleave 
human secretory IgAs (Tan et al., 2010) and to induce upregulation of 
proinflammatory cytokines (Puthia et al., 2008a). A prosurvival role of legumain, a 
cysteine protease, has also been reported recently for Blastocystis (Wu et al., 2010). 
Accumulating data in recent years suggest the therapeutic potential of protease 
inhibitors in parasitic infections (Abdulla et al., 2007; Olson et al., 1999). Several 
cysteine protease inhibitors are being investigated as potential chemotherapeutic 
agents against parasites as diverse as Plasmodium (Olson et al., 1999; Parikh et al., 
2005; Rosenthal et al., 1993), trypanosomes (Engel et al., 1999), and schistosomes 
(Wasilewski et al., 1996). In this study, we found all four isolates to be highly 
susceptible to IA, a cysteine protease inhibitor, irrespective of their susceptibility to 
Mz. These findings suggest a potential role of cysteine protease inhibitors as a 
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therapeutic option for Blastocystis isolates resistant to conventional antiprotozoal 
agents.  
PAR is a broad-spectrum aminoglycoside (Davidson et al., 2009). Although clinical 
studies suggest its effectiveness in the treatment of Blastocystis infections (Armentia 
et al., 1993; Pasqui et al., 2004; Valsecchi et al., 2004), in-vitro data are equivocal 
(Vdovenko and Williams, 2000; Yakoob et al., 2004). In this study, PAR was found to 
be ineffective against the isolates of both subtypes tested. The high clinical efficacy 
of the drug against Blastocystis could be due to its broad-spectrum antibiotic activity 
(Davidson et al., 2009). Although predominantly used for parasitic infections, PAR is 
also bactericidal (Donald et al., 2000). It might act by destruction of the gut bacterial 
flora essential for Blastocystis survival (Tan, 2008).  
All four isolates tested were found to be nonsensitive to several other broad-
spectrum antibiotics, PAR, PYR, CQ, DOX, and AMP. This feature could be exploited 
for the isolation and axenization of Blastocystis from clinical samples.  
Clinical (Stensvold et al., 2009b) and animal infection (Hussein et al., 2008b) studies, 
as well as in-vitro data (Mirza and Tan, 2009), suggest a subtype-dependent 
variation in the pathobiology of Blastocystis. Although strain-to-strain variation in 
parasite susceptibilities to drugs has been reported previously, subtype-dependent 
variation in parasite responses to chemotherapeutic agents has not been described 
before. To the best of our knowledge, this is the first study of its kind suggesting a 
variation in parasite susceptibilities to six common antiparasitic agents between 
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isolates of two subtypes known to infect humans (Stensvold et al., 2009b). It will be 
interesting to conduct a more extensive evaluation analyzing variability in the drug 
responses of different isolates across all 11 subtypes of the parasite.  
Although the vacuolar form is the most commonly reported form of the parasite, 
Blastocystis is also known to exist in amoeboid, granular, and cyst forms. Blastocystis 
cysts have been reported to be Mzr, suggesting that different forms might respond 
differently to drug pressure (Zaman and Zaki, 1996). Since there are no 
standardized methods available for maintaining axenic cultures of other Blastocystis 
forms, only vacuolar forms were evaluated in this study, limiting the application of 
our findings across different life cycle stages of the parasite. Despite this limitation, 
this is the first study suggesting subtype-dependent variation in the parasite 
response to chemotherapeutic pressure.  
In conclusion, Blastocystis spp. subtypes 4 and 7 exhibit extensive variation in 
morphology and protease activity. Considerable variations in cell size distribution 
were observed for Blastocystis sp. subtype-7. Cell size distribution and protease 
activity of different isolates vary over time and all isolates exhibit peaks in cysteine 
protease activity as well as cell size. The generation time of various isolates also 
differ significantly. There appears to be an association between cell size 
distributions, protease activity and generation time of Blastocystis cultures. 
Furthermore, this study describes two cost-effective assays for high-throughput 
antimicrobial susceptibility analysis of Blastocystis. Using one of these assays, we 
demonstrated for the first time subtype-dependent variations in the susceptibility of 
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Blastocystis to six different antiprotozoal agents. We identified 4 new potential 
therapeutic options against Blastocystis, namely, MQ, TMP-SMZ (1:2), Oz, and FUR. 
Furthermore, we confirmed the antiprotozoal activities of 10 compounds already 
reported to be effective against Blastocystis. We also demonstrated in-vitro Mz and 
EM resistance in Blastocystis. By assessing the susceptibility of the parasite to 
different 5-NIs, we also demonstrated that 5-NI resistance could be overcome in 
Blastocystis with more effective 5-NI compounds. Based on our findings, there is 
clearly a need to reevaluate currently established treatment regimens for 
Blastocystis infections. Extensive intra- and inter-subtype variations in antibiotic 
susceptibility observed in this study appears to be related to variation in parasite 
biology.  Later Chapters in this study will compare the pathological effects of these 
subtypes on colonic epithelial cells and investigate the role of cysteine proteases in 










VARIATIONS IN NITRIC OXIDE SUSCEPTIBILITY AND 
POTENTIAL FOR EPITHELIAL INOS INHIBITION 





A report on anaerobic parasite Trichomonas suggested that metronidazole 
resistance makes the organism more vulnerable to oxidative stress (Rasoloson et al., 
2001). Metronidazole-resistant (Mzr) Trichomonas strains were found to have 
inferior oxygen scavenging capacity (Rasoloson et al., 2001) even though no 
apparent changes were observed in ferredoxin or NADH oxidase activity in these 
strains.  An important part of human defense arsenal is the ability of its immune 
cells to generate oxidative/ nitrosative stress in response to microbes (Eckmann et 
al., 2000; Elnekave et al., 2003; Lewis et al., 2010). Nitrosative stress prevents 
colonization of host tissues by parasites and bacteria susceptible to nitric oxide 
(Eckmann et al., 2000; Elnekave et al., 2003; Lewis et al., 2010). A microorganism 
more susceptible to nitrosative stress will be at a disadvantage in such an 
environment (Rasoloson et al., 2001). In the previous Chapter we identified Mzr 
strains of Blastocystis. We hypothesize that, although Mz resistance helps 
Blastocystis survive antibiotic treatment, it makes these strains more susceptible to 
nitrosative stress. In order to colonize host intestine and induce pathology, these 
strains must have evolved strategies to overcome the disadvantage of higher NO 
susceptibility. This Chapter investigates NO susceptibility of Mzr, ST-7 (B) and Mzs 
ST-4 (WR-1) isolates of Blastocystis. We further explored how this strain overcomes 
this disadvantage by suppressing host NO production. 
NO plays multiple functions in human body such as maintenance of vascular tone 
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(Gkaliagkousi and Ferro, 2011), modulation of epithelial barrier function (Kuebler 
et al., 2010), as well as neurotransmission (Steinert et al., 2010). Antimicrobial 
activity of NO is reported against a wide range of prokaryotic (Major et al., 2010) as 
well eukaryotic organisms (Lloyd et al., 2003; Park et al., 1997; Ramos et al., 2007). 
A recent study suggested that NO also induces apoptosis like cell death in 
Blastocystis (Eida et al., 2008). It is suspected that the parasites, successfully 
colonizing the gut, either possess NO scavenging mechanisms like Trichomonas 
(Sarti et al., 2004) or suppress host cell NO production like Giardia (Eckmann et al., 
2000) and Entamoeba (Elnekave et al., 2003). How Blastocystis thrives in the 
intestinal lumen despite the toxicity of NO against the parasite is not known.  
Although reports of obvious mucosal inflammatory changes in human gut are 
inconclusive (Zuckerman et al., 1994), Blastocystis infections do induce a host 
immune response (Chandramathi et al., 2010b; Iguchi et al., 2009; Puthia et al., 
2008b). Recent studies have shown that the parasite causes NF-kβ mediated up 
regulation of pro-inflammatory cytokines IL-8 (Puthia et al., 2008b) in human T-84 
colonic epithelium. Up-regulation of IL-8 and GM-CSF has also been reported in the 
parasite infected HT-29 colonic cells (Long et al., 2001). Rats infected with the 
parasite also exhibited goblet cell hyperplasia and significant up-regulation of pro-
inflammatory cytokines, INF-γ and IL-12 (Iguchi et al., 2009). Amongst the potential 
host antiparasitic defense mechanisms, antibodies against Blastocystis are suspected 
to play an important role (Santos and Rivera, 2009). In mice infected with 
Blastocystis, IgA was the predominant antibody isotype in intestinal secretions 
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(Santos and Rivera, 2009). In symptomatic human Blastocystis infections an increase 
in secretory as well as humoral IgA response was also observed (Mahmoud and 
Saleh, 2003). Asymptomatic carriers showed no difference in secretory IgA 
response (Mahmoud and Saleh, 2003), suggesting that the parasite might have 
inhibited host anti-Blastocystis immune response to successfully colonize human 
gut. Evidence of the parasite cysteine proteases cleaving human secretory IgA’s 
(Puthia et al., 2005) and a higher cysteine proteases in Blastocystis isolates 
recovered from a symptomatic patients (Mirza and Tan, 2009) provide further 
evidence that the parasite is capable of modulating host immune response to its 
own advantage.  
NO in intestinal epithelial cells is produced by inducible nitric oxide synthase (iNOS) 
that catalyzes the conversion of L-arginine to reactive oxygen species of nitrogen. L-
arginine consumption by microbial arginase is considered a survival mechanism of 
pathogens against host macrophage NO response (Eckmann et al., 2000). H. Pylori 
and Entamoeba arginases were reported to limit macrophage NO production by 
consuming L-arginine (Lewis et al., 2010) in their microenvironment. Inhibition of 
iNOS activity in both conditions occur at post-transcriptional level and does not in 
volve down regulation of iNOS mRNA. On the other hand, Toxoplasma (Rozenfeld et 
al., 2005) and Leishmania (Matte and Descoteaux, 2010) infections lead to down 
regulation of iNOS mRNA expression in microglial cells and macrophages, 
respectively. Non-invasive lumen dwelling pathogens like Giardia and Blastocystis 
seldom come in contact with macrophages. Since these organisms are in close 
 90 
proximity to NO producing enterocytes they should be able to suppress intestinal 
epithelial NO production to survive in this hostile environment. Giardia is the only 
organism known to inhibit intestinal epithelial iNOS activity. It does so in the same 
manner as H. pylori and Entamoeaba in macrophages, by competing with host cells 
for L-arginine (Eckmann et al., 2000). In this study we investigated whether 
Blatocystis also inhibits epithelial NO production and discuss possible mechanisms 
employed by the parasite to evade nitrosative stress generated by the host 
epithelium. 
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3.2 MATERIALS AND METHODS 
3.2.1 Culture of Caco-2 colonic epithelial cell line 
All Blastocystis-host interaction experiments were performed using Caco-2 human 
colonic cell line (ATCC). Caco-2 stock cultures were maintained in T-75 flasks in a 
humidified incubator with 5% CO2 at 37°C. Cell cultures were grown in Dulbecco’s 
modified Eagle’s medium (HyClone) supplemented with 10% heat-inactivated fetal 
bovine serum (HyClone) and 1% each of sodium pyruvate, MEM and antibiotic 
“Pensterp” (Gibco). Culture health was evaluated using trypan blue assay and only 
cultures with >95% viability, were used for the experiments. Cells were trypsinzed 
with 0.25% trypsin-EDTA. Cell cultures for PCR experiments were grown on 
standard cell culture 6-well plates (corning). For Blastocystis induced nitric oxide 
production inhibition experiments, cells were grown on Millipore transwell filters 
with PET membranes of 3 micron pore size, placed in 24-well tissue culture plates. 
Since epithelial NO production varies with maturity of the cells, to measure health 
and maturation of Caco-2 epithelium, the transepithelial resistance (TER) of the 
monolayers were assessed once every 3 days till they reach maturity on day 21 
(TER ~ 1000 Ω/cm2). In order to synchronize cells before experiments, all cultures 
were serum-starved overnight in antibiotic free and serum free DMEM. For cytokine 
stimulation experiments, a cytokine cocktail comprising of a combination of 20 
ng/ml human IL-1α, 20 ng/ml human TNF-α, and 50 ng/ml human IFN-γ (Sigma) 
was added to cultures.  
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3.2.2 Parasite culture and lysates 
Blastocystis ST-7 (B) and ST-4 (WR-1) cultures were maintained as described 
previously (2.2.1). For arginase assay, parasite lysates were prepared as described 
by the QuantiChrom Arginase Assay Kit (DARG-200) manual. In short, parasites 
were suspended in 10mM Tris-HCL (pH 7.4) containing 1μM pepstatin A, 1μM 
leupeptin, and 0.4% (w/v) Triton X-100. Samples were centrifuged at 20,000g at 
4°C for 10 min. Supernatant was used for arginase assay. 
3.2.3 Parasite viability assay 
The optimized Blastocystis viability assay described in Chapter 2 was used to 
measure NO toxicity. IC-50’s of nitric oxide donors, sodium nitroprusside (SNP), S-
nitroso-N-acetyl-penicillamine (SNAP), S-nitrosoglutathione (GSNO) and sodium 
nitrite (NaNO2) was against Mzr and Mzs isolates, ST-7 (B) and ST-4 (WR-1) 
respectively. Stock solutions of all NO-donor compounds were prepared in DMSO 
and are diluted in pre-reduced Blastocystis media and transferred to 96-well plates. 
0.5 × 106 cells/ well were incubated for 24 h with different dilutions of NO-donor 
agents, ranging between 0-100 μg/ml. Final DMSO concentration was kept constant 
at 0.5% in each well, while the total volume per well was kept constant at 200 μl. 
After 24 h exposure, resazurin solution (Sigma) was added to each well at a final 
concentration of 10% v/v. 3 h after incubation, fluorescence readings of resazurin 
were taken at 550 nm excitation and 570 nm emission wavelengths using TECAN 
Infinite M200 reader. 
3.2.4 Confocal microscopy (annexin-FITC/PI staining) 
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Confocal micrographs were taken to confirm NO cytotoxicity against Blastocystis 
reported by resazurin assay by observing typical morphological features of cell 
death in nitrosative stress exposed parasites,. ST-7 was treated for 24 h with a 10-
µg/ml concentration of SNAP. After drug exposure, the parasites were washed and 
re-suspended in annexin V binding buffer (BioVision). Annexin V and propidium 
iodide (PI) (BioVision) were then added to the cell suspension. Confocal imaging of 
cell suspensions was done using an Olympus Fluoview FV1000 (Japan) equipped 
with a dual filter set for fluorescein isothiocyanate (FITC) and rhodamine. Images 
were captured using Olympus Fluoview version 1.6b. 
3.2.5 Determination of nitrite/nitrate in culture supernatants: 
For estimation of reactive NO species produced by Caco-2 after 24 h, culture 
supernatant was collected from apical compartments of the transwell set-up. Before 
testing NO concentration, post-incubation viability of all Caco-2 cultures was 
confirmed using trypan blue assay and only supernatant of inserts with >95% viable 
cells were used. 2,3-Diaminonaphthalene (DAN) reacts with NO2 to give a 
fluorescent product naphthotriazole. To determine levels of the stable NO end 
products nitrite and nitrate, nitrate was first reduced to nitrite by incubating the 
samples for 60 min at room temperature with 0.05 U/ml nitrate reductase in the 
presence of ß-NADH and FAD. 2,3- DAN was then incubated with the sample for 15 
mins at room temperature. After the incubation, fluorescent product of the reaction 
between DAN and nitrite – naphthotriazole - was measured by ELISA reader at 
excitation and emission wavelengths of 360 and 415 nm respectively. 
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3.2.6 Real-time PCR 
Total RNA was extracted from Caco-2 cultures using the RNeasy Mini Kit (Qiagen, 
Chatsworth, CA), following the manufacturer’s instructions. iNOS gene expression 
was quantified by real-time RT-PCR reaction using the SYBR Green PCR Master Mix 
System (Qiagen, Chatsworth, CA, USA) on PCR thermocycler Stratagene MX3000P 
(Stratagene, La Jolla, CA, USA). cDNA samples (2µl for a total volume of 20 µl per 
reaction) analyzed for gene of interest were normalized to reference gene β-actin . 
The level of expression of iNOS in each sample was then calculated as 2-∆∆Ct. All 
samples were repeated at least three times. Real-time RT-PCR was performed at 
95oC for 15 minutes followed by 40 cycles of 15 seconds denaturation at 94oC, 30 
seconds annealing at 55oC, and 30 seconds elongation at 72oC. We used following 
iNOS primers: forward 5'-GGC CCC ACA CCC CAC CAG AC-3' and reverse, 5'-GCC AGG 
CCC GAT GAG GAT G-3'. 
3.2.7 Arginase assay 
QuantiChrom Arginase Assay Kit/DARG-200 (BioAssay System) was used to 
measure parasite arginase activity, following the manufacturer’s instructions. In 
short, 40 μl of parasite lysate (2, 4, 6 or 8 x 107 cells) was co-incubated with 10 μl of 
5x L-arginine substrate buffer in a standard clear bottom 96-well plate (Corning) for 
2 h at 37°C. 40μl sample without substrate buffer (sample blank control, ODsample), 
50 μl H2O (standard background, ODbackground) or 50 μl 1 mM urea standard 
(ODstandard) were added in separate wells as controls. To stop the reaction and to 
calculate final urea concentrations, add 200 μl of urea reagent to all wells and 10 μl 
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of 5x L-arginine substrate buffer to sample blank control. The plate was tapped 
gently and incubated for 60 mins at room temperature. After incubation optical 
density was measured at 430 nm. Arginase activity (unit/liter) of the sample was 
calculated as; 
Arginase Unit = ODsample - ODblank / ODstandard – ODwater x [Urea Standard] x 50 x 103 / 
(40 x t)  
Where,  
ODsample, ODblank, ODstandard and ODwater are optical density values of sample, sample 
blank, standard and water, respectively 
[Urea Standard] = 1 mM 
t = reaction time (120 min) 
50 and 40 are reaction volumes. 
1 unit of arginase converts 1 μmole of L-arginine to ornithine and urea per minute at 
pH 9.5 and 37°C). 
3.2.8 Statistical analysis: 
To determine statistical significance of the data, ANOVA test was used. 
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3.3 RESULTS 
3.3.1 Variation between ST-4 (WR-1) and ST-7 (B) susceptibility to nitrosative 
stress 
It was previously reported that nitrosative stress induces apoptosis like features in 
Blastocystis (Eida et al., 2008). We are reporting for the first time that Blastocystis 
ST-4 (WR-1) and ST-7 (B) are susceptible to nitrosative stress (Table 3.1). With the 
exception of NaNO2, 24 h exposure to common NO donors killed both Blastocystis 
isolates at concentrations known to suppress growth of other parasites (Fernandes 
and Assreuy, 1997; Ramos et al., 2007) (Table 3.1). Susceptibility to SNAP, GSNO 
and NaNO2, varied between the two isolates tested (Table 3.1). ST-7 (B), reported in 
the previous Chapter to be resistant to Mz, was more susceptible to all these NO 
donors compared to Mzs ST-4 (WR-1) (Table 3.1). IC-50’s of ST-7 B to SNAP, GSNO 
and NaNO2 were, 5.86±1.83, 36.66±3.78 and 54±16.16 μg/ml respectively (Table 
3.1). IC-50’s for SNAP and GSNO against ST-4 WR-1 were, 17.2±7.37 and 83.33±2.49 
respectively, while NaNO2 had no effect on ST-4 (WR-1) even at the highest tested 
concentration of 100μg/ml (Table 3.1). SNP had similar effect against both isolates. 
ST-7 (B) and ST-4 (WR-1) was calculated to be 2.07±0.43 and 2.03±0.68 μg/ml 
respectively (Table 3.1). Overall, these findings suggest that compared to ST-4 (WR-
1) ST-7 (B) is better equipped to cope with nitrosative stress. Lack of variation in 
ST-4 (WR-1), and ST-7 (B) susceptibility as well as considerably lower IC-50 values 
of SNP (Table 3.1) might be due to toxicity of cyanide derivatives produced by this 
compound (Thomas et al., 2009).  
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Blastocystis also exhibited features of apoptosis and/or necrosis as early as 3 h after 
exposure to 10μg/ml of SNAP (Fig. 3.1). Blastocystis ST-7 (B) cultures exposed to 
nitrosative stress exhibited an increase in number of cells binding to either annexin-
FITC alone or to annexin-FITC and PI both (Fig 3.2). Annexin binds to exposed 
phophotidylserine (PS) in apoptotic cells. Permeability of cells to PI suggests 
necrosis.  
3.3.2 Infection of intestinal epithelial cells by ST-7 (B) inhibited apical NO 
release. 
Blastocystis is a non-invasive luminal parasite. Under physiological conditions, only 
apical side of the polarized intestinal epithelium comes in contact with Blastocystis. 
Apical infection of polarized epithelial monolayers with 2 or 3 x 107 parasites of ST-
7 (B), resulted in significant inhibition of apical NO release by the enterocytes (p-
value 0.01) (Fig. 3.2). Interestingly, no change in NO release was observed in ST-4 
(WR-1) infected epithelium (Fig. 3.2). The ability of ST-7 (B) to suppress host 
antiparasiticidal NO response, might provide it an advantage over other strains to 
colonize the hostile intestinal lumen.  
Cytokine stimulation of the epithelium was provided from the basolateral side. 
Cytokines IL-1α, TNF-α, and IFN-γ used for these studies are physiologically 
produced by cells, such as T cells, NK cells, and macrophages, found in the intestinal 
lamina propria underlying the epithelium. Apical infection with ST-7 reduced the 
cytokine stimulated, epithelial NO production by >60% (Fig 3.3).  This suggests that 
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Blastocystis ST-7 (B) not only inhibits baseline NO production but also prevents NO 
production by other pro-inflammatory stimuli. 
3.3.3 iNOS down regulation. 
To identify the role of iNOS in the Blastocystis-induced inhibition of epithelial NO 
production, we quantified the expression of iNOS mRNA in ST-7 (B) and ST-4 (WR-
1) infected Caco-2 cells (Fig 3.4). ST-7 (B) infection significantly inhibited epithelial 
iNOS expression at 6 and 12 h post-infection time points (p-values 0.01) (Fig 3.4). 
ST-4 (WR-1) did not have any effect on epithelial iNOS expression. 
3.3.4 Variation in arginase activity between ST-7 (B) and ST-4 (WR-1) isolates. 
Arginase-deficient H. Pylori strains do not inhibit iNOS macrophages, making them 
more susceptible to host NO defense. In our experiments, L-arginine degradation by 
ST-7 (B) was found to be significantly higher (5-6 times) compared to ST-4 (WR-1) 
(Fig 3.5). In the previous section we found that ST-7 and not ST-4 inhibit epithelial 
iNOS. These findings suggest that iNOS inhibition by Blastoycstis might be associated 
with its arginase activity. Although more experiments are needed, perhaps the 
higher arginase activity of ST-7 (B) helps the parasite to evade host NO defense 
response.
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Table 3.1: Table stating IC-50’s of anti-Blastocystis activity of NO donors 
 ST-7 (B) ST-4 (WR-1) 
NO-Donors μg/ml μM μg/ml μM 
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a  SNP is Sodium nitroprusside 
b  SNAP is S-nitro-acetyl-penicillamine  
c  GSNO is S-Nitrosoglutathione 





Figure 3.1. Confocal micrographs illustrating cell-death features of Blastocystis 
under nitrosative stress. Blastocystis ST-7 (B) was cultured under normal parasite 
culture conditions, in the presence of 10 μg/ml of SNAP. Features of necrosis 
(yellow arrows) and programmed cell death (red arrows) were observed as early as 
3 h incubation with NO donor. Necrotic cells incorporated both PI and annexin-V-
FITC stain. Blastocystis undergoing PCD, bind annexin-V-FITC alone. Very few dying 
cells were observed in SNAP free cultures of the parasite. Micrographs are 
representative of 6 pictures taken in two separate experiments, triplicate each. 
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Figure 3.2. Graph representing NO production by Blastocystis-infected Caco-2 
intestinal epithelium. Blastocystis ST-4 (WR-1) or ST-7 (B) were incubated with, 
21 days old mature and polarized Caco-2 intestinal epithelial monolayers on a 
traswell set-up. 24 h post infection, samples of co-culture media from apical 
compartments were analyzed for nitrate and nitrite concentration. Incubation with 
parasite concentrations of 2 as well as 4 x 107 cells of ST-7 (B) per well, significantly 
reduced apical NO secretion of intestinal epithelium (p-values < 0.01). ST-4 (WR-1) 
did not alter the baseline NO concentration significantly. Viability of monolayers 
remained > 95% during infections. Error bars represent, standard error of 6 























Figure 3.3. Graph representing NO production by Caco-2 intestinal epithelium. 
24 h post infection, Blastocystis ST-7 (B) significantly inhibited antiparasitic 
epithelial NO production (p-value < 0.01). Stimulation of Caco-2 epithelium with 
pro-inflammatory cytokine cocktail (IL-8, INF-γ and TNF-α) from the basolateral 
side, significantly increased NO-production by Caco-2 epithelium. Blastocystis ST-7 
(B) infection reduced cytokine stimulated NO up-regulation by > 50%. Error bars 




























# P-value < 0.01 
## P-value <0.01 
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Figure 3.4. Graph representing down regulation of epithelial iNOS expression 
by Blastocystis ST-7 (B) infection. Caco-2 iNOS mRNA levels were quantified by 
real-time PCR. As expected, significant, time-dependent reductions in iNOS mRNA 
levels were observed in Caco-2 epithelium after 6 and 12 hr infections with ST-7 (B) 
(p values <0.01), while ST-4 (WR-1) infected Caco-2 monolayers remained 
unaffected. These results are consistent with our earlier findings that Blastocystis 
ST-7 (B) inhibit antiparasitic NO production by intestinal epithelium. Error bars 


















Figure 3.5. Arginase activity of Blastocystis ST-4 (WR-1) and ST-7 (B). (a) 
Lysate of 6 x 10 7 Blastocystis isolate (ST-7 (B) cells showed significantly higher 
arginase activity compared to ST-4 (WR-1) (p-value <0.05). 5 mins incubation of the 
parasite lysates to 95°C temperature completely inhibited arginase activity. (b) Cell 
density dependent increase in arginine degradation by parasite lysate was observed 
in ST-7 (B), while arginase activity of ST-4 (WR-1) did not change much between 
lysates of 2 x 107 and 8 x 107 parasites. These findings suggest that higher arginine 
degradation by Blastocystis ST-7 (B) might be responsible for epithelial iNOS 


















































Figure 3.6. Illustration summarizing potential mechanisms of host NO 
response inhibition by Blastocystis. The parasite evades host nitric oxide 
antiparasitic response by either competing for l-argninine, a crucial substrate for 
epithelial iNOS to produce nitric oxide or by directly inhibiting iNOS.
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3.4 DISCUSSION 
Our findings suggest that Blastocystis directly inhibits the NO-mediated antiparasitic 
response of host cells. Parasiticidal nitrosative stress generated by host epithelium 
is significantly inhibited by a Blastocystis isolate found to be pathogenic as well as 
Mzr in the previous Chapters.  In this study we identified a possible association of 
NO susceptibility with Mz resistance. Moreover, a possible role of Blastocystis 
arginase as a potential virulence factor was demonstrated. Blastocystis is known to 
induce epithelial pathology in humans as well as zoonotic hosts with frequent 
reports of chronic and recurrent infections (Boorom et al., 2008; Gupta and Parsi, 
2006; Tan et al., 2010). In order to survive in the hostile microenvironment close to 
NO producing enterocytes, our study suggests that the Blastocystis ST-7 (B) has 
evolved an interesting immunosuppressive mechanism.  
Our findings suggest that Blastocystis is susceptible to NO and signs of both necrosis 
and apoptosis like cell death were observed in the parasite as early as 3 h after 
exposure to nitrosative stress. Cytotoxicity and therapeutic potential of NO against a 
range of microbial agents is well established (Lloyd et al., 2003; Park et al., 1997; 
Ramos et al., 2007). NO prevents growth as well as encystation of Giardia (Eckmann 
et al., 2000), while it induces apoptosis like features in Entamoeba (Ramos et al., 
2007). One report suggests that Blastocystis, when exposed to NaNO2 undergoes 
apoptosis like cell death (Eida et al., 2008). Our study provides a detailed 
cytotoxicity analysis of NO donors against two clinically significant Blastocystis 
subtypes. Mzr clinical strain of Blastocystis ST-7 (B) as well as Mzs ST-4 (WR-1) 
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reported in the previous Chapter (Mirza et al., 2011) were found to be susceptible to 
most of the NO donors tested at concentrations reported for other parasites. 
Interestingly, compared to ST-4 (WR-1), Mzr ST-7 (B) was found to be 2 and 3 times 
more susceptible to GSNO and SNAP respectively, and NaNO2 was effective against 
ST-7 (B) alone at the concentrations tested. This suggests a superior NO scavenging 
ability of Mzs ST-4 (WR-1) Blastocystis.  This might help its survival in NO rich 
intestinal lumen. ST-7 (B), on the other hand is able to escape Mz chemotherapy due 
to defective oxygen scavenging mechanisms as seen in metronidazole-resistant 
Trichomonas (Rasoloson et al., 2001), but this compromises its ability to cope with 
nitrosative stress. 
Although higher NO susceptibility of Blastocystis ST-7 (B) makes its survival difficult 
in the gut lumen, this isolate has developed an interesting survival mechanism. In 
this study, Blastocystis ST-7 (B) inhibited epithelial NO production by down 
regulating epithelial iNOS expression. Several bacteria and parasites have evolved 
mechanisms to thrive in the gut lumen (Eckmann et al., 2000; Lewis et al., 2010). 
Parasites such as Entamoeba (Elnekave et al., 2003) and bacteria like H. Pylori 
(Lewis et al., 2010) significantly inhibit macrophage NO production. Since 
Blastocystis is non invasive, it does not come in direct contact of macrophages. 
Similar to Giardia, Blastocystis inhibited host epithelial NO production (Eckmann et 
al., 2000). Epithelial NO inhibition might help ST-7 (B) to colonize and induce host 
pathology and help it overcome the disadvantage of increased susceptibility to 
nitrosative stress. 
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H.pylori, Giardia and Entamoeba inhibit host NO response by competing with host 
cell iNOS for the crucial substrate L-arginine (Eckmann et al., 2000; Elnekave et al., 
2003; Lewis et al., 2010). Bacterial and parasitic arginase are known to modulate 
epithelial NO production by limiting L-arginine availability (Elnekave et al., 2003; 
Lewis et al., 2010). Arginase deficient strains of H. Pyolri were not able to inhibit NO 
production by macrophages (Lewis et al., 2010). Simmilarly, Blastocystis ST-7 (B) 
isolates, with 3 times higher arginase activity, inhibited NO production while ST-4 
(WR-1) with limited arginase activity did not. A strain-to-strain variation in 
Blastocystis pathogenesis has been reported (Hussein et al., 2008b; Mirza and Tan, 
2009; Stensvold et al., 2009b). These findings suggest that, apart from cysteine 
proteases activity (potential virulence factor) observed in Chapter 2 amd Mz 
susceptibility observed in Chapter 3, ST-7 (B) also differs from ST-4 (WR-1) in its 
ability to inhibit epithelial NO production and it might involve parasite arginases. 
Interestingly, however like Toxoplasma and Leishmania infected host cells, we 
observed a down-regulation of iNOS mRNA expression in Blastocystis ST-7 (B) 
infected enterocytes. Reduction in L-arginine bioavailability by H.pylori arginase 
does not inhibit iNOS mRNA levels (Lewis et al., 2010). In fact l-argnine 
bioavailability controls nitric oxide production at post transcriptional level without 
effecting iNOS mRNA levels in the cell (Lee et al., 2003). Although iNOS inhibiting 
Blastocystis ST-7 (B) possesses much higher arginase activity compared to ST-4 
(WR-1), our results suggest that inhibition of NO production by ST-7 (B) might not 
just be due to degradation of L-arginine by the parasite, but involve some other 
unknown host immunmodulatory mechanisms. Characterization of Blastocystis 
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arginases as well as further dissection of host epithelial pathways modulated by the 
parasite will give us a better idea of how Blastocystis escapes epithelial NO response.  
An earlier study reported increased NO concentration in various tissues of mice 
infected with Blastocystis (Eida et al., 2008) as opposed to iNOS inhibition observed 
in our study. Host-specificity has been reported in Blastocystis (Iguchi et al., 2007) 
and since mice are not considered a natural host for the parasite (Tan, 2008) 
increase NO in mice tissues is not surprising. NO is an indiscriminate, innate 
immune response, and introduction of new organism to the gut flora would lead to 
NO up-regulation in the host. Moreover, increase in NO was observed in mice 
caecum and ileum but the study (Eida et al., 2008) did not report NO concentration 
of colon, the part of gut colonized by the parasite. Our infection model might be 
more physiologically relevant since the experiments were performed on the colonic 
epithelium of a natural Blastocystis host. 
To conclude, this is the first study highlighting the ability of Blastcystis to manage 
antiparasitic host NO defense. ST-4 (WR-1) isolate was found to be more efficient in 
coping with nitrosative stress. ST-7 (B), although more susceptible to nitrosative 
stress, exihibited significantly higher arginase activity, compared to ST-4 (WR-1). 
This strain also inhibited epithelial iNOS. Lower NO concentration not only helps ST-
7 (B) to escape host defenses, but it might also assist other pathogens to evade 
nitrosative stress and colonize the gut lumen. Further understanding of 
immunosuppressive mechanisms employed by Blastocystis would help in the 
development of therapeutic strategies for effective treatment of Blastocystis 
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infections, such as restoration of physiological intestinal L-arginine concentration or 







BLASTOCYSTIS CYSTEINE PROTEASES INDUCE 
INTESTINAL EPITHELIAL BARRIER DYSFUCTION IN 
A STRAIN-DEPENDENT MANNER  
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4.1 INTRODUCTION 
A limited understanding of the parasite’s life cycle and virulence factors (Tan et al., 
2010) as well as a high percentage of asymptomatic carriers (Tan et al., 2010) cast 
doubts over the pathogenic potential of Blastocystis. An appropriate infection model 
for Blastocystis has not been developed yet, although several attempts have been 
made in the past (Hussein et al., 2008a; Iguchi et al., 2007; Iguchi et al., 2009). The 
absence of a disease model for the parasite is one of the primary reasons why major 
clinical questions associated with Blastocystis infection have not been resolved thus 
far (Tan et al., 2010). 
As described in Chapter 1, Blastocystis is a species complex with most of the parasite 
subtypes exhibiting zoonotic potential. Apart from humans, other common hosts of 
Blastocystis are rats, pigs and chicken (Iguchi et al., 2007; Navarro et al., 2008; 
Tanizaki et al., 2005), and the parasite exhibits zoonoses. Contact with animals 
increases the risk of Blastocystis infections (Stensvold et al., 2009b). We observed in 
Chapters 2 that different subtypes of the parasites differ in their cell biology, as well 
as their response to chemotherapy. We also observed in Chapter 3 a variation in the 
ability of Blastocystis isolates from different subtypes to modulate antiparasitic, host 
NO response. Clinical reports also suggest a variation in their ability to cause 
symptomatic infections (Stensvold et al., 2009b). Subtype- or strain-dependent 
variation in virulence of the parasite has been reported in clinical and animal 
infection studies (Hameed et al., 2011; Hussein et al., 2008a; Iguchi et al., 2007; 
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Meloni et al., 2011; Stensvold et al., 2009b), but there is little understanding of the 
cellular mechanisms of this variation. 
Modulation of intestinal epithelial barrier function is one of the major mechanisms 
employed by pathogens to induce host pathology. Organisms ranging from viruses 
(Epple et al., 2009) to bacteria (Matysiak-Budnik et al., 2004) as well as parasites 
such as Giardia (Troeger et al., 2007) and Entamoeba (Rawal et al., 2005) are known 
to compromise epithelial barrier function. Compromise of epithelial barrier function 
exposes the sub-epithelial tissue to toxic luminal contents (Turner, 2009), which 
could lead to dire consequences for the host. There is ample evidence suggesting 
that Blastocystis causes intestinal epithelial barrier compromise (Chandramathi et 
al., 2010b; Hussein et al., 2008a; Puthia et al., 2006), but these findings are limited to 
rodents. So far there is limited knowledge, if any, about the cellular mechanisms 
employed by the parasite to cause human epithelial dysfunction. 
An important event leading to pathogen induced epithelial barrier compromise is 
the reorganization of apical tight junction protein complex (Turner, 2009). 
Pathogens employ different mechanisms to modulate the functional localization of 
tight junction proteins (Chin et al., 2002; da Costa et al., 2005; Lauwaet et al., 2004; 
Scott et al., 2002). Actin-cytoskeleton anchoring tight junctions at their apical 
location are reported to be rearranged by Blastocystis in rat epithelium (Puthia et al., 
2006) but expression of ZO-2, a protein associated with tight junctions was not 
found to be up-regulated in a rodent model (Iguchi et al., 2009). So far there is no 
direct evidence suggesting that Blastocystis modulates epithelial tight junctions and 
 114 
a variation in the ability of different Blastocystis strains to induce human epithelial 
barrier compromise has not been observed yet.  
Cysteine proteases play diverse roles in Blastocystis pathobiology (Nasirudeen et al., 
2001; Puthia et al., 2008a; Puthia et al., 2005; Wu et al., 2010; Yin et al., 2010a). In 
Chapter 2 we observed using the high-throughput viability assay that cysteine 
protease inhibition leads to parasite death. These are also suspected to be parasite 
virulence factors (Puthia et al., 2005; Puthia et al., 2008b; Tan et al., 2010). Not only 
do they cleave human secretory IgAs (Puthia et al., 2005), but cysteine proteases are 
also implicated in activation of NF-κB in colonic epithelium, leading to pro-
inflammatory cytokine IL-8 up-regulation (Puthia et al., 2008b). Cysteine proteases 
derived from microbes are known to regulate epithelial barrier function (Groeger et 
al., 2010; Lauwaet et al., 2004; Li et al., 1994). In this Chapter we examined the role 
of cysteine proteases in Blastocystis-induced epithelial barrier dysfunction in human 
colonic cell line. Experiments in the Chapter 2 suggested inter- and intra- subtype 
dependent variation in Blastocystis cyteine protease activity. Our experiments also 
examined whether these isolates differ in their pathogenic potential of these isolates 
as well. 
 In order to understand the variation in human pathogenicity of clinically important 
Blastocystis subtypes this study uses an epithelial model, closely mimicking human 
intestinal conditions. Using this Caco-2 cell line based model we are reporting for 
the first time that Blastocystis ST-7 (B) induces breakdown of epithelial barrier 
function as well as rearrangement of ZO-1, a tight junction associated protein, in 
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human enterocytes. Inhibition of ST-7 (B) cysteine proteases prevented parasite 
mediated epithelial pathology. On the other hand, ST-4 isolates (WR-1 and S-1) and 
ST-7 isolate E of ST-did not cause epithelial barrier dysfunction.  
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4.2 MATERIALS AND METHODS 
4.2.1 Culture of Caco-2 colonic epithelial cell line 
All Blastocystis-host interaction experiments were performed using Caco-2 human 
colonic cell line (ATCC). Caco-2 stock cultures as well as cultures on transewll set-up 
and converslips were maintained as described in Chapter 2. Cytochalasin-D (Sigma) 
was used as a positive control for epithelial resistance and permeability and ZO-1 
rearrangement experiments at a concentration of 2 μM. 
4.2.2 Parasite culture and lysate 
Parasite cultures were maintained and lysates were prepared as described in 
Chapter 2. Unless stated otherwise, monolayers in all experiments were treated 
with 108parasite/ml lysate or live cells. For cysteine proteases inhibition 
experiments, Blastocystis lysates were incubated with 50µM of cysteine protease 
inhibitor E-64 (Sigma) for 1 hr at 37°C before being added to the Caco-2 cultures.  
Unless stated otherwise, lysates instead of live parasite were used in our 
experiments. There are a few reasons why we preferred lysates over live parasites.  
 Live parasites interfere with transepithelial resistance readings, during 
epithelial barrier function analysis (Figs. 4.1, 4.3 and 4.4).  
 Cysteine protease inhibition can alter Blastocystis physiology and can even 
lead to parasite death as discussed in Chapter 2. Expected rescue of parasite-
induced epithelial pathology by inhibition of parasite cysteine proteases in 
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live cells might be due to altered parasite physiology instead of specific 
inhibition of cysteine proteases.  
 Lysates are commonly used in host-pathogen interaction studies (Chin et al., 
2002; Lewis et al., 2010). Previous studies (Puthia et al., 2008b; Puthia et al., 
2006) as well as one of the experiments in this chapter (Fig. 4.6) also 
suggested that host pathology induced by Blastocystis lysates and live cells 
exhibit a similar trend.  
4.2.3 Transepithelial electrical resistance 
Transepithelial resistance (TER) across Caco-2 monolayer was measured using 
Millipore-ERS-2 Volt-Ohm-Meter (Fig. 4.1). Caco-2 monolayers were grown on 
Millipore transwell system as described above and TER was measured every 
alternate day until it peaked (~ day 21) (1000 Ω cm2). Blastocystis ST-7 and ST-4 
isolates were co-incubated with epithelium for 3, 6, 12 and 24 h. For dose 
dependent experiments, monolayers were coincubated with 0.25 to 2 × 108 
parasites/ml for 24 h. After incubation monolayers were carefully washed with 
Hank’s balanced salt solution (HBBS) twice. 200 μl of warm media was added to the 
apical compartment before taking TER measurements. All measurements were done 
at 37° C to minimize fluctuations. 
4.2.4 Epithelial permeability 
Caco-2 monolayers were cultured on transwell system as explained earlier till they 
reach confluency and tight junction maturation on day 21. After confirmation of 
maturation by TER measurement, monolayers were co-incubation with parasite for 
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24 h. Following co-incubation, epithelial and basolateral compartments were 
washed twice, followed by addition of 400 μl of warm HBSS at the bosolateral 
compartments and 200 μl of 100μg/ml FITC-conjugated Dextran 4000 solution in 
HBSS to apical compartments. After 3 h, 300 μl of basolateral HBSS was transferred 
to a 96-well plate (corning) to estimate Dextran-FITC flux across monolayers.  
Fluorescence was measured using ELISA reader (Tecan Infinite M200) at excitation 
and emission wavelengths of 492 and 512 respectively.  
4.2.5 Immunohistochemistry and confocal microscopy 
For immunohistochemistry experiments focusing on ZO-1 rearrangement in Caco-2 
cells, monolayers were incubated with Blastocystis for 6 h. After coincubation, 
monolayers were washed twice and fixed with 3.5% (w/v) formaldehyde in PBS. 
Cell were then washed and incubated overnight with 1000 × dilution of primary 
anti-body against ZO-1 tight junction protein (Sigma) (1:1000 in PBS) at 4°C.  
Monolayers were then washed thrice with PBS and incubated for 1 h with 
fluorescent-tagged secondary antibody, followed by another round of washing. After 
treatment, cells were washed and fixed as described above. Hoescht DNA stain 
(Sigma) was added to all monolayers before they were mounted. Monolayers were 
mounted on glass slides using fluorescence mounting media (VECTASHIELD) before 
being observed under confocal microscope (Olympus BX60; Olympus, Japan). 
ImageJ software was used for image analysis.  
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4.2.6 Statistical analysis 
To confirm the statistical significance of our results ANOVA test was used. 
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4.3 RESULTS 
4.3.1 Strain-to-strain variation in Blastocystis induced drop in Caco-2 TER 
Blastocystis ST-7 (B) induced a dose and time dependent drop in Caco-2 TER (p-
values < 0.01) (Figs. 4.3 and 4.4). A significant drop in Caco-2 TER was observed as 
early as after 3 h of co-incubation (p=value < 0.01). Minimum dose of 0.25 × 108/ ml 
of ST-7 (B) induced a significant drop in epithelial resistance (Fig.  4.3). ST-7 isolate 
E as well as ST-4 isolates WR-1 and S-1 did not cause a significant change in Caco-2 
TER (Fig. 4.3), even at the highest parasite dose (2 × 108) (Fig. 4.3). This suggests a 
strain-to-strain variation in parasite-induced drop in Caco-2 TER. 
4.3.2 Blastocystis ST-7 (B) induces an increase in Caco-2 epithelial 
permeability to FITC conjugated Dextran 
In order to confirm the parasite-mediated epithelial dysfunction, suggested by drop 
in TER, we measured the flux of Dextran-FITC probe, across Caco-2 monolayers (Fig. 
4.5 and 4.6). As expected, a significant increase in epithelial permeability was 
observed when 108 parasites/ml of ST-7 (B) lysate and live cells (Figs. 4.6) were co-
incubated with Caco-2 for 24h (p-values 0.01) (Fig. 4.4). Similar to the TER 
experiment, lysates of ST-7 (E) and both ST-4 isolates had no effect on monolayer 
permeability (Fig. 4.5). 
4.3.3 Blastocystis ST-7 (B) cysteine proteases induce ZO-1 rearrangement in 
Caco-2 
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Compromise of epithelial barrier function observed in this study, is often associated 
with alterations of tight junction proteins. In this study we observed that 
Blastocystis ST-7 (B) induced an alteration in tight junction protein complex in 
conjunction with epithelial barrier dysfunction. Confocal micrographs suggest that 
exposure of Caco-2 monolayer to ST-7 (B) lysates, induced a decrease in ZO-1 
antibody binding to the apical junctional ring of the epithelium compared to 
negative controls (Figs. 4.7, 4.8, 4.9).  
4.3.4 Inhibition of Blastocystis ST-7 (B) cysteine proteases prevented Caco-2 
epithelial barrier dysfunction 
In a previous study, inhibition of Entamoeba cysteine proteases by E-64, prevented a 
drop in infected Caco-2 TER (Li et al., 1994). In this study, treatment of Blastocystis 
ST-7 (B) with E-64 significantly prevented parasite induced TER drop (p-value < 
0.01) in Caco-2 cell line (Fig. 4.4). Similarly, parasite induced increase in epithelial 
permeability to Dextran-FITC was prevented by ST-7 (B) cysteine protease 
inhibition (p-value < 0.01) (Fig. 4.6). Furthermore, loss of the tight junction protein 
ZO-1, was also prevented by pretreatment of Blastocystis ST-7 (B) lysate with E-64 
(Figs. 4.7, 4.8, 4.9). Altogether these findings suggest that intestinal epithelial barrier 
function is modulated by cysteine proteases of Blastocystis ST-7(B).  
E-64 is a broad spectrum cysteine protease inhibitor. Inhibition of host caspase, 
might be a possible mechanism through which E-64 could prevent epithelial barrier 
dysfunction. To exclude this possibility, uninfected Caco-2 cells were pretreated 
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with E-64 for 1 h before addition of staurosporine. No rescue of staurosporine-





Figure 4.1.Experimental set-up of epithelial barrier function model for 
Blastocystis-host interaction studies. Caco-2 monolayers were cultured on 
hanging inserts fitted with porous membrane and placed on a 24 well plate.In these 
conditions, mature Caco-2 cultures polarize with distinct apical and basolateral 
compartments. After 21 days, Caco-2 cells mature and start mainting a constant 
transepithelial resistance (TER), suggesting maturation of tight junction complex. 
TER can be measured by electrodes connected to an electrovoltohmeter (explained 
in appendix I).  
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Figure 4.2: Illustration representing gate function of ZO-1 tight junction 
protein at the epithelial barrier. Tigh junction complex are located at the apical 
side of polarized epithelial cells. They guard the paracellular space, limiting the 
exposure of subepithelial tissue to luminal contents. Tight junction complex 
comprise of transmembrane proteins such as claudins and occludin anchor to the 
actin cytoskeleton (green) via zonnula occludin (ZO-1). Laterations in cytoskeletal 




Figure 4.3. Dose-dependent effect of Blastocystis ST-4 and ST-7 isolates on 
transepithelial resistant (TER) of Caco-2 cell monolayers. Confluent monolayers 
were co-incubated with varying doses of ST-4 and ST-7 isolates for 24 h. Compared 
to negative control Blastocystis ST-7 (B) induced a significant drop in Caco-2 TER at 
0.25, 0.5, 1 as well as 2 ×108parasite/ml (p-values < 0.01). None of the other isolates 
tested exhibited any significant changes in Caco-2 TER even at the highest lysate 
























Figure 4.4. Time-dependent drop in Caco-2 TER by Blastocystis ST-7 (B) 
cysteine proteases. Confluent monolayers of Caco-2 cells were incubated with ST-7 
(B) after pretreatment of parasite lysate with cysteine protease inhibitor E-64. 
Thereafter, TER was measured as described in Materials and Methods at 3, 6, and 12 
h post-incubation. Parasite cysteine protease inhibition rescued Caco-2 cells from 
Blastocystis ST-7-induced effect at all time points (p-values < 0.01). On the other 
hand, staurosporine induced epithelial barrier dysfunction was not rescued by E-64 
(at 50µM conc.). Cytochalasin-D (cyt-D) was used as positive control. Values are 
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Figure 4.5. Flux measurement with FITC-conjugated Dextran. Confluent 
monolayers of Caco-2 cells were coincubated for 24 h with Blastocystis ST-4 
and ST-7 isolates. Permeability was determined by measurement of Dextran-FITC 
fluxes across the monolayer as described in Materials and Methods. A significant 
increase in the epithelial permeability to Dextran-FITC can be noticed after 
incubation with ST-7 (B) lysate (p-value < 0.01). None of the other isolates exhibited 
increase in dextran-FITC flux. Cytochalasin-D (cyt-D) was used as a positive control. 
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Figure 4.6. Role of Blastocystis cysteine proteases in ST-7 (B)-induced increase 
in Caco-2 permeability. Blastocystis ST-7 (B) lysate with cysteine protease 
inhibitor E-64 significantly inhibited parasite induced increase in epithelial 
permeability to FITC conjugated Dextran (p-value <0.01). Infection of Caco-2 
monolayer with ST-7 (B) live cells also resulted in significant increase in Caco-2 
permeability (p-vale < 0.01). Cytochalasin-D (cyt-D) was used as a positive control. 










Figure 4.7. Representative confocal micrographs of alterations in ZO-1 and  F-
actin organization in Caco-2 monolayers. In control monolayers (left) or 
monolayers incubated for 3h with Blastocystis ST-7 (B) lysate (right). 
Immunostaining for ZO-1 in epithelial monolayers exposed to the parasite lysate 
exhibited focal disruptions of ZO-1, punctate concentrations of ZO-1 along the 
pericellular junctions, and cytoplasmic accumulation of ZO-1 (yellow arrows). In 
contrast, ZO-1 appeared as continuous, even, and sharp pericellular staining 
patterns in control monolayers (left). Cy3 intensity in the micrographs illustrating 
parasite treated monolayers was intentionaly increased for better visualization. F-
actin appears as fine filament located at the apical junctional region, colocalizing 
with ZO-1 in control monolayers (left). Treatment with the parasite lysate (right) 
alters F-actin organization and it appears flocculated (red arrows).  Colocallization 






Figure 4.8. Representative confocal micrographs illustrating ZO-1 tight junction and 
F-actin localization in Caco-2 monolayers. Monolayers were grown to confluency on 
poly-L-lysine treated coverslips. Caco-2 cells were then co-incubated for 3h with 
Blastocystis ST-7 (B) lysates (with or without E-64). Uninfected Caco-2 monolayers in 
normal culture media with or without E-64 (50µM) were used as controls. Compared to 
negative control, ST-7 (B) treatment resulted in obvious reduction in ZO-1 staining and 
reorganization of ZO-1 and F-actin distribution in Caco-2 cell line. Parasite cysteine 




Figure 4.9. Quantification of ZO-1 staining in Blatocystis infected Caco-2 
monolayers. Y-axis illustrates the number of pixels present at the apical junction 
area, where ZO-1 is localized in polarized epithelium under physiological conditions. 
Monolayers treated with ST-7 (B) resulted in marked reduction in number of pixels 
compared to normal control (p-value < 0.01).  Inhibition of Blastocystis cysteine 
proteases by E-64 resulted in inhibition of ST-7 induced ZO-1 changes in the 
monolayer (p-value < 0.01). Results shown are mean of 3 separate Z-stacks taken 
randomly (each Z-stack comprise of 4 images of apical junctional region 1 µm 






















This study suggests for the first time that a Blastocystis isolate induces human 
epithelial barrier dysfunction. Using a Caco-2 cell line based in-vitro human 
epithelial barrier model, we observed that Blastocystis ST-7 (B) increased epithelial 
permeability and decreased TER. The intestinal epithelium serves as body’s first line 
of defense against luminal contents comprising of a diverse flora including 
pathogenic and non-pathogenic prokaryotes and eukaryotes (Turner, 2009). 
Intestinal epithelial cells or enterocytes regulate the back and forth flow of contents 
between the gut lumen and sub-epithelial tissue (Turner, 2009). Dysfunction of this 
barrier is the cause of a wide range of human diseases (Turner, 2009), and several 
pathogens have evolved mechanisms to sabotage this gate function (Scott et al., 
2002; Turner, 2009). Extracellular luminal parasites similar to Blastocystis have 
been reported to cause bowel pathology by increasing intestinal epithelial 
permeability (Scott et al., 2002; Turner, 2009). A number of recent reports 
regarding Blastocystis pathogenesis suggest that Blastocystis is capable of inducing 
host pathology (Chandramathi et al., 2010b; Hussein et al., 2008a; Iguchi et al., 2007; 
Iguchi et al., 2009), (Dagci et al., 2002; Stensvold et al., 2009b; Vogelberg et al., 2010; 
Yakoob et al., 2010b). There are a few reports of Blastocystis compromising 
intestinal epithelial barrier in rats, in-vitro and in-vivo (Puthia et al., 2006). There is 
also one clinical study correlating increased intestinal absorption of Technetium-
99m labeled diethyl triamine penta acetic acid (99mTc-DTPA), with Blastocystis 
infections in humans (Dagci et al., 2002). However, a direct effect of Blastocystis on 
human epithelium was not observed till now. Blastocystis-induced compromise of 
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human epithelial barrier, observed in our study, further supports its status as a 
human pathogen. 
We also observed that Blastocystis ST-7 (B) induces rearrangement of ZO-1 and F-
actin in the intestinal epithelium. ZO-1 is an important component of the apical-
junctional complex, anchoring tight junctions to actin-cytoskeleton (Turner, 2009). 
Tight junctions are key regulators of epithelial barrier function (Marchiando et al., 
2011; Turner, 2009). Several parasites are known to cause ZO-1 alterations by a 
wide array of mechanisms (Khan and Siddiqui, 2009; Scott et al., 2002; Turner, 
2009). Acanthamoeba activates Rho/Rho-kinase pathway (Khan and Siddiqui, 
2009), whereas Giardia utilizes myosin light chain kinase (Scott et al., 2002) and 
caspases (Chin et al., 2002), to induce changes in ZO-1 organization.  Non-human 
proteases are also known to modulate human epithelial permeability by directly 
degrading or indirectly reorganizing tight junction complex proteins (Khan and 
Siddiqui, 2009; Lauwaet et al., 2004; Li et al., 1994; Runswick et al., 2007). They 
either degrade specific tight junction proteins (Groeger et al., 2010; Runswick et al., 
2007), or activate proteinase activate receptors (PAR) leading to tight junction re-
arrangement (Reed and Kita, 2004; Wan et al., 1999). Proteases from Entamoeba as 
well as Acanthamoeba were reported to compromise epithelial barrier function by 
tight junction alterations (Khan and Siddiqui, 2009; Lauwaet et al., 2004; Li et al., 
1994). Cysteine protease activities of pollens (Runswick et al., 2007) are also known 
to modulate human epithelial barrier function. Inhibition of Blastocystis cysteine 
proteases in this study prevented ZO-1 alterations and epithelial barrier 
compromise in a model of intestinal epithelium. As discussed in Chapter 2, cysteine 
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proteases play a crucial role in a pathogen’s virulence. Our findings suggest that 
Blastocystis cysteine proteases are not only involved in modulation of mucosal 
immune system (Puthia et al., 2008a; Puthia et al., 2005), but they also play a direct 
role in breaching intestinal epithelial barrier. 
We also observed a strain-to-strain variation in Blastocystis induced epithelial 
barrier compromise. A major controversy surrounding the pathogenic potential of 
Blastocystis is the presence of a large number of asymptomatic carriers (Stensvold et 
al., 2009b; Tan et al., 2010). Strain-to-strain variation in virulence has been 
observed in other intestinal parasites such as Giardia, Cyptosporidium and 
Entamoeba (Chin et al., 2002; Davis et al., 2007; Hashim et al., 2006), providing a 
plausible explanation for the large number of asymptomatic carriers of these 
pathogens (Haque et al., 2006; Yakoob et al., 2010a). Several studies have suggested 
a subtype-dependent variation in Blastocystis virulence (Hussein et al., 2008a; 
Stensvold et al., 2009b). In previous Chapters, we observed that Blastocystis exhibits 
a subtype-dependent variation in the activity of potential virulence factors, cysteine 
proteases (Puthia et al., 2005; Puthia et al., 2008b; Tan et al., 2010; Wu et al., 2010). 
In this study we examined whether differences in cysteine protease activity 
between Blastocystis strains translates into variation in their virulence. We found 
that Blastocystis ST-7 (B) with significantly higher cysteine protease activity 
compared to ST-4 isolates WR-1 and S-1 caused epithelial barrier compromise. In a 
previous study, Blastocystis ST-4 (WR-1) was observed to induce barrier 
dysfunction in rat intestinal epithelium (Puthia et al., 2006). Inability of this isolate 
to cause pathology in a human cell line suggests that Blastocystis strains might be 
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host specific, as observed in Cryptosporidium (Hashim et al., 2006). Another 
explanation could be that ST-4 (WR-1) does not cause pathology in Caco-2 cell line. 
Experiments on other human intestinal cells line should be performed to rule out 
this possibility. 
Surprisingly, Isolate E of the same subtype as pathogenic isolate B did not cause 
epithelial barrier compromise. We reported earlier that this isolate exhibited the 
highest cysteine protease activity of all the isolate tested. This suggests that 
although cysteine proteases are responsible for Blastocystis induced epithelial 
pathology, but qualitative and not quantitative variations in their activity might be 
responsible for differences in pathogenicity between virulent and avirulent 
Blastocystis isolates. Recently published genome sequence of Blastocystis ST-7 (B) 
suggests that this strain is capable of producing a number of secretory proteases 
that mifght be involved in modulating host physiology (Denoeud et al., 2011). A 
comparison of the reportoir of secretory proteases produced by virulent and 
avirulent strains of Blastocystis will assist in identification of specific virulent factors 
of the parasite.  Furthermore, our findings also point out that although Blastocystis 
subtypes may vary in antibiotic susceptibility but subtyping alone cannot predict 
virulence of a particular Blastocystis isolate. Lastly, several host factors could be 
necessary for the establishment of symptomatic parasitic infections (Hamano et al., 
2008; Mehraj et al., 2008), but a strain-to-strain variation in pathogenic potential of 
different Blastocystis isolates might also help in explaining the large number of 
asymptomatic carriers of the parasite. Identification of pathogenic Blastocystis 
isolates will also help us in identifying parasite virulence factors. 
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To conclude, this is the first study suggesting that Blastocystis induces human 
epithelial barrier compromise, highlighting the role of Blastocytis as a human 
pathogen. ST-7 (B), increased permeability and decreased TER of Caco-2 cell line. 
Blastocystis ST-7 (B) also caused rearrangement of ZO-1 protein and apical 
junctional F-actin. Inhibition of Blastocystis cysteine proteases prevented parasite 
induced epithelial barrier dysfunction as well as ZO-1 and cytoskeletal 
rearrangement. Furthermore, the inability of ST-4 isolate WR-1 to induce any 
changes in Caco-2 provides some evidence of host-specificity in Blastocystis. A 
strain-to-strain variation in parasite virulence might be a plausible explanation for 
the large number asymptomatic human carriers of Blastocystis. However, our data 
was limited and inconclusive about the significance of subtyping in predicting 
virulence of Blastocystis isolates (Mirza et al., 2011), since two isolates belonging to 
ST-7 (B and E) gave different results on Caco-2 barrier disruption. 
It is important to note that Blastocystis ST-7 (B) isolate is not only pathogenic, but 
Chapter 3 also indicated that it is metronidazole-resistant. It will be particularly 
difficult to manage infections with such strains. Understanding the epithelial 
pathways modulated by this strain to alter epithelial permeability might help us in 
identification of novel, alternate treatment strategies against the parasite. This will 









SIMVASTATIN PREVENTS RHO KINASE-MEDIATED 
EPITHELIAL BARRIER DYSFUNCTION CAUSED BY 
METRONIDAZOLE-RESISTANT BLASTOCYSTIS   
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5.1 INTRODUCTION 
Chapters 3 and 4 demonstrated that Blastocystis isolate ST-7 (B) is capable of 
immune evasion and cause epithelial barrier compromise. This isolate also displays 
metronidazole resistance (Mzr) as seen in Chapter 2. Antibiotic resistance and 
parasitic infections pose a significant threat to more vulnerable 
immunocompromised individuals, elderly and children. Currently too few drugs are 
available to treat parasitic infections, and most of these were developed over 50 
years ago (Sibley and Hunt, 2003). Some still retain efficacy, but these are frequently 
so toxic that the treatment itself is life threatening (Jackson et al., 2010; Marino et 
al., 1990). Prudent use and appropriate management can slow the selection of 
resistant microbial populations but in all cases, the development of new therapeutic 
strategies is necessary. The current study aims to address this issue by evaluating a 
novel treatment strategy for Blastocystis infections targeting host cells rather than 
parasites. A first step towards development of such therapeutic options is to 
understand the host molecular mechanisms modulated by pathogenic Blastocystis.  
Rho associated kinase (ROCK) is a 158 kDA serine-threonine kinase (Riento and 
Ridley, 2003). It was first discovered as an effector of the small GTPase, RhoA. It 
induces the formation of actin stress fibers and focal adhesions by phosphorylating 
myosin light chain (MLC) at Ser-19 position (Kosako et al., 2000). Phosphorylation 
of the regulatory light chain of the myosin-motor protein increases contractility of 
the actomyosin complex (Kosako et al., 2000; Van Itallie et al., 2009). The 
actomyosin complex anchors tight junction proteins in the apical region of epithelial 
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cells (Luton, 2005; Van Itallie et al., 2009). Contraction of actomyosin by ROCK leads 
to disruption of tight junction organization and epithelial barrier function (Van 
Itallie et al., 2009). In Chapter 4 we observed that Blastocystis ST-7 (B) causes 
epithelial barrier dysfunction. Pathogenic parasites employ different methods to 
modulate host epithelial barriers (Chin et al., 2002; Khan and Siddiqui, 2009; Scott 
et al., 2002; Taoufiq et al., 2008). Acanthamoeba (Khan and Siddiqui, 2009) and 
Plasmodium falciparum (Taoufiq et al., 2008) utilize ROCK to increase endothelial 
permeability. An interesting feature in the case of Giardia-induced epithelial barrier 
dysfunction is phosphorylation of regulatory MLC at Ser-19 position by myosin light 
chain kinase (MLCK) instead of ROCK (Scott et al., 2002). It will be interesting to 
identify pathways modulated by Blastocystis to breach host epithelial barrier.  
ROCK inhibition has been reported in patients undergoing statin therapy (Fig. 5.1) 
(Nohria et al., 2009; Wang et al., 2008). Statins are commonly prescribed lipid-
lowering drugs. They inhibit HMG CoA-reductase, a rate-limiting enzyme of the 
mevalonate (cholestrol biosynthesis) pathway (Zhou and Liao, 2009). Apart from its 
lipid lowering effect, in recent years there has been an increasing interest in the 
therapeutic potential of these drugs beyond their conventional use (Wang et al., 
2008; Zhou and Liao, 2009). They are proposed to be useful in immune disorders 
(Blankier et al., 2011), infections (Taoufiq et al., 2011), hypertension (Li et al., 
2011), emphysema (Wright et al., 2011) and cancer (Yang et al., 2011). 
Antimicrobial activities of these drugs have also been reported against Trypanosoma 
(Andersson et al., 1996) , Schistosoma (Soliman and Ibrahim, 2005), Plasmodium 
(Parquet et al., 2010; Wurtz et al., 2010) and Toxoplasma (Cortez et al., 2009). A 
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pleotropy of these agents came into light after several clinical studies suggested that 
cardio-protective effects of statins go beyond their lipid-lowering activity (Wang et 
al., 2008; Zhou and Liao, 2009). They were later found to reduce vascular 
inflammation (Muñoz-García et al., 2006) and calcification (Kizu et al., 2004), induce 
vascular dilation (Rawlings et al., 2009) and protect endothelial barrier integrity 
(Rodríguez et al., 2009). The combined effect of these actions translates into 
prevention of atherosclerotic plaque formation in vessels. ROCK inhibition is central 
to these actions (Muñoz-García et al., 2006). Although anti-inflammatory properties 
of statins have been evaluated in intestinal pathology (Naito et al., 2006), their role 
as intestinal antiparasitic and barrier protective drugs has not been assessed thus 
far. 
This study will evaluate whether Blastocystis ST-7 (B) influences MLC 
phosphorylation like Giardia (Scott et al., 2002) . We will also assess the role of 
ROCK in parasite-induced MLC phosphorylation. The effects of ROCK inhibitors 
against parasite-induced epithelial barrier dysfunction, observed in Chapter 4, will 
also be studied. Furthermore, we will evaluate the antiparasitic effect of Simvastatin, 
a commonly prescribed HMG CoA reductase inhibitor against Mzr Blastocystis. 
Finally, the protective effect of Simvastatin against Blastocystis-induced intestinal 





5.2 MATERIALS AND METHODS 
5.2.1 Parasite culture and lysates 
Parasite cultures were maintained and parasite lysates were prepared as described 
in the previous section (2.2.1). Lysates instead of live cells were used in all 
experiments due to reasons described in the previous Chapter (4.2.2). Lysate 
concentrations were maintained at 2 × 107 cell/ ml in all experiments.  
5.2.2 Caco-2 cultures 
Caco-2 cultures were maintained and prepared for different experimental 
conditions as described in the last Chapter (4.2.1). ROCK was inhibited by 
incubating the epithelium (Caco-2 cells) with either Y-27632 or Fasudil at 
concentrations of 3.3 μg/ml and 5 μg/ml respectively, 4 h before infection. For 
HMG-CoA reductase inhibition, monolayers were incubated with Simvastatin at 5 
μg/ml concentration for 12 h before infection with Blastocystis ST-7 (B) lysate. 
5.2.3 Immunohistochemistry 
Caco-2 monolayers infected with Blastocystis ST-7 (B) were prepared for confocal 
microscopy of ZO-1 and F-actin as described in the previous Chapter (4.2.5) 
5.2.4 Western blot to detect MLC phophorylation 
For Western blot analysis, Caco-2 monolayers were grown on 6-well cell culture 
plates (Corning) until 100% confluency. Monolayers were then incubated with 
parasites, washed with PBS twice and then scraped and collected. Monolayers were 
then incubated with “cell lytic M” lysis buffer (Sigma) supplemented with protease 
and phosphatase inhibitors (Sigma). Lysed samples were centrifuged at 21,000 rpm 
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at 4°C for 30 minutes. Protein concentration of the supernatant was determined 
with the DC Protein Assay (Bio-Rad Laboratories). SDS-PAGE gels (12% and 15% 
Tris-HCL Ready-Gels; Bio-Rad Laboratories) were used to separate total proteins. 
Proteins were then transferred using a polyvinylidene difluoride (PVDF) membrane 
(Immobilon-P; Millipore). 5% nonfat dry milk in 0.1% TBS-T was then used to block 
the membranes. After blocking, membranes were incubated with primary 
antibodies against myosin light chain (MLC), MLC phosphorylated at Ser-19 (MLCp), 
or α-tubulin (1:1000; Sigma) overnight at 4°C. After incubation with primary 
antibodies, membranes were washed and incubated with HRP-tagged secondary 
antibodies (1:1000; Sigma). Bands were detected using AmershamTM ECL Plus 
Western blotting detection system (GE Healthcare). Autoradiographic films (Kodak) 
were then exposed to the membranes and developed on X-ray film processor SRX-







5.3.1 Blastocystis ST-7 (B) induces epithelial barrier dysfunction in a Rho 
Kinase-dependent manner 
We observed in Chapter 5 that Blastocystis ST-7 (B) cysteine proteases induce 
intestinal epithelial barrier dysfunction. In this study, mature Caco-2 monolayers 
grown on transwell filters were treated with Blastocystis ST-7 (B) lysate in the 
presence or absence of ROCK inhibitors. TER readings were taken at 0, 3, 6 and 12 h 
time points. We observed that Blastocystis ST-7 (B)-induced, time-dependent 
decrease in TER was significantly inhibited by pretreatment of monolayers with 
ROCK inhibitors, Y-27632 and Fasudil (Figs. 5.2 and 5.3) (p-values <0.05). Dextran-
FITC permeability of monolayers was also assessed 24 h after treatment with 
parasite lysate (Fig. 5.4).  Parasite-induced increase in epithelial permeability to 
FITC-conjugated Dextran was significantly prevented by pretreatment of epithelium 
with Y-27632 and Fasudil (Fig 5.4) (p-values <0.05). Cytochalasin D was used as a 
positive control. 
5.3.2 Blastocystis ST-7 (B) induced ZO-1 and F-actin reorganization is 
prevented by epithelial Rho kinase inhibition 
Results from Chapter 5 suggested that Blastocystis ST-7 (B) causes epithelial barrier 
dysfunction by alteration of ZO-1 organization. Inhibition of parasite cysteine 
proteases prevented parasite-induced ZO-1 alterations. In this study we evaluated 
the role of ROCK in Blastocystis-induced ZO-1 and actin cytoskeleton reorganization 
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along with preservation of epithelial barrier function (figs. 5.5 and 5.6). We 
observed that ROCK inhibition by both Y-27632 and Fasudil prevented parasite-
induced reorganization of ZO-1 and actin cytoskeleton (Figs. 5.5 and 5.6). ZO-1 
intensity was decreased at the apical junctional region after Blastocystis ST-7 (B) 
treatment in the previous Chapter. This decrease in apical junction intensity was 
also significantly inhibited by pretreatment of epithelial monolayers with both Y-
27632 and Fasudil (Fig. 5.6) (p-values <0.05). 
5.3.3 Blastoycstis induces Rho kinase-mediated phosphorylation of Myosin 
Light Chain at Ser-19 position 
Studies suggest that pathogens as well as pro-inflammatory cytokines induce 
cytoskeletal and tight junction alterations in host epithelium by phosphorylating the 
regulatory light chain of myosin motor at Ser-19 position (McKenzie and Ridley, 
2007; Scott et al., 2002). This phophorylation is often mediated by ROCK (McKenzie 
and Ridley, 2007). Western blot analysis in this study suggested that Blastocystis ST-
7 (B) causes significant increase in phosphorylation of myosin light chain in Caco-2 
epithelium (Fig. 5.7) (p-value <0.05). Inhibition of epithelial ROCK by Y-27632 and 
Fasudil significantly inhibited this increase in MLC phophorylation (Fig. 5.7) (p-
values <0.05). 
5.3.4 HMG CoA-reductase inhibition in Caco-2 prevents Blastocystis-induced 
epithelial barrier dysfunction  
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Statins or HMG CoA-reductase inhibitors exert their pleotropic, endothelial barrier 
protective effect by inhibition of ROCK mediated MLC phosphorylation (Chen et al., 
2008). In this study we evaluated whether Simvastatin, prevents Blastocystis ST-7 
(B) induced epithelial pathology. Pretreatment of Caco-2 monolayers with 
Simvastatin singnificantly inhibited Blastocystis ST-7 (B)-induced increase in 
epithelial permeability (fig 5.4) and drop in TER (Figs. 5.3, 5.4) (p-values 0.05). 
Furthermore, ZO-1 and cystoskeletal reorganization was also inhibited (figs. 5.5 and 
5.6). Lastly, ROCK-dependent increase in MLC phosphorylation by Blastocystis ST-7 
(B) was also significantly inhibited by pretreatment with Simvastatin (fig. 5.7) (p-
value <0.05). 
5.3.5 Simvastatin is moderately cytotoxic to metronidazole-resistant ST-7 (B) 
The antimicrobial effect of statins is well reported in organisms such as Toxoplasma, 
Plasmodium and Schistosoma (Andersson et al., 1996; Parquet et al., 2010; Soliman 
and Ibrahim, 2005). Using the in-vitro drug susceptibility assay described in Chapter 
2 we evaluated susceptibility of metronidazole-resistant Blastocystis ST-7 (B) to 
Simvastatin (Fig. 5.8). We observed that 24 h treatment of the parasite with 
Simvastatin reduced parasite viability in a dose dependent manner with IC-50 value 





Figure 5.1. Simplified schematic of the molecular changes for RhoA 
prenylation leading to RhoA/ROCK activation. HMG-CoA reductase exerts 
upstream regulation of RhoA prenylation via geranylgeranyltransferase I (GGTase 
I). The latter catalyzes the covalent attachment of the geranylgeranyl group from 
GGPP to RhoA (RhoA prenylation). RhoA prenylation plays an important role in the 
translocation of RhoA to the membrane followed by the activation of RhoA/ROCK. 
Data show that Simvastatin blocks this upstream regulation of RhoA 
prenylation/RhoA/ROCK pathways, thus causing a decrease in MLC 
phosphorylation. 








Figure 5.2. Graph illustrating prevention of Blastocystis ST-7 (B)-induced drop 
in Caco-2 TER by epithelial ROCK and HMG-CoA reductase inhibition. 
Blastocystis ST-7 (B) lysates were added to Caco-2 monolayers with or without 
pretreatment of Y-27632, Fasudil or simvastain. TER measurements were taken at 
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pretreatment exhibited significantly higher TER measurements at all 3 time points, 
as opposed to infected monolayers with no pretreatment (p-values < 0.05) 
suggesting prevention of parasite induced drop in Caco-2 TER. Compared to lysate 
alone, significantly higher TER readings were also observed in infected Caco-2 
monolayers with Fasudil at 6 and 12 h time points (p-values < 0.05). A similar trend 
was also observed at 3 h time point but the difference between lysate treated Caco-2 





Figure 5.3. Graph representing drop in Caco-2 TER, 12 h after treatment with 
Blastoycstis ST-7 (B) lysate in the presence or absence of inhibitors (ROCK or 
HMG CoA reductase inhibitors). We observed in the previous Chapter that 
Blastocystis ST-7 (B) induced a drop in Caco-2 TER. In this study, we observed that 
parasite lysate induced drop in TER was significantly prevented by pre treatment of 
the epithelial monolayers with Y-27632 or Fasudil (rho kinase inihibitors) or 
Simvastatin (HMG CoA reductase inhibitor) (p-values < 0.05). Normal serum free 
culture media and cytochalasin D were used as negative and positive controls. Error 
bars represent standard error. Each value is mean of 6 samples taken from 2 
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Figure 5.4. Graph representing increase in Caco-2 permeability to FITC 
conjugated Dextran, 24 h after treatment with Blastocystis ST-7 (B) lysate in 
the presence or absence of inhibitors (ROCK or HMG CoA reductase 
inhibitors). Increased flux of Dextran-FITC across epithelial monolayer was 
observed in Blastocystis ST-7 (B) infected Caco-2. In this study we observed 
significant inhibition of this increase in epithelial permeability to Dextra-FITC, when 
monolayers were pretreated with ROCK inhibitors Y-27632 or Fasudil (p-values < 
0.05). Pretreatment of the epithelium with Simvastatin significantly inhibited 
parasite induced increase in epithelial permeability (p-value < 0.05). Each value 
represents mean of 6 samples, taken from 2 independent experiments, triplicate 
each. Error bars = standard error. Normal serum free cell culture media and 
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Figure 5.5. Representative confocal micrographs illustrating prevention of 
Blastocystis-induced ZO-1 and actin rearrangement in Caco-2 monolayers by 
ROCK and HMG CoA reductase inhibition. Monolayers were grown to confluency 
on poly-L-lysine treated coverslips. Caco-2 cells were then co-incubated for 3h with 
Blastocystis ST-7 (B) lysates, with or without inhibitors (Simvastatin, Y-27632 or 
Fasudil). Uninfected Caco-2 monolayers in normal culture media were used as 
controls. Compared to negative control, ST-7 (B) treatment resulted in obvious 
reduction in ZO-1 staining and reorganization oF-actin cytoskeleton (described in 
detail in Chapter 5) in Caco-2 cell line. Treatment of epithelial monolayers with Y-
27632, Fasudil or Simvastatin prior to Blastocystis infection, rescued ST-7 (B) 
induced ZO-1 and actin cytoskeleton changes. Results shown are mean of 4 





Figure 5.6 Quantification of ZO-1 staining in Blatocystis-infected Caco-2 
monolayers. Y-axis illustrates the number of pixels present at the apical junction 
area, where ZO-1 is localized in polarized epithelium under physiological conditions. 
Monolayers treated with ST-7 (B) resulted in marked reduction in number of pixels 
compared to normal control (p-value < 0.01).  Pretreatment of monolayers with 
ROCK inhibitors (Y-27632 or Fasudil) or HMG-CoA reductase inhibitor 
(Simvastatin) prevented parasite induced ZO-1 changes in the monolayer (p-values 
< 0.01). Results shown are mean of 3 separate Z-stacks taken randomly (each Z-




























Figure 5.7. Representative western blot illustrating phosphorylation of 
myosin light chain in Caco-2 epithelium. Treatment with Blastocystis ST-7 (B) 
lysate caused increase in MLC phosphorylation in Caco-2 monolyers in time 






Figure 5.8. ROCK and HMG CoA reductase inhibitors prevent Blastocystis induced 
phosphorylation of MLC. Representative western blots exhibiting increase in MLCp after incubation 
with Blastocystis ST-7 (B) lysate. MLCp concentration is reduced in Caco-2 samples pretreated with 
Y-27632, Fasudil or Simvastatin before incubation with parasite lysate. Graph represents % increase 
in MLCp/MLC ratio in Caco-2 cells calculated through densitometery analysis of Western blot 
radiographs. A significant increase (20%) in MLCp/MLC ratio was observed in ST-7 (B) treated 
epithelium compared to negative control (p-value <0.05). Pretreatment of epithelium with Y-27632, 
Fasudil or Simvastatin significantly inhibited parasite induced increase in MLC phosphorylation (p-
values < 0.05). Erro r bars represent standard error of the mean of 3 values obtained from 3 
independent Western blots. Α-tubulin was used as loading control. 
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  
Figure 5.9. Dose dependent curve representing antiparasitic effect of 
Simvastatin against Mzr Blastocystis. Blastocystis ST-7 (B) exhibited a decrease in 
viability 24 h after treatment with varying doses of Simvastatin ranging between 0.8 
to 100 μg/ml. IC-50 of Simvastatin cytotoxicity against the parasite was calculated 
to be 38.66 ± 5.33 μg/ml. Error bars represent standard error of the mean of 6 


















In the previous chapter we identified cysteine proteases as potential parasite 
virulence factors inducing host epithelial barrier dysfunction. In this study we are 
highlighting for the first time the molecular mechanisms modulated by Blastocystis 
to increase host epithelial barrier dysfunction. Blastocystis ST-7 (B) is an Mzr strain. 
In this study we also demonstrated the usefulness of HMG-CoA-reductase inhibitors 
or statins as an alternative or adjunctive treatment strategy against Mzr Blastocystis. 
Intestinal pathogens are known to modulate epithelial barrier function by 
manipulating the tight junction complex (Chin et al., 2002; Lauwaet et al., 2004; 
Scott et al., 2002; Troeger et al., 2007). Some pathogens like Giardia achieve this by 
phosphorylating regulatory light chain of myosin motor at p-Ser-19 (Scott et al., 
2002). The activation of the myosin motor results in modulation of F-actin 
cytoskeleton that anchors tight junction complex in the apical region of the 
polarized epithelium (McKenzie and Ridley, 2007). We observed that Blastocystis 
induced phophorylation of MLC. This phosphorylation was dependent on ROCK, an 
effector protein of RhoA (McKenzie and Ridley, 2007). As expected ROCK inhibition 
also prevented parasite-induced F-actin and ZO-1 reorganization and protected 
epithelial barrier. Although several pathogens modulate the ROCK\MLCp pathway 
the (Epple et al., 2009; Khan and Siddiqui, 2009; Lapointe et al., 2010; Taoufiq et al., 
2008), this is the first study suggesting that ROCK/MLCp pathway is utilized by a 
parasite to induce intestinal pathology. Fasudil is a clinically useful ROCK inhibitor 
under investigation for treatment of cerebral vasospasm (Shibuya et al., 1992), 
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pulmonary hypertension (Doggrell, 2005) and Alzheimer’s disease (Huentelman et 
al., 2009). We observed that it effectively prevented Blastocystis-induced epithelial 
pathology. Fasudil can be a potential treatment option for Blastocystis infections. 
Epithelial barrier dysfunction induced by Mzr strain of Blastocystis was improved in 
our study by pre-incubation of epithelium with Simvastatin. Studies suggest that 
statins are effective endothelial barrier protective agents (Chen et al., 2008; 
Rodríguez et al., 2009; Taoufiq et al., 2011). Through inhibition of cholestrol 
biosynthesis pathway, statins block formation of isoprenoid intermediates, essential 
for isoprenylation of Rho GTPases such as Rho, Rac and CDC-42. Isoprenylation is a 
critical step for their intracellular trafficking and function. Alteration of RhoA 
function also results in inhibition of MLC phosphorylation by its effecter protein 
ROCK (Figure 6.1). In short, prevention of endothelial barrier dysfunction by statins 
is due to their inhibitory effect on ROCK\MLCp pathway. Though several clinical 
applications of this pleotropic effect of statins are suggested (Kizu et al., 2004; 
Rawlings et al., 2009; Sarkar et al., 2006; Wang et al., 2008), this is the first 
observation of a statin preventing intestinal barrier dysfunction. Our findings 
suggest that similar to vascular endothelium (Chen et al., 2008), statins also prevent 
intestinal epithelial barrier dysfunction and tight junction rearrangement by 
inhibiting ROCK mediated MLC phsphorylation. They could be useful in treatment of 
conditions in which intestinal epithelial barrier function in compromised, specially 
as adjunctive or alternative treatment strategy against drug resistant pathogens as 
seen in our study. 
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In addition to protection of epithelial barrier, statins were also found to be 
moderately toxic to Mzr Blastocystis ST-7 (B). Antiparasitic effect of statins alone 
(Cortez et al., 2009) or in combination with other chemotherapeutic agents, is well 
reported (Parquet et al., 2010; Wurtz et al., 2010). HMG-CoA reductase inhibition 
prevents growth of trypanosomes (Andersson et al., 1996) as well as Toxoplasma 
(Cortez et al., 2009). Atorvastatin exhibits a synergistic aniparasitic activity along 
with mefloquine or quinine against Plasmodium falciparum (Parquet et al., 2010; 
Wurtz et al., 2010). Schistosoma were also found to be susceptible to a statin alone 
or in combination with medroxyprogesteron acetate (Soliman and Ibrahim, 2005). 
In this study, we found Mzr strain of Blastocystis to be susceptible to Simvastatin. 
Although in-vivo and clinical studies are needed, the dual effect of statins as 
antiparasitic as well as host epithelial protective agents highlights their potential as 
an alternate or adjunctive treatment strategy against Mzr Blatocystis infections. 
Future studies should focus on evaluation of synergistic activity of statins with other 
antiparasitic agents against Blastocystis.  
To conclude, our findings further highlighted the pathogenic potential of Blastocystis 
by identification of host molecular pathways modulated by the parasite. Using this 
information we identified the role of Simvastatin and Fasudil in prevention of 
parasite-induced pathology. An Mzr strain of Blastocystis ST-7 (B) induced ZO-1 
reorganization and increase in epithelial permeability by phosphorylating MLC. 
Inhibition of epithelial ROCK by Y-27632 and a pharmaceutical agent Fasudil 
partially rescued the parasite-induced effect. We are also reporting for the first time 
a novel use of Simvastatin as an intestinal barrier protective agent. Simvastatin 
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prevented parasite-induced epithelial MLC phosphorylation to protect intestinal 
epithelial barrier. This is the first report of a parasite inducing ROCK-dependent 
tight junction reorganization and epithelial barrier dysfunction in a non-vascular 
epithelium. Additionally, simvastain also exhibited mild antiparasitic effect against 
Blastocystis. Future studies should focus on the clinical evaluation of these drugs as 
antiparasitic as well as intestinal barrier protective agents.
 
Figure 5.10. Illustration representing possible mechanisms employed by 
Blastocystis to induce intestinal epithelial barrier dysfunction.  
Blastocystis cysteine proteases activate epithelial ROCK possibly via PAR-2 mediated 
Rho A activation. ROCK activation causes phosphorylation of MLC at P-ser-19, 
resulting in contraction and reorganization of actomyosin complex (anchoring ZO-1 
tight junction protein). ZO-1 and actomysin rearrangement leads to epithelial 
barrier dysfunction. Simvatatin and Fasudil prevented Blastocystis induced 
epithelial barrier dysfunctiobn by inhibition of Rho A and ROCK respectively. 
MLC; myosin light-chain kinase, MLC-p; phosphorylated MLC, PAR-2; protease 
activated receptor type 2, RhoA; Rho-GTPase family member A, ROCK; Rho-












GENERAL DISCUSSION & CONCLUSIONS  
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6.1 DISCUSSION 
Despite recent advances in our understanding of Blastocystis cell biology, genetic 
diversity and epidemiology, the pathogenic potential of the parasite remains 
controversial. Due to lack of proper diagnostic techniques and absence of 
appropriate animal models, molecular mechanisms of the parasite pathogenesis are 
largely unknown. A large number of asymptomatic carriers of the parasite further 
complicate the situation (Stensvold et al., 2009b). The development of in-vitro host-
pathogen interaction models of the parasite has helped in highlighting the 
pathogenic potential of certain Blastocystis strains (Puthia et al., 2008a; Puthia et al., 
2006) but a detailed analysis of the parasite’s pathogenic mechanisms in human 
intestinal epithelium has not been done yet. The overall aim of this thesis was to use 
in-vitro model systems to address clinically relevant questions concering 
Blastocystis. The study identified virulent and antibiotic resistant strains of the 
parasite. It also provided a detailed analysis of various steps involved in the parasite 
induced pathology starting from immune evasion and leading to epithelial barrier 
compromise. Furthermore, several treatment options against virulent and 
antibiotic-resistant strains were also evaluated. Lastly, this is the first study 
identifying the molecular basis of subtype- or strain-dependent variations in 
Blastocystis pathogenic potential. 
Before inducing epithelial pathology a microorganism must effectively colonize the 
intestinal lumen. Microorganisms have evolved several means to counter the host 
immune system, in order to make the microenvironment in the host tissues more 
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conducive to their growth. In Chapter 3 of this study we observed that a potentially 
pathogenic strain of Blastocystis ST-7 (B), modulates host anti-microbial nitric oxide 
response. ST-7 (B) was found to be highly susceptible to nitrosative stress 
compared to an isolate of ST-4. In order to contain NO to a tolerable concentration 
in its microenvironment, we found that ST-7 (B) down-regulated epithelial inducible 
nitric oxide synthase and reduced epithelial, anti-parasitic NO secretion. Although 
Blastocystis is known to cleave human secretory IgA response, this is the first study 
suggesting suppression of the innate immune response of human enterocytes by 
Blastocystis. Nitrosative stress generated by enterocytes in the gut lumen keeps 
luminal colonization of pathogens in check (Eckmann et al., 2000). Suppression of 
enterocyte NO production not only helps Blastocystis to survive and reproduce, but 
it might also facilitate the survival of pathogenic microorganisms in the immediate 
vicinity. Frequent reports of Blastocysits co-infection with other pathogens support 
this idea (Hu et al., 2008; Kurniawan et al., 2009; Rayan et al., 2007). 
Suppression of NO response by pathogenic Blastocystis leaves the epithelium 
defenseless against the parasite’s assault. In this study we observed for the first time 
that Blastocystis increases human intestinal epithelial permeability. Although 
Blastocystis is considered a mild pathogen, there are multiple in-vitro and in-vivo 
reports of the parasite increasing intestinal permeability in rodent models 
(Chandramathi et al., 2010b; Dagci et al., 2002; Hussein et al., 2008b; Puthia et al., 
2006). There is also indirect evidence of increased intestinal permeability in 
Blastocystis infected humans (Chandramathi et al., 2010a; Dagci et al., 2002), but 
this is the first direct observation of human epithelial cell line damage caused by the 
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parasite. Blastocystis virulence factors causing increase in epithelial permeability 
are not known. Cysteine proteases are suspected to be Blastocystis virulence factors 
(Puthia et al., 2008a; Puthia et al., 2005). They cleave human secrotory IgA (Puthia 
et al., 2005) and cause up-regulation of IL-8 production by colonic epithelial cells 
(Puthia et al., 2008a). In Chapter 4 we observed that inhibition of parasite cysteine 
proteases completely rescued Blastocystis induced increase in epithelial 
permeability along with preservation of ZO-1 and F-actin architecture.  
Why the parasite increases epithelial permeability is not known. Since Blastocystis is 
non-invasive, increasing the epithelial permeability might provide it access to 
nutrient-rich subepithelial fluids. Another possibility is that, in order to complete its 
life cycle Blastocystis needs to be flushed out of the host intestine. To achieve this, 
Blastoycstis induces diarrhea in its hosts (Dawes et al., 1990; Kurniawan et al., 2009; 
Yakoob et al., 2010a) by increasing intestinal epithelial permeability. Intestinal 
symptoms resolve once the parasite has completed the objectives of intestinal part 
of its life cycle, manifested clinically by self limitation of intestinal symptoms (Doyle 
et al., 1990; Wilson et al., 1990; Zdero et al., 1997). Cyclical changes in Blastoycystis 
cysteine protease activity observed in Chapter 1 also suggest that Blastocystis might 
modulate epithelial permeability to suit its life-cycle requirements. The parasite 
might upregulate cysteine protease production at specific life cycle stages to induce 
diarrhea (by increasing epithelial permeability), facilitating feco-oral transmission. 
In fact periodic changes in shedding of Blastoycsits in infected patients has been 
reported (Suresh et al., 2009). Once the objective of feco-oral transmission is 
achieved the parasite, cysteine protease activity comes down to baseline level and 
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manifests clinically as self limitation of symptoms (Doyle et al., 1990; Wilson et al., 
1990; Zdero et al., 1997) and recurrence as the cycle starts again (Vannatta et al., 
1985; Vogelberg et al., 2010). Although a detailed analysis of the parasite life cycle 
in an in-vivo infection model is needed but our findings, in addition to clinical 
reports of self-limitation of symptoms (Doyle et al., 1990; Wilson et al., 1990; Zdero 
et al., 1997), recurrence of Blastocystis infections (Vannatta et al., 1985; Vogelberg et 
al., 2010) and periodic changes in shedding of parasite (Suresh et al., 2009) support 
this possibility. 
Several reports, including this one, suggest that Blastocystis causes host pathology 
by increasing intestinal epithelial permeability (Dagci et al., 2002; Hussein et al., 
2008a; Puthia et al., 2006) but there is limited information on the mechanisms 
employed by the parasite to achieve this. Understanding of host pathways 
modulated by the parasite might help in the identification of new treatment 
strategies to manage Blastocystis-induced symptoms. Parasites such as 
Acanthamoeba (Khan and Siddiqui, 2009), Giardia (Scott et al., 2002) and 
Entamoeaba (Lauwaet et al., 2004) alter epithelial tight junction complexes that 
function to guard the paracellular space. This leads to host epithelial barrier 
dysfunction.  Giardia achieves this by phosphorylating regulatory light chain of 
myosin (MLC) in an MLC kinase-dependent manner, leading to increased epithelial 
permeability. We observed that Blastocystis also phophorylates MLC but similar to 
Acanthamoeba (Khan and Siddiqui, 2009) it employs Rho kinase (ROCK) instead of 
MLCK. The ensuing cytoskeletal and ZO-1 rearrangement lead to increase in 
epithelial permeability. Interestingly enough, ROCK inhibition did not completely 
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rescue Blastocystis induced increase in permeability, suggesting that Blastocystis 
utilizes more than one mechanism to breach the epithelial barrier. 
Despite our current knowledge of its pathogenic mechanisms, it is difficult to argue 
the clinical significance and pathogenic potential of Blastocystis, since infections do 
not lead to intestinal symptoms consistently (Eroglu et al., 2009; Kaneda et al., 2000; 
Stensvold et al., 2009b). A large number of infected individuals remain 
asymptomatic (Eroglu et al., 2009; Kaneda et al., 2000; Stensvold et al., 2009b). 
Studies attempt to address the issue of asymptomatic carriage in Blastocystis by 
suggesting a strain- or subtype-dependent variation in Blastocystis pathogenecity 
(Hussein et al., 2008b; Iguchi et al., 2007; Stensvold et al., 2009b). Strain-to-strain 
variation in virulence of intestinal pathogens is well reported. In our study we also 
observed that out of all the isolates tested, only ST-7 (B) isolate was found to 
increase epithelial permeability and suppress enterocyte NO immune response, 
suggesting that Blastocystis has virulent and avirulent strains. Presence of avirulent 
strains provides a plausible explanation for asymptomatic carriage of Blastocystis 
infections. This variation in virulence though, might not be subtype-dependent since 
Isolate E belonging to the same subtype as pathogenic isolate B, did not induce 
epithelial pathology in our experiments in Chapter 4. Altogether these findings 
suggest that subtyping of Blastocystis might not come handy in predicting clinical 
outcome of infections. 
Another issue concerning the pathogenic potential of Blastocystis are reports of 
treatment failure (Moghaddam et al., 2005; Stensvold et al., 2008; Stensvold et al., 
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2010). Metronidazole is the treatment of choice, but physicians are often skeptical 
about prescribing antibiotics for Blastocystis infections. It is argued that since anti-
Blastocystis treatment does not lead to resolution of intestinal symptoms, 
Blastocystis might not be the etiological agent and the symptoms might be caused by 
some undiagnosed pathogen (Stensvold et al., 2010). Giardia intestinalis was 
recognized as a clinically significant organism only after it became possible to 
effectively eliminate it from the gut (Markell, 1995). In Chapter 2 of this study we 
observed metronidazole and tinidazole resistance in subtype-7 isolates of 
Blastocystis, suggesting that antibiotic resistance could be a reason for non-
resolution of symptoms after treatment. Moreover, we observed a subtype-
dependent variation in susceptibility of Blastocystis to a range of conventional and 
experimental antibiotic agents. Although subtyping might not be useful in predicting 
the virulence of Blastocystis but our findings suggest the clinical relevance of 
subtyping in predicting treatment outcomes in Blastocystis infections.  
Interestingly, experiments in Chapter 2 revealed that pathogenic Blastocystis ST-7 
(B) isolate is also metronidazole-resistant. This study prescribed several alternative 
anti-protozoal agents to overcome Mz resistance. Unfortunately resistance to some 
of these agents has also been reported by previous studies (Dunn and Boreham, 
1991; Yakoob et al., 2004). Patients infected with antibiotic resistant virulent 
Blastocystis strains might be difficult to manage and pose a significant threat. There 
is a need to develop alternative or adjunctive treatment options for such infections. 
In chapter 5 we evaluated a novel approach for treatment of metronidazole-
resistant Blastocystis infections. Instead of targeting the parasite, we targeted host 
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pathways modulated by the parasite. Since the parasite causes epithelial barrier 
dysfunction by ROCK mediated MLC phosphorylation, we inhibited epithelial ROCK 
by Fasudil or HMG CoA-reductase by Simvastatin. These drug prevented ROCK 
mediated MLC phsphorylation and cytoskeletal rearrangement in Caco-2 epithelium 
caused by metronidazole-resistant Blastocystis and significantly improved epithelial 
barrier function in infected epithelium. Fasudil has been in clinical use since 1992 
(Shibuya et al., 1992) while Simvastatin is an FDA approved drug commonly 
prescribed to manage hypercholesterolemia (Chen et al., 2008). Another advantage 
of simvastatin is that it has antiparasitic effect against metronidazole-resistant 
Blastocystis. These drugs might be useful as alternative or adjunctive treatment 
options for metronidazole-resistant Blastocystis and their clinically efficacy against 
Blastocystis infections should be evaluated. 
6.2 CONCLUSIONS 
1. Singnificant biological differences between ST-4 and ST-7 zoonotic subtypes 
of Blastocystis were observed 
a. ST-7 isolates were found to be approximately 4 times the size of ST-4 
isolates, with significantly higher cysteine protease activity. ST-4 
isolates on the other hand were found to have significantly faster 
doubling times. 
b. Using redox based high throughput in-vitro drug susceptibility assays 
we found ST-7 isolates of Blastocystis to be metronidazole resistant. 
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Significant variations between susceptibility of ST-4 and ST-7 isolates 
to conventional and experimental antiparasitic agents were also 
observed. 
2. We also observed that isolate B of subtype-7 inhibits epithelial nitric oxide 
production by downregulating epithelial inducible nitric oxide synthase, as 
an immune evasion mechanism. Subtype-4 isolate on the other hand, did not 
effect epithelial NO production. 
3. This study also suggested that cysteine proteases of Blastocystis increase 
intestinal epithelial barrier permeability and decrease TER. Interestingly 
cysteine proteases of only ST-7 (B) isolate out of the 4 isolates tested induced 
this effect, suggesting strain-to-strain and not subtype-dependent variation 
in parasite virulence. 
4. We also observed that Blastocystis compromises epithelial barrier function 
by Rho kinase (ROCK) mediated phosphorylation of regulatory light chain of 
myosin. MLC phosphorylation leads to reorganization oF-actin cytoskeleton 
and ZO-1 resulting in epithelial barrier dysfunction. 
5. Using this information regarding Blastocystis pathogenesis and antibiotic 
resistance, we identified therapeutic potential of epithelial Rho kinase and 
HMG CoA reductase inhibition by Fasudil and Simvastatin respectively, 







Figure 6.1: Illustration representing possible pathogenic and immune evasion 
mechanisms of virulent Blastocystis subtype-7. (Right) Using Caco-2 cell line as 
an in-vitro host-pathogen interaction model, we observed that Blastocystis ST-7 (B) 
induces barrier dysfunction in intestinal epithelium, by alteration of 
Rho/ROCK/MLCp pathway. Blastoycstis cysteine proteases might be involved. 
Simvastain and Fasudil (black boxes) prevented ST-7 B induced epithelial barrier 
dysfunction. (Left) Blastocystis ST-7 (B) reduced antiparasitic NO₂ (red box) 
production of host epithelium, by inhibiting iNOS (inducible nitric oxide synthase). 
L-Arg (green boxes) is an essential substrate that is converted by iNOS into NO₂. 
Blastocystis ST-7 (B) arginase might compete with epithelial iNOS for L-Arg or 
inhibit iNOS directly by some unknown mechanism, compromising an essential host 
antimicrobial defense mechanism. None of the other isolates tested induced these 
effects on intestinal epithelium, suggesting a strain-to-strain variation in Blastocystis 
induced host pathology. 
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Appendix I 
Medium for culturing Blastocystis 
For culturing Blastocystis, each 15 ml culture test-tube contained following: 
a) Isocove’s Modified Dulbecco’s Medium (IMDM) (Gibco) 9ml 
b) Inactivated horse serum (Gibco) 1ml 
Loose-capped tubes with medium were kept for 24 h in anaerobic jar with gas pack 
inside to remove oxygen (prereduction of medium). Prereduced medium was 
inoculated with Blastocystis cells, they were placed in an anaerobic jar and 
incubated at 37°C for optimal growth. 
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Appendix II 
Optimized parameters for resazurin and XTT, drug suscpetibility assays 
Parameter Value 
 
Dye concn  
    Resazurin 5% 
    XTT 50 µg/ml 
Growth medium IMDM + 10% HSa + 0.5% DMSO 
Volume/well 200 µl 
Temperature 37°C 
Culture conditions Anaerobic 
Contact time with dye (h)  
    Semiquantitative/visual 5 
    Quantitative 3 
Excitation/emission (nm) 
 
    Resazurin 550/580 
    XTT 450 
Optimal cell density (parasites/well) 0.5 x 106 
 




Poly-L-lysine coating of glass coverslips 
1) Acid wash glass coverslips 
a. Soak coverslips in hydrochloric acid (HCL) overnight (keep in fume 
hood) 
b. Rinse under tap water for 15-30 minutes 
c. Rinse in sterile waster, autoclave and dry 
d. Coverslips are ready for coating 
2) Add 50 ml of sterile tissue culture grade water to 5 mg of poly-L-lysine 
3) Aseptically coat culture surface of the coverslips with poly-L-lysine solution 
enough to cover surface 
4) Rock gently to ensure eve coating of the culture surface 
5) After 5 minutes, remove solution by aspiration and thoroughly rinse surface 
with sterile tissue culture grade water. 
6) Allow to dry at least two hours. 
7) Expose the coated converslips to UV for 15 mins before culturing cells. 
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Appendix VI 
Coomassie (Bradford) protein Assay (Pierce) 
Microplate protocol (working range = 1-25 μg/ml) 
a. Pipette 150 μl of each standard or unknown sample into the appropriate 
microplate wells. 
b. Add 15μl of the coomassie reagent to each well and mix with plate shaker for 
30 seconds. 
c. Remove plate from the shaker and incubate plate for 10 mins at room 
temperature for consistent results. 
d. Measure the absorbance at 595 nm on a plate reader 
e. Subtract the average 595 nm measurements for the black replicates from the 
595 nm measurements of all the other individual standard and unknown 
sample replicates 
f. Prepare a standard curve by plotting the average black corrected 595 nm 
measurements for each BSA standard vs. its concentration in μg/ml 
g. Using the standard curve, determine the protein concentration estimate for 
each unknown sample. 
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Appendix V 
Measuring cell monolayer resistance by electovoltohmeter 
(http://www.millipore.com) 
Set-up the laminar flow hood with a: 
 Millicell-ERS (electrovoltohmeter)  
 Millicell culture plate inserts without cells 
 Millicell culture plate inserts with cells 
 70% ethanol 
Procedure: 
To sterlize electrodes, immerse the electrode in 70% ethanol for 15 minutes. Allow 
them to air dry for 15seconds. 
a. Rinse electrodes in sterile cell culture medium 
b. For resistance measurements, the electrode in now ready to use 
c. Switch mode to “R” 
d. Turn the POWER switch “ON” 
e. Immerse the electrodes so that the shorter electrode is in the millicell culture 
plate insert and the longer electrode is in the outer well. The shorted 
electrode should not contact the cells grown on the membrane of inserts 
f. Do not push the “R” button while the electrodes are outside the solution or 
the meter could be damaged.  
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g. Completely immerse the metal sheath at the electrode tips in the solution to 
obtain accurate measurements 
h. Press the measure button. The meter should indicate a stable resistance 
reading of the solution 
i. Record the resistance 
j. The blank resistance must be measured and then substracted from the 
resistance reading across monolayer in order to obtain the true tissue 
resistance 
k. The unit area resistance is obtained by multiplying the meter readings by the 
effective surface area of the filter membrane 
l. Resistance of a unit area = Resistance (W) x Effective Membrane Area (cm2). 
 
  Published Ahead of Print 19 September 2011. 
2011, 79(12):5019. DOI: 10.1128/IAI.05632-11. Infect. Immun. 
Haris Mirza, Zhaona Wu, Fahad Kidwai and Kevin S. W. Tan
 
by a Novel Parasite Survival Mechanism 
Epithelial Inducible Nitric Oxide Synthase 
Oxide and Downregulates Intestinal
Blastocystis spp. Is Susceptible to Nitric 
A Metronidazole-Resistant Isolate of
http://iai.asm.org/content/79/12/5019




This article cites 46 articles, 12 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://iai.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 January 12, 2012 by A*STAR,C/O







INFECTION AND IMMUNITY, Dec. 2011, p. 5019–5026 Vol. 79, No. 12
0019-9567/11/$12.00 doi:10.1128/IAI.05632-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
A Metronidazole-Resistant Isolate of Blastocystis spp. Is Susceptible to
Nitric Oxide and Downregulates Intestinal Epithelial Inducible Nitric
Oxide Synthase by a Novel Parasite Survival Mechanism
Haris Mirza,1 Zhaona Wu,1 Fahad Kidwai,2 and Kevin S. W. Tan1*
Laboratory of Molecular and Cellular Parasitology, Department of Microbiology, Yong Loo Lin School of Medicine,
National University of Singapore, 5 Science Drive 2, Singapore 117596, Singapore,1 and Faculty of Dentistry,
National University of Singapore, 11 Lower Kent Ridge Road, Singapore2
Received 8 July 2011/Returned for modification 5 August 2011/Accepted 8 September 2011
Blastocystis, one of the most common parasites colonizing the human intestine, is an extracellular, nonin-
vasive, luminal protozoan with controversial pathogenesis. Blastocystis infections can be asymptomatic or cause
intestinal symptoms of vomiting, diarrhea, and abdominal pain. Although chronic infections are frequently
reported, Blastocystis infections have also been reported to be self-limiting in immunocompetent patients.
Characterizing the host innate response to Blastocystis would lead to a better understanding of the parasite’s
pathogenesis. Intestinal epithelial cells produce nitric oxide (NO), primarily on the apical side, in order to
target luminal pathogens. In this study, we show that NO production by intestinal cells may be a host defense
mechanism against Blastocystis. Two clinically relevant isolates of Blastocystis, ST-7 (B) and ST-4 (WR-1), were
found to be susceptible to a range of NO donors. ST-7 (B), a metronidazole-resistant isolate, was found to be
more sensitive to nitrosative stress. Using the Caco-2 model of human intestinal epithelium, Blastocystis ST-7
(B) but not ST-4 (WR-1) exhibited dose-dependent inhibition of Caco-2 NO production, and this was associated
with downregulation of inducible nitric oxide synthase (iNOS). Despite its higher susceptibility to NO,
Blastocystis ST-7 (B) may have evolved unique strategies to evade this potential host defense by depressing host
NO production. This is the first study to highlight a strain-to-strain variation in the ability of Blastocystis to
evade the host antiparasitic NO response.
Blastocystis is an extracellular and noninvasive unicellular
enteric parasite with zoonotic potential (28, 41, 42). It is among
the most common parasites found in the human intestine, with
prevalence ranging between 10% of the population in devel-
oped countries and 50% in developing countries (42). It is a
species complex belonging to the Stramenopile group. Accord-
ing to a recent classification, it is divided into 11 subtypes, 9 of
which are known to infect humans. Other common hosts are
chickens, rats, pigs, reptiles, and insects (41). Despite recent
advances in our understanding of the parasite’s classification
and pathobiology, several questions concerning the parasite’s
biology remain unanswered. The parasite’s pathogenicity is
also controversial owing to asymptomatic carriage, coinfection
with other pathogens, and nonresponsiveness to conventional
chemotherapeutic agents.
Blastocystis infections or blastocystosis present with common
intestinal symptoms, such as abdominal pain, vomiting, and
bloating, as well as mucous and watery diarrhea (42). Derma-
tological disorders (15, 45) and irritable bowel syndrome (39)
are also frequently associated with Blastocystis infections. It is
transmitted through the feco-oral route, and metronidazole is
the treatment of choice for Blastocystis infections. The parasite
has a high prevalence in immunocompromised individuals (17,
29, 43). In immunocompetent individuals, Blastocystis infec-
tions are often asymptomatic (7, 39) or self-limiting (39), sug-
gesting effective host defense mechanisms against the parasite.
Chronic cases, in the absence of obvious immunodeficiencies,
are common (39). Because virulence factors of Blastocystis are
largely unknown, it is not clear what key interactions between
the parasite and host determine the variability in infection
chronicity and clinical symptoms.
Although reports of mucosal inflammatory changes in the
human gut are inconclusive (46), Blastocystis infections do in-
duce a host immune response (1, 14, 32). Recent studies have
shown that the parasite causes NF-B-mediated upregulation
of the proinflammatory cytokine interleukin-8 (IL-8) (32) in
human T-84 colonic epithelium. Upregulation of IL-8 and
granulocyte-macrophage colony-stimulating factor (GM-CSF)
has also been reported in parasite-infected HT-29 colonic cells
(22). Rats infected with Blastocystis also exhibited goblet cell
hyperplasia and significant upregulation of proinflammatory
cytokines gamma interferon (IFN-) and IL-12 (14). Among
the potential host antiparasitic defense mechanisms, antibod-
ies against Blastocystis have been suggested to play an impor-
tant role (36). In mice infected with Blastocystis, IgA was the
predominant antibody isotype in intestinal secretions (36). In
symptomatic human Blastocystis infections, an increase in se-
cretory as well as humoral IgA response was also observed
(23). Asymptomatic carriers showed no difference in secretory
IgA response (23), suggesting that the parasite might have
inhibited the host’s anti-Blastocystis immune response to suc-
cessfully colonize the human gut. Evidence of the parasite
cysteine proteases cleaving human secretory IgAs (31) and the
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higher cysteine protease activity in Blastocystis isolates recov-
ered from symptomatic patients (26) provide further evidence
that certain strains of the parasite are capable of modulating
host immune response to their advantage.
Nitric oxide (NO) plays multiple functions in the human
body, such as maintenance of vascular tone (9), modulation of
epithelial barrier function (16), and neurotransmission (38).
Generation of nitrosative stress in response to microbes is also
an important component of the human cellular defense arsenal
(3, 6, 19). The antimicrobial activity of NO has been reported
for a wide range of prokaryotic (24) and eukaryotic (20, 30, 33)
organisms. A recent study suggested that NO also induces
apoptosis-like cell death in Blastocystis (4). It has been sug-
gested that parasites successful in colonizing the mucosa either
possess NO-scavenging mechanisms, like Trichomonas (11,
37), or suppress host cell NO production, like Giardia (3) and
Entamoeba (6). How Blastocystis thrives in the intestinal lumen
despite the toxicity of NO is not known.
A report on anaerobic parasites Trichomonas and Giardia
suggested that metronidazole resistance makes the organisms
more vulnerable to oxidative stress (5, 34). Metronidazole-
resistant (Mzr) Trichomonas strains were found to have infe-
rior oxygen-scavenging capacity (34), even though no apparent
changes were observed in ferredoxin or NADH oxidase activity
in these strains. No such association between susceptibility to
nitrosative stress and Mz resistance in anaerobes has been
investigated thus far. Nitrosative stress prevents colonization
of host tissues by parasites and bacteria susceptible to nitric
oxide (3, 6, 19). A microorganism more susceptible to nitrosa-
tive stress will be at a disadvantage in such an environment
(34). In a previous study, we identified Mzr and metronidazole-
susceptible (Mzs) strains of Blastocystis. We posit that although
Mz resistance helps Blastocystis survive antibiotic treatment, it
might make Mzr strains more susceptible to nitrosative stress.
NO in intestinal epithelial cells is produced by inducible
nitric oxide synthase (iNOS) that catalyzes the conversion of
L-arginine to reactive oxygen species of nitrogen. L-Arginine
consumption by microbial arginase is considered a survival
mechanism of pathogens against host macrophage NO re-
sponse (3). Arginases of extracellular pathogens such as Heli-
cobacter pylori and Entamoeba were reported to limit macro-
phage NO production by consuming L-arginine (19) in their
microenvironment. Inhibition of iNOS activity under both con-
ditions occurs at a posttranscriptional level and does not in-
volve downregulation of iNOS mRNA. On the other hand,
infections of intracellular parasites such as Toxoplasma (35)
and Leishmania (25) lead to downregulation of iNOS mRNA
expression in microglial cells and macrophages, respectively.
Noninvasive, lumen-dwelling, extracellular pathogens like Gi-
ardia and Blastocystis seldom come in contact with macro-
phages. Since these organisms are in close proximity to NO-
producing enterocytes, to survive this hostile environment, it is
reasonable to suggest that they suppress intestinal epithelial
NO production. Giardia is the only organism known to inhibit
intestinal epithelial iNOS activity. It does so in the same man-
ner as extracellular pathogens like H. pylori and Entamoeaba
do in macrophages, by competing with host cells for L-arginine
(3). It would be interesting to investigate the mechanisms Blas-
tocystis has evolved to counter the host antiparasitic NO re-
sponse.
Clinical (39) as well as in vitro (26) and in vivo (12, 13)
studies suggest strain-to-strain variations in Blastocystis patho-
genicity as well as antibiotic susceptibility (27). Variations in
pathogenicity of the parasite strains are often proposed as a
possible explanation for the large number of asymptomatic
Blastocystis infections (42). On the other hand, difference in
susceptibilities of Blastocystis strains to antiparasitic agents is
suspected as the reason for frequent reports of treatment fail-
ure in parasite infections (27). A strain-to-strain variation in
the ability of Blastocystis to evade host immune response has
not been investigated yet. A superior ability of a Blastocystis
strain to cope with host defense mechanisms such as entero-
cyte-generated nitrosative stress might provide it with a sur-
vival advantage over other strains in colonizing the human gut.
In this study, we evaluated the susceptibility of Mzr ST-7 (B)
and Mzs ST-4 (WR-1) isolates of Blastocystis to nitrosative
stress. Furthermore, we studied the modulation of epithelial
antiparasitic NO production by Blastocystis. Finally, a variation
between the abilities of Blastocystis ST-7 (B) and ST-4 (WR-1)
to inhibit host NO production was also investigated.
MATERIALS AND METHODS
Culture of Caco-2 colonic epithelial cell line. All Blastocystis-host interaction
experiments were performed using the Caco-2 human colonic cell line (ATCC
HTB-37). Caco-2 stock cultures were maintained in T-75 flasks in a humidified
incubator with 5% CO2 at 37°C. Cell cultures were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (HyClone) supplemented with 10% heat-inactivated
fetal bovine serum (HyClone) and 1% each sodium pyruvate, nonessential amino
acids in minimum essential medium (MEM), and antibiotic (Penstrep; Gibco).
Culture health was evaluated using the trypan blue exclusion assay, and only
cultures with 95% viability were used for the experiments. Cells were trypsin-
zed with 0.25% trypsin–EDTA. Cell cultures for PCR experiments were grown
on standard cell culture 6-well plates (Corning). For Blastocystis-induced nitric
oxide inhibition experiments, cells were grown on Millipore Transwell filters with
polyethylene terephthalate (PET) membranes of 3-m pore size and placed in
24-well tissue culture plates. Since epithelial NO production varies with maturity
of the cells, it was decided to measure the health and maturation of Caco-2
epithelium, as described previously (3). The transepithelial resistance (TER) of
the monolayers was assessed once every 3 days until they reached maturity on
day 21 (TER, 1,000  cm2) (3). In order to synchronize cells before experi-
ments, all cultures were serum-starved overnight in antibiotic-free and serum-
free DMEM. For cytokine stimulation experiments, a cytokine cocktail compris-
ing a combination of 20 ng/ml human IL-1, 20 ng/ml human tumor necrosis
factor alpha (TNF-), and 50 ng/ml human IFN- (Sigma) was added to cultures.
Parasite cultures. Blastocystis ST-7 (B) and ST-4 (WR-1) cultures were main-
tained as described previously (26). ST-7 (B) was recovered from a patient
admitted to Singapore General Hospital with intestinal symptoms (26, 27). ST-4
(WR-1) was isolated from a healthy rat during an animal survey (2, 26, 27). Both
ST-7 and ST-4 represent zoonotic subtypes. They commonly infect humans and
are often associated with intestinal symptoms (39). Other than humans, common
hosts for ST-7 and ST-4 isolates are birds and rats, respectively (41). For the
arginase assay, parasite lysates were prepared as described by the QuantiChrom
arginase assay kit (DARG-200) manual (BioAssay Systems, Hayward, CA). In
short, parasites were suspended in 10 mM Tris-HCl (pH 7.4) containing 1 M
pepstatin A, 1 M leupeptin, and 0.4% (wt/vol) Triton X-100. Samples were
centrifuged at 20,000  g at 4°C for 10 min. Lysate supernatant was used for the
arginase assay.
Parasite viability assay. The optimized Blastocystis viability assay, as described
previously (27), was used to measure NO toxicity. Fifty percent inhibitory con-
centrations (IC50s) of nitric oxide donors sodium nitroprusside (SNP), S-nitroso-
N-acetyl-penicillamine (SNAP), S-nitrosoglutathione (GSNO), and sodium ni-
trite (NaNO2) were calculated for the Mzr and Mzs isolates ST-7 (B) and ST-4
(WR-1), respectively. Stock solutions of all NO donor compounds were prepared
in dimethyl sulfoxide (DMSO), diluted in prereduced Blastocystis medium, and
transferred to 96-well plates. A total of 0.5  106 cells/well were incubated for
24 h with dilutions of NO donor agents ranging between 0 and 100 g/ml. The
final DMSO concentration was kept constant at 0.5% in each well, while the total
volume per well was kept constant at 200 l. After 24 h of exposure, resazurin
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solution (Sigma) was added to each well at a final concentration of 10% (vol/vol).
Three hours after incubation, fluorescence readings of resazurin were taken at
550-nm excitation and 570-nm emission wavelengths using a TECAN Infinite
M200 reader.
Confocal microscopy (annexin-FITC-PI staining). Confocal micrographs of
the parasites were taken in order to confirm NO cytotoxicity against Blastocystis.
ST-7 was treated for 24 h with a 10-g/ml concentration of SNAP. After drug
exposure, the parasites were washed and resuspended in annexin V binding
buffer (BioVision). Fluorescein isothiocyanate (FITC)-labeled annexin V and
propidium iodide (PI) (BioVision) were then added to the cell suspension.
Confocal imaging of cell suspensions was done using an Olympus Fluoview
FV1000 (Japan) equipped with a dual filter set for fluorescein isothiocyanate
(FITC) and rhodamine. Images were captured using Olympus Fluoview version
1.6b.
Determination of nitrite/nitrate in culture supernatants. For estimation of
reactive NO species produced by Caco-2 after 24 h, culture supernatants were
collected from apical compartments of the Transwell setup. To ensure that any
changes in NO production by Caco-2 are not due to induction of host cell death
by Blastocystis, before testing NO concentrations, the postincubation viability of
all Caco-2 cultures was confirmed using the trypan blue assay, and only super-
natants of inserts with 95% viable cells were used. 2,3-Diaminonaphthalene
(DAN) reacts with NO2 to give a fluorescent product, naphthotriazole. To
determine levels of the stable NO end products nitrite and nitrate, nitrate was
first reduced to nitrite by incubating the samples for 60 min at room temperature
with 0.05 U/ml nitrate reductase in the presence of 	-NADH and flavin adenine
dinucleotide (FAD). 2,3-DAN was then incubated with the sample for 15 min at
room temperature. After the incubation, the fluorescent product of the reaction
between DAN and nitrite, naphthotriazole, was measured by an enzyme-linked
immunosorbent assay (ELISA) reader at excitation and emission wavelengths of
360 and 415 nm, respectively.
Real-time PCR. Total RNA was extracted from Caco-2 cultures using the
RNeasy minikit (Qiagen, Chatsworth, CA), following the manufacturer’s instruc-
tions. Only cultures with 95% viability were used for RNA extraction to ensure
that Blastocystis-induced changes in Caco-2 iNOS mRNA levels are not due to
enterocyte cell death. iNOS gene expression was quantified by real-time reverse
transcription-PCR (RT-PCR) using the SYBR green PCR master mix system
(Qiagen, Chatsworth, CA) on a Stratagene MX3000P PCR thermocycler (Strat-
agene, La Jolla, CA). cDNA samples (2 l for a total volume of 20 l per
reaction) analyzed for the gene of interest were normalized to the reference gene
coding for 	-actin. The level of expression of iNOS in each sample was then
calculated by the threshold cycle (CT) method as 2
CT. All experiments were
repeated at least three times. Real-time RT-PCR was performed at 95°C for 15
min, followed by 40 cycles of 15 s of denaturation at 94°C, 30 s of annealing at
55°C, and 30 s of elongation at 72°C. The following iNOS primers were used:
forward primer 5-GGC CCC ACA CCC CAC CAG AC-3 and reverse primer
5-GCC AGG CCC GAT GAG GAT G-3.
Arginase assay. The QuantiChrom arginase assay kit/DARG-200 (BioAssay
Systems) was used to measure parasite arginase activity, following the manufac-
turer’s instructions. In short, 40 l of parasite lysate (2, 4, 6, or 8  107 cells) was
coincubated with 10 l of 5 L-arginine substrate buffer in a standard clear-
bottom 96-well plate (Corning) for 2 h at 37°C. Forty microliters of sample
without substrate buffer (optical density of sample blank control [ODsample]), 50
l H2O (optical density of standard background [ODbackground]), or 50 l 1 mM
urea standard (ODstandard) were added in separate wells as controls. To stop the
reaction and to calculate the final urea concentrations, 200 l of urea reagent was
added to all wells and 10 l of 5 L-arginine substrate buffer was used as a
sample blank control. The plate was tapped gently and incubated for 60 min at
room temperature. After incubation, optical density was measured at 430 nm
(OD430). Arginase activity (units/liter) of the sample was calculated as1 arginase
unit  ODsample 
 ODblank/ODstandard 
 ODwater  [urea standard]  50 
103/(40  t), where (i) ODsample, ODblank, ODstandard, and ODwater are the
optical density values of the sample, sample blank, standard, and water, respec-
tively, (ii) [urea standard]  1 mM, t is reaction time (120 min), and 50 and 40
are reaction volumes.
One unit of arginase converts 1 mol of L-arginine to ornithine and urea per
minute at pH 9.5 and 37°C.
Statistical analysis. Student’s t test was used to determine the statistical
significance of the data illustrated in Fig. 2, 4, and 5b, while the significance of
data represented in Fig. 3 and 5a as well as Table 1 was estimated using the
analysis of variance (ANOVA) test.
RESULTS
Blastocystis ST-4 (WR-1) and ST-7 (B) exhibit variation in
susceptibility to nitrosative stress. It was previously reported
that nitrosative stress induces apoptosis-like features in Blas-
tocystis (4). A recently optimized resazurin-based drug suscep-
tibility assay for Blastocystis that measures redox activity of the
cells was used to assess the cytotoxicity of NO donors against
the parasite (27). We are reporting for the first time that
Blastocystis ST-4 (WR-1) and ST-7 (B) are susceptible to ni-
trosative stress (Table 1). With the exception of NaNO2, 24 h
of exposure to common NO donors killed both Blastocystis
isolates at concentrations known to suppress growth of other
parasites (8, 33) (Table 1). Susceptibility to SNAP, GSNO, and
NaNO2 varied between the two isolates tested (Table 1). Mz
r
isolate ST-7 (B) was more susceptible to all of these NO
donors than Mzs isolate ST-4 (WR-1) (Table 1). The IC50s of
ST-7 (B) to SNAP, GSNO, and NaNO2 were 26.61, 109, and
782.6 M, respectively (Table 1). The IC50s for SNAP and
GSNO against ST-4 WR-1 were 78 and 247 M, respectively,
while NaNO2 had no effect on ST-4 (WR-1) even at the highest
concentration tested (100 g/ml) (Table 1). SNP had a similar
effect against both isolates. The IC50s of SNP against ST-7 (B)
and ST-4 (WR-1) were calculated to be 2.07  0.43 and 2.03 
0.68 g/ml, respectively (Table 1). Overall, these findings sug-
gest that compared to ST-7 (B), ST-4 (WR-1) is better able to
cope with nitrosative stress. The apparent lack of variation in
ST-4 (WR-1) and ST-7 (B) susceptibility to and considerably
lower IC50 values of SNP (Table 1) might be due to toxicity of
cyanide derivatives produced by this compound (44).
Blastocystis also exhibited typical features of cell death after
3 h of exposure to 10 g/ml of SNAP (Fig. 1). Annexin V binds
to exposed phosphatidylserine (PS) in apoptotic cells. The
permeability of cells to PI indicates that necrosis had occurred.
After exposure to nitrosative stress, some cells in the Blasto-
cystis culture only stained with annexin-FITC (without PI in-
clusion), while others exhibited PI inclusion, suggesting that
both apoptosis and necrosis had occurred (Fig. 1).
Coculture of intestinal epithelial cells by Blastocystis ST-7
(B) inhibited apical NO release. Blastocystis is a noninvasive
luminal parasite. Under physiological conditions, only the api-
cal side of the polarized intestinal epithelium should come in
contact with Blastocystis. Apical coculture of polarized epithe-
lial monolayers with 2 or 4  107 parasites of ST-7 (B) resulted
in significant inhibition of apical NO release by the enterocytes
(P  0.01) (Fig. 2). Interestingly, no change in NO release was




ST-7 (B) ST-4 (WR-1)
g/ml M g/ml M
SNP 2.07  0.43 6.947474 2.03  0.68 6.813224
SNAP 5.86  1.83 26.61217 17.2  7.37 78.11081
GSNO 36.66  3.78 109.0098 83.33  2.49 247.7847
NaNO2 54  16.16 782.6087 100
b
a SNP, sodium nitroprusside; SNAP, S-nitro-acetyl-penicillamine; GSNO, S-
nitrosoglutathione.
b One hundred micrograms per milliliter is the highest concentration of the
compound tested in our study.
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observed in ST-4 (WR-1)-cocultured epithelium (Fig. 2) at the
same doses. The ability of ST-7 (B) to suppress host antipara-
siticidal NO response might provide it with a survival advan-
tage over other strains in colonization of the hostile intestinal
lumen.
Cytokine stimulation of the epithelium was provided from
the basolateral side. The cytokines IL-1, TNF-, and IFN-
used for these studies are physiologically produced by cells
such as T cells, NK cells, and macrophages, found in the
intestinal lamina propria underlying the epithelium. Apical
coculture with ST-7 (B) significantly reduced cytokine-stimu-
lated epithelial NO production (P  0.05) (Fig. 3). This sug-
gests that Blastocystis ST-7 (B) not only inhibits baseline NO
production but also prevents NO production by other proin-
flammatory stimuli.
Blastocystis ST-7 (B) downregulates epithelial iNOS. NO
production in epithelial and other cells is controlled by
iNOS, the critical rate-limiting enzyme for the conversion of
L-arginine to NO. To identify the role of iNOS in the Blas-
tocystis-induced inhibition of epithelial NO production, we
quantified the expression of iNOS mRNA in ST-7 (B)- and
ST-4 (WR-1)-cocultured Caco-2 cells (Fig. 4). ST-7 (B) co-
culture significantly inhibited epithelial iNOS expression at
the 6- and 12-h postincubation time points (P  0.01) (Fig.
4). ST-4 (WR-1) did not have any effect on epithelial iNOS
expression.
FIG. 2. Graph representing NO production by Blastocystis-cocul-
tured Caco-2 intestinal epithelium. Blastocystis ST-4 (WR-1) or ST-7
(B) cells were incubated with 21-day-old mature and polarized Caco-2
intestinal epithelial monolayers on a Transwell setup. Twenty-four
hours post-coculture, samples of media from apical compartments
were analyzed for nitrate and nitrite concentrations. Coculture with
2  107 and 4  107 cells of ST-7 (B) significantly reduced apical NO
secretion by intestinal epithelium (P  0.01). ST-4 (WR-1) did not
alter the baseline NO concentration significantly. Viability of mono-
layers remained 95% during cocultures. Error bars represent the
standard errors of 6 samples, taken from 2 independent experiments
(each in triplicate).
FIG. 1. Confocal micrographs illustrating cell death features of Blastocystis under nitrosative stress. Blastocystis ST-7 (B) was cultured under
normal parasite culture conditions, in the presence of 10 g/ml of SNAP. Features of necrosis (yellow arrows) and programmed cell death (red
arrows) were observed as early as 3 h of incubation with an NO donor. Necrotic cells incorporated both PI and annexin V-FITC stain. Blastocystis
undergoing programmed cell death bind annexin V-FITC alone. Very few dying cells were observed in SNAP-free cultures of the parasite. The
micrographs are representative of 6 pictures taken in two separate experiments (each in triplicate).
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ST-7 (B) and ST-4 (WR-1) isolates exhibit variation in ar-
ginase activity. Arginase-deficient H. pylori strains do not
inhibit iNOS in macrophages, making them more suscepti-
ble to host NO defense (10). In our experiments, L-arginine
degradation by ST-7 (B) was found to be significantly higher
than that of ST-4 (WR-1) (Fig. 5). In the previous section,
we found that ST-7 and not ST-4 inhibits epithelial NO
production. These findings suggest that inhibition of Caco-2
NO production by Blastocystis might be associated with its
arginase activity, as seen in H. pylori and Entamoeba infec-
tions (6, 10). Although more experiments are needed, per-
haps the higher arginase activity of ST-7 (B) might help the
parasite evade the host’s NO defense response. Potential
mechanisms of NO response inhibition by Blastocystis ST-7
(B) are shown in Fig. 6.
FIG. 3. Graph representing NO production by Caco-2 intestinal
epithelium. Twenty-four hours post-coculture, Blastocystis ST-7
(B) significantly inhibited antiparasitic epithelial NO production (P 
0.01). Stimulation of Caco-2 epithelium with a proinflammatory cyto-
kine cocktail (IL-1, IFN-, and TNF-) from the basolateral side
significantly increased NO production by Caco-2 epithelium. Blasto-
cystis ST-7 (B) coculture reduced cytokine-stimulated NO upregula-
tion by 50%. Error bars represent the standard errors of 6 samples,
taken from two independent experiments (each in triplicate).
FIG. 4. Graph representing downregulation of epithelial iNOS ex-
pression by Blastocystis ST-7 (B) coculture. Caco-2 iNOS mRNA levels
were quantified by real-time PCR. As expected, a significant time-
dependent reduction in iNOS mRNA levels was observed in Caco-2
epithelium after 6 and 12 h of coculture with ST-7 (B) (P 0.01), while
ST-4 (WR-1)-cocultured Caco-2 monolayers remained unaffected.
These results are consistent with our earlier findings that Blastocystis
ST-7 (B) inhibits antiparasitic NO production by intestinal epithelium.
Error bars represent standard errors (n  3). RQ, relative quantity of
mRNA.
FIG. 5. Arginase activity of Blastocystis ST-4 (WR-1) and ST-7 (B).
(a) Lysate of 6  107 Blastocystis ST-7 (B) cells showed significantly
higher arginase activity than ST-4 (WR-1) cells (P  0.01). Five min-
utes of incubation of the parasite lysates at 95°C completely inhibited
arginase activity. (b) Cell-density-dependent increase in arginine deg-
radation by parasite lysate was observed in ST-7 (B), while arginase
activity of ST-4 (WR-1) did not change much between lysates of 2 
107 and 8  107 parasites. These findings suggest that higher arginine
degradation by Blastocystis ST-7 (B) might be responsible for epithelial
iNOS inhibition by Blastocystis ST-7 (B). Each point represents a mean
of six samples collected from two independent experiments (each in
triplicate). Error bars represent standard errors.
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Our findings suggest that Blastocystisis is susceptible to NO,
and signs of both necrosis and apoptosis like cell death were
observed in the parasite as early as 3 h after exposure to
nitrosative stress. The cytotoxicity and therapeutic potential of
NO against a range of microbial agents are well established
(20, 30, 33). NO prevents growth as well as encystation of
Giardia (3), while it induces apoptosis-like features in Entam-
oeba (33). One report suggests that Blastocystis, when exposed
to NaNO2, undergoes apoptosis-like cell death (4). Our study
provides a detailed cytotoxicity analysis of NO donors against
two clinically significant Blastocystis subtypes. The Mzr clinical
strain of Blastocystis ST-7 (B) and Mzs ST-4 (WR-1) (27) were
found to be susceptible to most of the NO donors tested at
concentrations reported for other parasites. Interestingly, com-
pared to ST-4 (WR-1), Mzr strain ST-7 (B) was found to be 2
and 3 times more susceptible to GSNO and SNAP, respec-
tively, and NaNO2 was effective against ST-7 (B) alone at the
concentrations tested. These findings suggest a superior NO-
scavenging ability of Mzs Blastocystis strain ST-4 (WR-1),
which might help its survival in NO-rich intestinal lumen. Mzr
ST-7 (B), on the other hand, was able to escape Mz chemo-
therapy due to defective oxygen-scavenging mechanisms, as
seen in Mzr Trichomonas (21, 34), but this might have com-
promised its ability to cope with nitrosative stress.
Although the higher NO susceptibility of Blastocystis ST-7
(B) makes its survival difficult in the gut lumen, our present
study suggests that this isolate has developed an interesting
survival mechanism. In this study, Blastocystis ST-7 (B) inhib-
ited epithelial NO production by downregulating epithelial
iNOS expression. Several bacteria and parasites have evolved
mechanisms to thrive in the gut lumen (3, 19). Parasites such as
Entamoeba (6) and bacteria like H. pylori (19) significantly
inhibit macrophage NO production. Since Blastocystis is non-
invasive, it does not come in direct contact with macrophages.
Similar to Giardia, Blastocystis also inhibited host epithelial
NO production (3). Epithelial NO inhibition might help ST-7
(B) to colonize and induce host pathology and assist it to
overcome the disadvantage of increased susceptibility to nitro-
sative stress. Molecular mechanisms linking NO susceptibility
and inhibition of host NO production, as observed in ST-7 (B),
are not known and would be interesting to investigate. Also, an
association between metronidazole resistance and the ability to
evade host immunity in a pathogen has not been observed.
These findings are important to report because chronic Blas-
tocystis infections that are nonresponsive to chemotherapy are
frequently encountered clinically (40), and this study may ex-
plain Blastocystis persistence during infections.
H. pylori, Giardia, and Entamoeba inhibit the host’s NO
response by competing with the host cell for the crucial sub-
strate L-arginine (3, 6, 19). Bacterial and parasitic arginases are
known to modulate epithelial NO production by limiting L-
arginine bioavailability (6, 10, 19). Arginase-deficient strains of
H. pylori were not able to inhibit NO production by macro-
phages (10). Similarly, the Blastocystis ST-7 (B) isolate, with
3-times-higher arginase activity, inhibited NO production,
while ST-4 (WR-1), with limited arginase activity, did not. A
strain-to-strain variation in Blastocystis pathogenesis is fre-
quently reported (12, 26, 39). These findings suggest that apart
from cysteine protease activity (a potential virulence factor)
(26) and Mz susceptibility (27) observed in previous studies,
ST-7 (B) also differs from ST-4 (WR-1) in its ability to inhibit
epithelial NO production, and this might be arginase depen-
dent. Studies suggest that reduction of L-arginine bioavailabil-
ity in the microenvironment does not inhibit iNOS mRNA
levels (3, 19). In fact L-arginine bioavailability controls nitric
oxide production without affecting iNOS mRNA levels in the
cell (18).On the contrary, we observed a downregulation of
iNOS mRNA expression in live enterocytes cocultured with
Blastocystis ST-7 (B), as seen in Toxoplasma (35)- and Leish-
mania (25)-infected macrophages. Although iNOS-inhibiting
Blastocystis strain ST-7 (B) possesses much higher arginase
activity than ST-4 (WR-1), the inhibition of Caco-2 NO pro-
duction by ST-7 (B) (without altering host cell viability) is
primarily due to the downregulation of epithelial iNOS mRNA
expression, as reported for Toxoplasma- and Leishmania-in-
fected macrophages (25, 35). A secondary role of Blastocystis
arginase in inhibiting epithelial NO production (as seen in
cases of H. pylori and Giardia infections) cannot be ruled out.
The characterization of Blastocystis arginases as well as further
dissection of host epithelial pathways modulated by the para-
site will give us a better idea of how Blastocystis escapes epi-
thelial NO response.
An earlier study reported increased NO concentration in
various tissues of mice infected with Blastocystis (4), as op-
posed to the iNOS inhibition observed in our study. Host
specificity has been reported in Blastocystis (13), and since mice
FIG. 6. Illustration summarizing potential mechanisms of entero-
cyte NO response inhibition by Blastocystis ST-7 (B). The parasite
evades host nitric oxide antiparasitic response by competing with L-
arginine, a crucial substrate for epithelial iNOS, to produce nitric oxide
by directly inhibiting iNOS.
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are not considered a natural host for the parasite (41), an
increase in NO in mouse tissues is not surprising. NO is an
indiscriminate, innate immune response, and introduction of a
new organism to the gut flora may lead to NO upregulation in
the host. Moreover, an increase in NO was observed in mouse
cecum and ileum, but that study (4) did not report the NO
concentration in the colon, the part of the gut colonized by the
parasite. Our infection model is more physiologically relevant
since the experiments were performed on the colonic epithe-
lium of a natural Blastocystis host.
To conclude, this is the first study highlighting the ability of
Blastcystis to modulate antiparasitic host NO defense. This is
the first study highlighting a possible association of NO sus-
ceptibility with Mz resistance in an anaerobic organism. Blas-
tocystis ST-7 (B), although more susceptible to nitrosative
stress, exhibited significantly higher arginase activity than ST-4
(WR-1) and inhibited epithelial NO production. These find-
ings make Blastocystis the only organism known to inhibit an
intestinal epithelial NO response apart from Giardia. Blasto-
cystis is the first known extracellular organism shown to down-
regulate host cell iNOS mRNA expression independent of host
cell death. We posit that a lowered NO concentration not only
helps ST-7 (B) to escape host defenses, it might also assist
other pathogens to evade nitrosative stress and promotes col-
onization of the gut lumen. Further understanding of NO-
suppressive and -coping mechanisms employed by Blastocystis
would help in the development of host immune-modulating
and chemotherapeutic strategies, respectively, against Blasto-
cystis infections.
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A Rapid, High-Throughput Viability Assay for Blastocystis spp. Reveals
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Variations in Drug Susceptibilities
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Blastocystis is an emerging protistan parasite of controversial pathogenesis. Although metronidazole (Mz) is
standard therapy for Blastocystis infections, there have been accumulating reports of treatment failure, sug-
gesting the existence of drug-resistant isolates. Furthermore, very little is known about Blastocystis suscepti-
bility to standard antimicrobials. In the present study, we established resazurin and XTT viability microassays
for Blastocystis spp. belonging to subtypes 4 and 7, both of which have been suggested to represent pathogenic
zoonotic subtypes. The optimized resazurin assay was used to screen a total of 19 compounds against both
subtypes. Interestingly, subtype 7 parasites were resistant to Mz, a 1-position-substituted 5-nitroimidazole
(5-NI), while subtype 4 parasites were sensitive. Some cross-resistance was observed to tinidazole, another
1-position 5-NI. Conversely, subtype 4 parasites were resistant to emetine, while subtype 7 parasites were
sensitive. Position 2 5-NIs were effective against both subtypes, as were ornidazole, nitazoxanide, furazolidone,
mefloquine, quinicrine, quinine, cotrimoxazole (trimethoprim-sulfamethoxazole), and iodoacetamide. Both
subtypes were resistant to chloroquine, doxycycline, paromomycin, ampicillin, and pyrimethamine. This is the
first study to report extensive variations in drug sensitivities among two clinically important subtypes. Our
study highlights the need to reevaluate established treatment regimens for Blastocystis infections and offers
clear new treatment options for Mz treatment failures.
Blastocystis is an emerging enteric protistan parasite with
zoonotic potential (39, 57, 58). It is one of the most common
parasites colonizing the human gut, with prevalences ranging
between 10% of the population in developed countries and
50% in developing countries (58). It frequently infects immu-
nocompromised individuals (27, 40, 59) and has a high preva-
lence in impoverished children (35) and HIV/AIDS (27) and
cancer (59) patients. Individuals infected with Blastocystis
present with common intestinal symptoms, such as abdominal
pain, vomiting, and bloating, as well as mucous and watery
diarrhea (58). Blastocystis infections are commonly associated
with dermatological disorders (25, 67) and irritable bowel syn-
drome (54).
Although metronidazole (Mz) treatment is considered first-
line therapy for Blastocystis infections, therapeutic intervention
is equivocal because of the large number of asymptomatic
carriers and frequent reports of treatment failure (3, 23, 37, 53,
55). The confusion concerning the status of Blastocystis as a
pathogen is primarily due to limitations of diagnostic tech-
niques, purported subtype-dependent variations in parasite
virulence, and variable host responses (55). The variation in
treatment response suggests the presence of metronidazole-
resistant (Mzr) subtypes of the parasite, but there are currently
no in vitro or in vivo data to support this hypothesis. Despite
these controversies, interest in the parasite has increased in
recent years, as signified by the establishment of organizations
like the Blastocystis Research Foundation, which actively sup-
port studies on subtype-dependent variations in Blastocystis
pathobiology and treatment (6). The clinical significance of the
intestinal parasite Giardia intestinalis was recognized only after
it became possible to effectively eliminate it from the gut (33).
To understand the role of Blastocystis as a human pathogen,
there is an urgent need to identify standardized and effective
treatment options for various Blastocystis subtypes.
At least 9 out of the 11 subtypes of Blastocystis are known to
colonize the human gut (57). The identification of antibiotic-
resistant subtypes of the parasite and development of new
therapeutic options to counter antimicrobial resistance require
a high-throughput screening tool. Conventional drug suscepti-
bility assays for Blastocystis (16, 68, 72, 75) are not suitable for
high-throughput drug screening (HTS) because they are ex-
pensive, laborious, time-consuming, potentially hazardous, and
prone to bias. Since the incidence of Blastocystis is higher in
developing countries (58), the cost and availability of sophis-
ticated equipment are also limitations for such screenings.
In this study, we evaluated two high-throughput viability
assays and applied them to drug susceptibility microassays for
Blastocystis. Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-
oxide) is the active compound of a propriety solution, Alamar
blue (41). The resazurin assay measures intrinsic cellular met-
abolic activity, which reduces resazurin and changes its color as
a measurable indicator of the number of viable cells that are
present in a test sample (34, 47). Resazurin-based assays are
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School of Medicine, National University of Singapore, 5 Science Drive
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commonly used for drug susceptibility analysis of prokaryotic
(29) and eukaryotic (20, 34, 41, 46) cells. Much like resazurin,
the tetrazolium salt 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide (XTT) is reduced by mito-
chondrial and cytoplasmic redox enzymes to a colored forma-
zan compound with a direct correlation with cell proliferation.
Tetrazolium compounds have also been widely utilized for
cytotoxic evaluation of both prokaryotic (14) and eukaryotic
(5) organisms.
In the current study, we report that optimized resazurin and
XTT redox-based assays are suitable for viability studies of the
parasite. Blastocystis subtype 4 and subtype 7 isolates are most
commonly found in rats and birds, respectively (57). Both
subtypes are known to colonize the human gut, and studies
suggest that both subtypes have pathogenic potential (54). We
utilized the optimized assays to determine the susceptibility of
Blastocystis isolates to a range of antimicrobial agents. We
observed extensive subtype-dependent variations in Blastocys-
tis susceptibility to a panel of conventional and experimental
antiprotozoal agents and identified Mz- and emetine (EM)-
resistant subtypes of the parasite. Importantly, we identified
several new and potentially effective treatment options for Mzr
Blastocystis infections.
MATERIALS AND METHODS
Cell culture. Four axenized isolates of Blastocystis were used (Table 1). All
four isolates were subtyped previously by small-subunit rRNA gene analyses
(39). Isolates WR-1 and S-1 belong to subtype 4, while isolates B and E belong
to subtype 7, according to a recent Blastocystis sp. classification system (52).
Cultures of all four isolates were maintained as described previously (36). In
brief, the parasites were maintained in 10 ml of prereduced Iscove’s modified
Dulbecco’s medium (IMDM) containing 10% horse serum in an anaerobic jar
(Oxoid) with an AnaeroGen gas pack (Oxoid) at 37°C. The parasites were
subcultured alternately at 72 and 96 h. Under these culture conditions, all four
parasites exhibited noncystic vacuolar morphology. This morphological state is
advantageous for assessment of MZ resistance because Blastocystis cysts are
known to be resistant to the drug (73), complicating our study. Cultures were
harvested from log-phase in vitro cultures for viability studies in 96-well plates.
Microculture technique. In order to establish and validate the analytical meth-
ods for Blastocystis viability determination, the microculture conditions were
optimized for standard 96-well plates. Subtype 7 parasites (isolate B) were
employed for the optimization experiments. Several parasite numbers between
103 and 106 cells were incubated in Blastocystis culture medium in a final volume
of 200 l/well in standard 96-well plates, unless otherwise stated. The 96-well
plates were then incubated at 37°C under anaerobic conditions for 24 h unless
otherwise stated. After 24 h, the cultures were incubated with redox dyes for an
additional 3 h and 5 h for quantitative and semiquantitative evaluation, respec-
tively. Unless otherwise stated, a 5% final dilution of the resazurin dye solution
(Sigma) was used for resazurin assays, whereas XTT (Sigma) was used at a final
concentration of 50 g/ml. At the end of incubation, readings of resazurin
fluorescence were taken at 550-nm excitation and 570-nm emission wavelengths,
while XTT assay measurements were made at an absorbance wavelength of 450
nm. A Tecan Infinite M200 reader was used for both fluorimetric and colori-
metric measurements. For semiquantitative evaluation, the color change in each
well was visually observed and recorded after 5 h.
Drug preparation. Compounds purchased from Sigma included Mz, ornida-
zole (Oz), ronidazole (Rz), furazolidone (FUR), mefloquine (MQ), quinacrine
(QC), quinine (QN), chloroquine (CQ), emetine (EM), doxycycline (DOX),
trimethoprim sulfate-sulfamethoxazole (TMP-SMZ), paromomycin (PAR), am-
picillin (AMP), pyrimethamine (PYR), and iodoacetamide (IA). Tinidazole (Tz)
was purchased from AK Scientific, whereas nitazoxanide (NTZ) was purchased
from Romark Laboratory. C-17 is an experimental, chemically synthesized, 2-po-
sition 5-nitroimidazole (NI) compound (66). Stock solutions of each compound
to be tested were prepared fresh in dimethyl sulfoxide (DMSO). For drug
sensitivity determination, stock solutions were diluted in prereduced Blastocystis
medium and transferred to 96-well plates. A total of 0.5  106 cells/well were
incubated for 24 h with different dilutions of the drugs ranging between 0 and 100
g/ml. The final DMSO concentration was kept constant at 0.5%.
Confocal microscopy. Confocal micrographs of the parasites were taken in
order to determine whether the alteration in Blastocystis redox activity under
drug tension observed in previous assays was also associated with morphological
changes. Metronidazole-susceptible (Mzs) ST-4 (isolate WR-1) and Mzr ST-7
(isolate E) were treated for 24 h with a 12.5-g/ml concentration of FUR and
Mz. After drug exposure, the parasites were washed and resuspended in annexin
V binding buffer (BioVision). Annexin V and propidium iodide (PI) (BioVision)
were then added to the cell suspension. Confocal imaging of cell suspensions was
done using an Olympus Fluoview FV1000 (Japan) equipped with a dual filter set
for fluorescein isothiocyanate (FITC) and rhodamine. Images were captured
using Olympus Fluoview version 1.6b.
Statistical analysis and validation of reproducibility. Before a particular assay
was used for a full-scale HTS, smaller pilot screenings were used to predict its
usefulness for large-scale applications. The Z factor predicts the robustness of
an assay for HTS by taking into account the mean and standard deviation of both
positive and negative controls of the pilot screening (74). We calculated the Z
factors of both assays for Blastocystis drug screening using the following equation:
Z factor  1  [(3c  3c)/c  c], where, c is the positive control
(0.5% DMSO), c is the negative control (6.25 g/ml FUR),  is the standard
deviation, and  is the mean.
Assays having a Z factor score between 0.5 and 1 are considered excellent for
HTS (74).
Comparison of data sets with wide differences between their means should be
made using the coefficient of variation (Cv) instead of the standard deviation ().
It represents the  in the context of the mean () and is another test used to
evaluate the robustness of an assay for HTS. We calculated the Cvs of both assays
using the following formula (30): Cv  /, where, Cv is the coefficient of
variation,  is the standard deviation of the positive control (5  105 parasites in
200 l culture medium plus 0.5% DMSO), and  is the mean of the positive
control (5  105 parasites in 200 l culture medium plus 0.5% DMSO).
Assays with a Cv of 	1 are considered low variance and fit for HTS (30).
The final validation step was the screening of the dose-dependent antiproto-
zoal activity of Mz against 4 different isolates of Blastocystis repeated twice in
triplicate. The results were statistically compared for reproducibility.
The statistical significance of variations between the drug susceptibility values
of 4 isolates was determined using one-way analysis of variance (ANOVA). A
one-way ANOVA test is ideal to test the statistical significance of the variations
observed between means of three or more groups of data.
RESULTS
Resazurin and XTT result in fluorimetric and colorimetric
reactions with Blastocystis in a cell density-dependent manner.
For semiquantitative analysis, visible color changes were ob-
served after 5 h of incubation of resazurin and XTT with
Blastocystis sp. subtype 7 in 200 l parasite culture medium.
Several shades of resazurin dye, ranging from blue to pink,
developed with increasing cell density. Similarly, XTT devel-
oped shades ranging from yellow to deep orange with increas-
ing cell density. Minimums of 105 parasites/well were needed
to obtain visual evidence of color change for both dyes, al-
though the color change was more obvious in the resazurin dye
than with XTT.
For quantitative analysis, fluorescence and absorbance mea-
TABLE 1. Sources of Blastocystis isolates
Isolate Subtype Source Common hostsb
B ST-7 Symptomatic human, SGHa Humans, birds
E ST-7 Symptomatic human, SGHa Humans, birds
WR-1 ST-4 Wistar rat, animal surveyc Humans, rats
S ST-4 Sprague-Dawley rat, animal surveyc Humans, rats
a Isolated from symptomatic patients presenting at the Singapore General
Hospital (SGH) (36).
b Based on Tan (57).
c Isolated during an animal survey (11).
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surements were taken for resazurin and XTT dyes, respec-
tively, after 3 h of incubation. Negligible changes in absorbance
and fluorescence measurements were observed between the
blank medium control and up to 104 parasites/well (Fig. 1), but
a linear increase in fluorimetric, as well as colorimetric, mea-
surements was noted from 104 parasites to 106 parasites/well
(Fig. 1). The R2 values for resazurin and XTT dyes were cal-
culated to be 0.995 and 0.983, respectively (Fig. 1; see Table 3).
A density of 5  105 parasites/well was chosen as the optimal
cell density for further experiments because it lies within the
linear range of cell density versus dye reduction for both assays
(Fig. 1) and provides visible color changes in a short time.
Blastocystis requires 200-l/well volumes for optimal meta-
bolic activity. For viability assays, cells should be at their op-
timal metabolic activity. A recent study reported an increase in
metabolic activity of Acanthamoeba with a reduction of the
culture volume from 200 to 100 l/well (34). In this study, a
decrease in volume per well resulted in a drop in Blastocystis
metabolic activity (Fig. 2). Blastocystis, an anaerobic organism
(57), should have higher metabolic activity in high well vol-
FIG. 1. Correlation between the number of subtype 7 parasites and relative fluorescence units (RFU) (A) and relative absorbance units (RAU)
(B) after 24 h of incubation and 3 h of development with resazurin and XTT, respectively. Each point represents an average of 6 values derived
from two independent sets of experiments. The error bars represent standard errors.
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umes as opposed to Acanthamoeba, which is an aerobic pro-
tozoan (34). Therefore, a 200-l/well volume was used in all
subsequent experiments (Table 2 and Fig. 2).
Blastocystis exhibits exponential growth in microcultures.
Blastocystis sp. subtype 7, when incubated under optimal mi-
croplate growth conditions, exhibited an increasing degrada-
tion of resazurin over time, suggesting a rise in the redox
activity of the culture (Fig. 3). This increase in redox activity
could be due to an increase in either parasite numbers or
metabolic activity. The redox activity of the parasite cultures
FIG. 2. Correlation of total volume per well and dye concentration with relative fluorescence units (RFU) (A) and relative absorbance units
(RAU) (B) for resazurin (res) and XTT dyes, respectively. Higher volumes per well and dye concentrations resulted in higher sensitivity of
resazurin and XTT, denoted by higher RFU and RAU readings, respectively. Each point represents a mean of 6 values derived from two
independent sets of experiments. The error bars represent standard errors.
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peaked at 24 h, followed by a drop, suggesting a slowing down
of the culture growth or metabolism due to overcrowding. The
24-h time point was chosen for drug susceptibility assays (Table
2). The complete optimized parameters for both resazurin and
XTT assays are summarized in Table 2.
Resazurin and XTT are suitable for HTS of antimicrobials
against Blastocystis. HTS quality control parameters, i.e., a Z
factor of 
0.5 (74) and a Cv of 	10% (30), were met by both
resazurin and XTT assays (Table 3). Both assays exhibited
statistical reproducibility for dose-dependent activity assays of
antimicrobial agents against Blastocystis (Fig. 4).
Blastocystis exhibits subtype-dependent variation in suscep-
tibility and resistance to Mz. Using the optimized resazurin
assay, the 50% inhibitory concentrations (IC50s) of Mz against
subtype 4 and subtype 7 isolates of Blastocystis were calculated.
Mz inhibited 50% of growth of subtype 4 isolates WR-1 and
S-1 at concentrations of 5.5  2.89 g/ml and 1.9  1.32 g/ml,
respectively (Table 4; Fig. 4 and 5). These values were within
the range of previously reported values of Mz susceptibility for
Blastocystis (16, 75). The IC50 of Mz against isolate B (subtype
7) was 32.5  3.4 g/ml. This value is significantly higher than
the IC50 of subtype 4 isolates (P 	 0.01) and exceeds the
average fecal Mz concentration of 9.5 g/ml (26). Isolate E of
subtype 7 exhibited minimal susceptibility to Mz (Table 4 and
Fig. 4), even at concentrations as high as 100 g/ml. These
results suggest that isolates B and E of subtype 7 are Mzr
















Optimal cell density (parasites/well)..................0.5  106
a HS, heat-inactivated horse serum.
FIG. 3. Blastocystis subtype 7 exhibits a time-dependent increase in redox activity when cultured in a 96-well plate under the resazurin assay
conditions described in this study. The starting parasite density was 0.5  106 cells in 200 l of IMDM supplemented with 10% horse serum and
0.5% DMSO. The redox activity of the culture peaked at 24 h, followed by a steady decline. A drug contact duration of 24 h was chosen based
on these results. Each point represents a mean of 6 values derived from two independent experiments, with each experiment conducted in
triplicate. The error bars represent standard errors.
TABLE 3. Statistical evaluation of the quality of resazurin and
XTT assaysa
Assay Z factor Cv (%)b Linearity (R2)c
Resazurin 0.9  0.02 7.6  0.35 0.995
XTT 0.89  0.1 2.4  0.54 0.983
a Ideal HTS parameters are a Z factor of 
0.5 (74) and a Cv of 	10% (30).
b Cv %, coefficient of variance of cell controls.
c Linearity of the dye reduction-versus-parasites/well curve.
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strains of Blastocystis. The XTT assay further confirmed these
strains to be Mzr (Table 4).
An Mzs isolate of Blastocystis exhibits typical morphological
features of cell death after exposure to Mz, as opposed to an
Mzr isolate. Our findings, based on resazurin and XTT assays,
indicate suppression of parasite redox activity under drug ten-
sion. Concomitantly, to determine whether Blastocystis under-
goes morphological changes after drug exposure, parasites
were stained with propidium iodide and annexin V-FITC. Both
PI and annexin V stain only dying parasites (71). PI binds to
the parasite nuclear material (71). Annexin V binds with high
affinity to phosphatidylserine (PS). PS is located at the cytoso-
lic face of the cell membrane and has access to annexin V only
when it becomes exposed at cell death (71). Healthy parasites
are impermeable to both PI and annexin V (71). Mzs ST-4
(isolate WR-1) exhibited nuclear incorporation of PI and an-
nexin V binding after 24 h of exposure to a 12.5-g/ml con-
centration of Mz, suggesting a breach in the parasite cell mem-
brane (Fig. 6A). No changes were observed in Mzr ST-7
(isolate E) after Mz treatment (Fig. 6B). MZs and Mzr isolates
exhibited cell death morphology after treatment with a 12.5-
g/ml concentration of FUR (Fig. 6A and B), whereas neither
of the isolates incorporated PI or annexin V after treatment
with the DMSO control (Fig. 6A and B). These findings sug-
gest that after treatment with Mz, morphological alterations
typical of dying cells were observed in the Mzs isolate, while the
Mzr isolate remained unaffected.
Mzr isolates of Blastocystis exhibit cross-resistance with a
1-position-substituted 5-NI. Tz, a compound closely related to
Mz due to the presence of its side chain at position 1 of the
imidazole ring (Fig. 5), was effective in killing both Mzr and
Mzs isolates. Interestingly, Mzs subtype 4 isolates WR-1 and S
exhibited IC50s (0.51  0.02 and 0.3  0.1 g/ml, respectively)
of Tz lower than those of Mzr subtype 7 isolates B and E
(5.13  0.16 and 9.33  0.45 g/ml, respectively) (P 	 0.01)
(Table 5). Even within subtype 7, the IC50 of Tz for Mz
r isolate
E was significantly higher than that for isolate B (Table 5).
These findings in Blastocystis suggest a cross-resistance pattern
FIG. 4. Graph representing percent inhibition of Blastocystis subtype 4 and 7 cultures by Mz using the resazurin assay. The IC50s of Mz against
subtype 4 isolates were found to be significantly lower than those of subtype 7 isolates (P 	 0.01). Mz induced 50% inhibition of subtype 7 isolate
B cultures at a concentration (conc.) of 32.5  3.4 g/ml, whereas isolate E cultures exhibited only minimal inhibition even at concentrations as
high as 100 g/ml. Each point represents a mean of six readings derived from two independent experiments. The error bars represent standard
errors.




Subtype 7 isolates Subtype 4 isolates
B E WR-1 S
Resazurin 32.5  3.4 (189.8) NSa 5.5  2.89 (32.16) 0.75  0.04 (4.38)
XTT 29  3.4 (169.36) NS 1.76  0.39 (10.27) 1.1  0.08 (6.4)
a NS, not susceptible to drug concentrations of 100 g/ml.
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similar to those exhibited by other parasites (7, 12). Oz, an-
other closely related 5-NI (Fig. 5), despite having a position 1
side chain, was found to be equally effective against both Mzr
and Mzs isolates. Interestingly, Mzr subtype 7 isolates exhibited
significantly higher susceptibility to the position 2 side chain
5-NIs Rz and C-17 (Fig. 5) than to position 1 5-NI. No signif-
icant subtype-dependent variation in Blastocystis susceptibility
to position 2 5-NIs was observed.
Blastocystis subtype 4 exhibits EM resistance. EM is an an-
tiamoebic agent with limited clinical use, reported to be effec-
tive against Blastocystis in vitro (16, 75). Our study found EM to
be effective against Mzr subtype 7 isolates (Table 6). Subtype 4
isolates S and WR-1, on the other hand, exhibited no inhibition
even at the highest test concentrations of 100 g/ml, suggesting
EM resistance in subtype 4 isolates.
Blastocystis exhibits subtype-dependent variations in suscep-
tibility to NTZ, MQ, and QC. NTZ, a well-documented pyru-
vate-ferredoxin oxidoreductase (PFOR) inhibitor (43), was
found to be more effective against Mzr strains of the parasite in
this study (Table 6). Subtype 7 (avian) isolates were signifi-
cantly more sensitive to NTZ than subtype 4 (rodent) isolates
(P 	 0.01). Similarly, the anti-malarial MQ and a closely re-
lated drug, QC, were also found to be significantly more ef-
fective against subtype 7 isolates than subtype 4 (Table 6).
No subtype-dependent variations in FUR and QN suscepti-
bility. Both Mzr and Mzs isolates exhibited sensitivity to FUR
and QN (Table 6), two well-known antiprotozoal agents.
Higher susceptibility of Blastocystis spp. to a TMP/SMZ
ratio of 1:2 than to one of 1:5. SMZ and TMP are administered
in two different ratios for protozoan infections. TMP/SMZ
ratios of 1:5 and 1:2 were tested for Blastocystis inhibition. All
isolates exhibited susceptibility to both combinations, but all
four isolates were significantly more sensitive (P 	 0.01) to a
TMP/SMZ ratio of 1:2 than to one of 1:5 (Table 6).
Nonsusceptibility of Blastocystis to broad-spectrum antibi-
otics. PAR, PYR, CQ, DOX, and AMP were found to be
ineffective against all four isolates of the parasite (data not
shown).
Cysteine protease inhibition causes parasite death. The sig-
nificance of cysteine proteases in Blastocystis pathobiology is
well reported (36, 48, 58, 71). In this study, Inhibition of cys-
teine protease activity of the parasite by IA resulted in com-
plete inhibition of all four isolates with similar IC50s, suggest-
ing the importance of cysteine proteases in parasite survival.
DISCUSSION
We found both resazurin and XTT assays to be suitable for
high-throughput analysis of drug susceptibility in Blastocystis
isolates. The HTS parameters (a Z factor of 
0.5 and a Cv of
	10%) provide a highly conservative estimate of the sensitivity
of an assay (30, 74). The high Z factor value, low Cv, and
reproducibility of both resazurin and XTT assays suggest that
they are robust and suitable for HTS. The option of semiquan-
titative visual evaluation of color gives these assays the flexi-
bility to be applied in the field without the need for sophisti-
cated equipment. The suppression of metabolic activity
observed in these redox assays was also found to be associated
with morphological signs of cell death (71), i.e., nuclear incor-
poration of PI and annexin V binding to the cell membrane,
further validating these assays in determining drug susceptibil-
ities. Considering the large number of variant Blastocystis iso-
lates and the predominance of the parasite in developing coun-
tries (58) with limited research funding, these assays will be
particularly useful due to their low cost and high yield.
Subtype 7 isolates were shown to be resistant to Mz and
cross-resistant to Tz, the 1-position-substituted 5-NI of choice
to treat a wide variety of anaerobic organisms (4, 22). This is
consistent with previous reports of cross-resistance between
the two drugs in Trichomonas (12, 31) and Giardia (7, 61). In
these organisms, resistance is proposed to be due to downregu-
lation of the enzymes PFOR (65) and thioredoxin oxidoreduc-
tase (28), which in conjunction with the electron acceptor
ferredoxin are believed to activate the 5-NI prodrugs to the
toxic radical states inside the parasite (28, 65). However, this
mechanism of activation has not been shown for Blastocystis,
although PFOR and other oxidoreductase enzymes are present
in the organism (70). The subtype 4 isolates showed no con-
vincing uniformity in susceptibility to Mz and Tz, indicating
that new, unknown mechanisms of activation and/or resistance
may be involved.
All isolates were similarly susceptible to another 1-position
5-NI, Oz. Compared to Mz, the drug has significantly higher
efficacy against Mzr isolates of Blastocystis (P 	 0.01), as ob-
served in other parasites (10, 64) and also reported for Blas-
tocystis previously (16). However, its superior efficacy against
Mzs isolates is not as obvious, again suggesting new, unknown
mechanisms of activation and/or resistance to 1-position 5-NIs
in the parasite. Oz is frequently used to treat amoebiasis in
India (21). Although the IC50s of Oz against all four isolates
tested here (4.9 to 6.44 M) were higher than the MIC of the
drug against Entamoeba (0.25 M) (10), its effectiveness
against both Mzr and Mzs isolates suggests the drug would be
a useful alternative to Mz to treat Blastocystis infections.
Similarly to Oz, 2-position 5-NIs, the commercially available
poultry drug Rz and the experimental drug C-17, were uni-
FIG. 5. Chemical structures of position 1 and position 2
5-nitroimidazoles.
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formly effective against the isolates of both subtypes tested.
These 2-position 5-NIs exhibited significantly higher efficacy
against Mzr isolates than 1-position 5-NIs (P 	 0.01), as ob-
served in Giardia and Trichomonas (66). Again, the improved
efficacy of 2-position 5-NIs against Mzs subtype 4 isolates is not
as obvious, suggesting a different mechanism of action in Blas-
tocystis than in other organisms (66). The IC90 of C-17 against
Giardia was recently reported to be 0.5 M (17), whereas
against Trichomonas it exhibited a MIC of 6.3 M (66). In this
study, the IC50 of C-17 against Blastocystis ranged from 0.89 to
1.54 M, suggesting the potential of the drug as a broad-
spectrum antiprotozoal agent against Mzr parasites. Two-po-
sition 5-NIs may prove to be effective alternatives to treat
Blastocystis infections in cases of Mz treatment failure.
The susceptibility of the Mzr subtype 7 isolates to NTZ and
the reduced susceptibility to the Mzs subtype 4 isolates are also
evidence for different mechanisms of action of NTZ in Blas-
tocystis than in Giardia and Trichomonas, where cross-resis-
tance between Mz and NTZ is apparent (2). These data sug-
gest that Mz treatment failures in blastocystosis may well
FIG. 6. Confocal micrographs of Blastocystis stained with propidium iodide (arrow) and annexin V-FITC. (A) Mzs ST-4 (WR-1) exhibited
nuclear incorporation of PI and annexin V-FITC binding after 24 h of exposure to 12.5 g/ml Mz. (B) Mzr ST-7 (isolate E) did not exhibit these
classical signs of cell death after Mz treatment. Both Mzs and Mzr isolates exhibited PI incorporation and annexin V-FITC binding after 24-h
treatment with 12.5 g/ml FUR, while no changes were observed in healthy parasites incubated with DMSO. Bars, 5 m.
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respond to NTZ, as in the case of Cryptosporidium parvum
infections. C. parvum infections do not respond well to Mz
(19), and NTZ is the treatment of choice, with in vitro IC50s of
	10 g/ml (60), similar to the IC50s of the drug against both
Mzr and Mzs isolates of Blastocystis in this study. Recent in
vitro (68) and clinical data (55) also suggest the usefulness of
the drug in Blastocystis infections.
Another alternative to treat Mzr Blastocystis isolates is FUR,
which was equally effective against all isolates in this study.
FUR is a nitrofuran commonly used to treat giardiasis (49). It
is activated inside the cell by NADH oxidase and generates
toxic products that interfere with DNA processes in the para-
site (9). The IC50s of FUR against both Mz
r and Mzs isolates
of Blastocystis were found to be similar to that against Giardia
(2 M) (5).
The prophylactic antimalarial MQ and a closely related
drug, QC, were also found to be more effective against Mzr
subtype 7 isolates than Mzs subtype 4 isolates. These findings
are surprising because in Giardia, cross-resistance against QC
has been observed between Mzr (8) and Tzr (63) strains, sug-
gesting a different mode of action of the drug in Blastocystis.
The exact mechanisms of action of these drugs against luminal
parasites are not known, although they have been suggested to
act on protozoan cell membranes (62). The activity of QC
against Blastocystis has been reported previously (16, 68), but
the current study is the first to report the potential usefulness
of MQ as an anti-Blastocystis drug.
EM is an effective antiamoebic agent with unpleasant side
effects. It targets ribosomes and limits protein synthesis (43).
The in vitro activity of EM against Blastocystis has been eval-
uated in two previous studies. While both studies suggested its
effectiveness against Blastocystis, Zierdt et al. reported strain-
to-strain variation in the susceptibility of the parasite to the
drug (75). The multidrug resistance (MDR) phenotype of En-
tamoeba histolytica exhibits resistance to a wide range of drugs,
including EM, while responding to Mz (43), but no such MDR
phenotypes have been reported in Blastocystis spp. Our study
describes the existence of EM resistance in Mzs isolates of
Blastocystis, suggesting that MDR phenotypes might be present
in the parasite. Clinically, however, EM has limited use be-
cause of its severe side effects (32, 56).
TMP and SMZ are often prescribed in combination at a
1:5 ratio as an alternative to Mz in Blastocystis infections.
Clinical studies suggest that this drug combination success-
TABLE 5. IC50 values of Blastocystis for 5-NIs by resazurin assay
Drug
IC50 g/ml (M)
Subtype 7 isolates Subtype 4 isolates
B E WR-1 S
1-Position 5-NIsa
Mzd 32.5  3.4 (189.8) NSc 5.5  2.89 (32.16) 0.75  0.04 (4.38)
Tzd 5.13  0.16 (20.52) 9.33  0.45 (37.32) 0.51  0.02 (2.04) 0.3  0.1 (1.2)
Oze 1.42  0.02 (6.44) 1.23  0.15 (5.58) 1.1  0.3 (4.9) 1.15  0.05 (5.22)
2-Position 5-NIsb
Rze 0.52  0.02 (2.6) 0.31  0.08 (1.55) 0.32  0.1 (1.6) 0.37  0.08 (1.85)
C-17f 0.63  0.1 (1.56) 0.36  0.13 (0.89) 0.42  0.08 (1.04) 0.5  0.05 (1.24)
a Side chain at position 1 of the imidazole ring of 5-NI.
b Side chain at position 2 of the imidazole ring of 5-NI.
c NS, not susceptible to drug concentrations of 100 g/ml.
d FDA-approved antimicrobial agent.
e Veterinary antiparasitic agent.
f Experimental antiparasitic agent effective against Trichomonas and Giardia (66).
TABLE 6. IC-50 values of anti-protozoal agents effective against Blastocystis isolates using the resazurin assay
Drug
IC50 g/ml (M)
Subtype 7 (Mzr) isolates Subtype 4 (Mzs) isolates
B E WR-1 S
NTZb 0.62  0.07 (2.01) 1.14  0.49 (3.7) 4.15  0.41 (13.48) 8  4.7 (26)
FURb 0.65  0.05 (2.88) 1.06  0.4 (4.7) 0.49  0.01 (2.17) 0.475  0.05 (2.1)
MQb 1.49  0.83 (3.93) 1.85  0.88 (4.88) 4.7  0.35 (12.4) 5.1  0.58 (13.46)
QCb 2.8  0.56 (7) 1.9  0.2 (4.75) 5.1  0.47 (12.75) 4.9  0.53 (12.25)
QNb 5.1  1.1 (15.7) 4.3  2.4 (13.24) 3.2  0.52 (9.8) 5.4  1.4 (16.63)
EMc 1.03  0.4 (2.13) 1.32  0.9 (2.73) NSa NS
TMP:SMZ 1:2b 4.7  0.5 5.3  0.62 3.2  0.8 4.3  0.48
TMP:SMZ 1:5b 22  3.2 18.5  1.3 24.5  2.4 19  0.46
IAd 0.34  0.05 (1.83) 0.2  0.03 (1.08) 0.33  0.06 (1.78) 0.26  0.02 (1.4)
a N/S, not susceptible to 100-g/ml concentration of the drug.
b FDA-approved antimicrobial agent.
c Antiparasitic agent with adverse side effects; not currently used in clinical practice.
d Carcinogenic cysteine protease inhibitor; not clinically useful.
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fully eradicates Blastocystis infections in 95% to 100% of
cases (53, 54). There are no reports of the effectiveness of a
1:2 combination against Blastocystis. Our findings suggest
the superiority of a 1:2 combination over a 1:5 combination
with no subtype-dependent variation in susceptibility. We
suggest that the 1:2 combination is likely to be more effec-
tive than the 1:5 combination in treatment of clinical infec-
tions of Blastocystis.
Cysteine proteases play an important role in the cell cycle
and pathophysiology of protozoan parasites. Blastocystis cys-
teine proteases have been reported to cleave human secretory
IgAs (58) and to induce upregulation of proinflammatory cy-
tokines (48). A prosurvival role of legumain, a cysteine pro-
tease, has also been reported recently for Blastocystis (71).
Accumulating data in recent years suggest the therapeutic po-
tential of protease inhibitors in parasitic infections (1, 42).
Several cysteine protease inhibitors are being investigated as
potential chemotherapeutic agents against parasites as diverse
as Plasmodium (42, 44, 50), trypanosomes (18), and schisto-
somes (69). In this study, we found all four isolates to be highly
susceptible to IA, a cysteine protease inhibitor, irrespective of
their susceptibility to Mz. These findings suggest a potential
role of cysteine protease inhibitors as a therapeutic option for
Blastocystis isolates resistant to conventional antiprotozoal
agents.
PAR is a broad-spectrum aminoglycoside (13). Although
clinical studies suggest its effectiveness in the treatment of
Blastocystis infections (3, 45, 67), in vitro data are equivocal (68,
72). In this study, PAR was found to be ineffective against the
isolates of both subtypes tested. The high clinical efficacy of the
drug against Blastocystis could be due to its broad-spectrum
antibiotic activity (13). Although predominantly used for par-
asitic infections, PAR is also bactericidal (15). It might act by
destruction of the gut bacterial flora essential for Blastocystis
survival (57).
All four isolates tested were found to be nonsensitive to
several other broad-spectrum antibiotics, PAR, PYR, CQ,
DOX, and AMP. This feature could be exploited for the
isolation and axenization of Blastocystis from clinical sam-
ples.
Clinical (54) and animal infection (24) studies, as well as in
vitro data (36), suggest a subtype-dependent variation in the
pathobiology of Blastocystis. Although strain-to-strain variation
in parasite susceptibilities to drugs has been reported previ-
ously, subtype-dependent variation in parasite responses to
chemotherapeutic agents has not been described before. To
the best of our knowledge, this is the first study of its kind
suggesting a variation in parasite susceptibilities to six common
antiparasitic agents between isolates of two subtypes known to
infect humans (54). It will be interesting to conduct a more
extensive evaluation analyzing variability in the drug responses
of different isolates across all 11 subtypes of the parasite.
Although the vacuolar form is the most commonly re-
ported form of the parasite, Blastocystis is also known to
exist in amoeboid, granular, and cyst forms. Blastocystis cysts
have been reported to be Mzr, suggesting that different
forms might respond differently to drug pressure (73). Since
there are no standardized methods available for maintaining
axenic cultures of other Blastocystis forms, only vacuolar
forms were evaluated in this study, limiting the application
of our findings across different life cycle stages of the par-
asite. Despite this limitation, this is the first study suggesting
subtype-dependent variation in the parasite response to che-
motherapeutic pressure.
In conclusion, this study describes two cost-effective as-
says for high-throughput antimicrobial susceptibility analy-
sis of Blastocystis. Using one of these assays, we demon-
strated for the first time subtype-dependent variations in the
susceptibility of Blastocystis to six different antiprotozoal
agents. We identified 4 new potential therapeutic options
against Blastocystis, namely, MQ, TMP-SMZ (1:2), Oz, and
FUR. Furthermore, we confirmed the antiprotozoal activi-
ties of 10 compounds already reported to be effective against
Blastocystis. We also demonstrated in vitro Mz and EM
resistance in Blastocystis. By assessing the susceptibility of
the parasite to different 5-NIs, we also demonstrated that
5-NI resistance could be overcome in Blastocystis with more
effective 5-NI compounds. Based on our findings, there is
clearly a need to reevaluate currently established treatment
regimens for Blastocystis infections.
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Abstract Blastocystis is an enteric protistan parasite of
uncertain clinical relevance. Recent studies indicate that the
parasite is a species complex and humans are potentially
hosts to nine Blastocystis subtypes, most of which are
zoonotic. Subtype 3 is the most common in prevalence
studies, followed by subtype 1. Laboratory diagnosis is
challenging; the currently recommended diagnostic ap-
proach is trichrome staining of direct smears coupled with
stool culture. Polymerase chain reaction testing from stools
or culture is useful for determining Blastocystis subtype
information. The controversial pathogenesis of Blastocystis
is attributed to subtype variations in virulence; although
current studies seem to support this idea, evidence suggests
other factors also contribute to the clinical outcome of the
infection. Clinical signs and symptoms of blastocystosis
include abdominal pain, diarrhea, bloating, and flatulence.
Extraintestinal manifestations, predominantly cutaneous,
also were reported. In vitro and animal studies shed new
light on the pathobiology of Blastocystis.
Keywords Blastocystis . Pathogenesis . Subtypes .
Diagnosis . Prevalence
Introduction
Blastocystis is an unusual protistan enteric parasite classified
under a highly diverse group of organisms called strameno-
piles, and is the only known member of this group associated
with human pathology [1••]. Blastocystis was first described
in the early 1900s but continues to be a controversial
organism. A renewed interest in this parasite resulted in the
revision of its classification, appreciation of its genetic
diversity and zoonotic potential, refinement of molecular
diagnostic techniques, and development of Blastocystis–host
interaction models [1••]. Historically, similar numbers of
studies either implicated or exonerated Blastocystis as a
cause of human disease, but in recent years an increasing
number of reports suggest that Blastocystis is an emerging
microbial pathogen [1••]. The discrepancies found in the
literature largely result from use of nonstandardized diag-
nostic techniques, difficulty in identifying the parasite in the
clinical laboratory setting, small sample sizes, and in some
cases, misinterpretation of data. Additionally, the parasite’s
extensive genetic diversity probably contributes to the
underestimation of its clinical significance. Recent studies
that take the genetic diversity of this organism into account
suggest that its association with several disorders is subtype-
dependent [2–5]. At least nine subtypes (genotypes) of
Blastocystis have been described on the basis of small
subunit ribosomal RNA gene analysis [6•], and nonhuman
primates, mammals, and birds appear to be reservoir hosts
for most subtypes (Table 1). In this regard, the use of the
term Blastocystis hominis is no longer appropriate; instead,
the parasite should be referred as Blastocystis spp or
Blastocystis spp subtype n, where n is the subtype number
according to the Stensvold classification [6•].
Clinical Presentation
Human infections with Blastocystis are called “blastocys-
tosis.” A variety of signs and symptoms are associated with
blastocystosis, ranging from nonspecific intestinal symp-
toms to cutaneous disorders.
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Intestinal Symptoms
Blastocystosis most commonly presents with diarrhea and
abdominal pain [1••, 2]. Other nonspecific gastrointestinal
symptoms (eg, flatulence, bloating, anorexia, weight loss,
nausea, vomiting, constipation, and dysentery) may be
associated with the infection [2]. Severity is reported to
range from mild and chronic diarrhea to acute gastroenter-
itis [1••]. Two recent reports were suggestive of invasive
Blastocystis infections [7, 8]. However, a coinfection with
Entamoeba histolytica in the first case, and an invasive
adenocarcinoma in the second, probably contributed to the
perforation of the intestinal lining, allowing extraintestinal
dissemination of Blastocystis.
Several studies associate the severity of disease with
parasite density. The presence of greater than five parasites
per high-power field (× 400) for wet mounts or under oil
immersion (× 1,000) in permanent-stained smears is frequent-
ly associated with an acute presentation of gastrointestinal
symptoms [9, 10]. Recent studies focus on the question of
whether pathology is subtype-dependent, without informa-
tion on infection density [2–5]. Because limited experimental
data are available to rule out the association of parasite
density with symptoms, it is important that future studies
investigate if Blastocystis-induced pathology may be both
parasite density- and subtype-dependent.
Extraintestinal Symptoms
Accumulating data suggest a correlation between Blastocystis
and cutaneous lesions, particularly urticaria [11]. Case
reports suggest a causal link between Blastocystis and acute
or chronic urticaria, delayed-pressure urticaria, angioedema,
and palmoplantar pruritus [1••]. Treatment of the parasite
leads to resolution of both the infection and the cutaneous
lesions. These cutaneous manifestations are likely immune-
mediated, although the mechanism is unclear.
Laboratory Identification
Stool Samples
The formol ether concentration technique (FECT), which is
commonly used to detect parasite ova and cysts, is not
recommended for laboratory identification of Blastocystis
because of extremely poor sensitivity [12•, 13]. This
shortcoming is attributed to the inability of FECT to isolate
Blastocystis spp subtype 3 [12•, 14], the most common
subtype in humans. The use of FECT as the sole method of
parasite isolation probably contributes to the underestimation
of parasite burden in epidemiologic studies. For parasite
detection, trichrome-stained fecal smears or short-term xenic
in vitro culture (XIVC) offer the best sensitivity. When
performing XIVC, it should be noted that slower-growing
subtypes (eg, subtype 7) [15•] and mixed infections contain-
ing slower- and faster-growing subtypes may be missed.
Emerging data suggest that pathogenesis is subtype-
dependent; therefore, reference laboratories particularly
should also determine which subtype is present in the
specimen. This determination may be achieved by sequence
analysis of Blastocystis-specific polymerase chain reaction
(PCR) products [16] or with the use of subtype-specific
diagnostic PCR primers [17]. Multiple stool specimens
should be examined because the parasite may exhibit
irregular shedding [18]. Recent surveys indicate that 20%
Table 1 Pathogenicity of Blastocystis subtypes: a tentative list
Study Subtype Nonhuman hosts Pathogenic characteristics
Stensvold et al. [2, 3], Eroglu et al. [5],
Hussein et al. [39•]
1 Primates, pigs, cattle, birds Associated with symptomatic infections; pathologic
outcomes in experimentally-infected rats
Eroglu et al. [5] 2 Mainly primates, occasionally
birds and pigs
Generally associated with asymptomatic infections
Stensvold et al. [3], Eroglu et al. [5] 3 Primates, pigs, cattle Generally associated with asymptomatic infections
Domínguez-Márquez et al. [4], Iguchi
[40], Puthia et al. [41•, 44]
4 Rodents Associated with symptomatic infections; exhibits cytopathic
effects in parasite-exposed tissue cultures; inflammatory
response in parasite-exposed tissue cultures and
experimentally infected rats
5 Pigs, cattle ?
6 Birds ?
Stensvold et al. [2, 3], Mirza [15•],
Puthia et al. [43]
7 Birds Associated with symptomatic infections; proteases
are putative virulence factors
8 Primates ?
9 None ?
?—It is currently not possible to gauge the pathogenic potential of these subtypes, because of the limited number of studies
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to 30% of stool samples contain the fecal cyst form of the
parasite [13, 14]. Hence, despite challenges in identification
because of their small size and morphology distinct from
vacuolar forms, laboratory staff should also be trained to
identify this parasite stage. Blastocystis continues to be one
of the more difficult enteric parasites to identify in clinical
samples. In a recent study comparing the diagnostic
performance of various European reference laboratories in
diagnosing intestinal parasites, laboratories revealed poorest
agreement in reporting Blastocystis-positive specimens [19•].
Serology
Serologic approaches provide rapid, sensitive, and quantita-
tive detection of microbe-specific antibodies. Only a handful
of reports have used this approach on Blastocystis. Some
studies using the enzyme-linked immunosorbent assay report
a correlation between antibody titers and symptoms [20, 21].
If a serologic method of diagnosis were to be established, the
genetic and hence antigenic diversity of the parasite must be
taken into consideration. Additionally, a panel of monoclonal
antibodies against specific subtypes would be an enormously
powerful tool to detect the parasite from stool specimens.
Epidemiologic Studies and Laboratory Detection Methods
A major hindrance in determining the pathogenic potential of
Blastocystis is the ambiguity in reports of its prevalence.
Given the variations in sensitivity of different diagnostic
methods, the choice of technique used to identify Blastocystis
in stool samples plays a pivotal role in the overall outcome of
a particular study. Despite these observations, authors often
fail to provide details on the diagnostic methods used in such
studies. The popular use of inefficient techniques (eg, FECT)
results in underestimation of Blastocystis-positive samples
and an incorrect assignment of individuals to case and control
groups. Future epidemiologic studies should incorporate data
for which Blastocystis was detected using optimal methods.
In addition, subtype information should be included.
An often overlooked aspect of Blastocystis biology is the
differences in doubling time between different subtypes
[15•]. Subtype 7 parasites have dramatically longer doubling
times, about 50 to 80 h when cultured in vitro at 37°C,
whereas subtype 4 parasites double every 20 to 30 h [15•].
Laboratory culture (XIVC) of stool samples might under-
represent such subtypes in epidemiologic surveys compared
to faster growing subtypes. Additionally, XIVC of mixed
infections was shown to preferentially amplify the growth of
one subtype over the other, resulting in underestimation of
mixed infections in prevalence studies [22, 23]. Therefore,
accurate identification of subtypes and precise estimation of
mixed infections requires that Blastocystis DNA genotyping
be performed directly from stool samples.
Prevalence
A lack of prevalence data in the past seriously hampered
our understanding of Blastocystis infection. In recent years,
and despite the discrepancy in diagnostic methods used,
interest in Blastocystis epidemiology has been renewed
[1••]. The recent prevalence studies of Blastocystis in recent
years have significantly increased our understanding of the
parasite’s geographic and demographic distribution, mode
of transmission, risk factors, and pathobiology.
Genotype Distribution
Genotyping studies have highlighted the diversity in Blasto-
cystis in humans and other animal hosts [22, 24•]. Yoshikawa
et al. [25] investigated the Blastocystis subtype distribution
among isolates from Bangladesh, Germany, Japan, Pakistan,
and Thailand and found that, apart from Thailand, where
subtype 1 was the most common subtype, subtype 3 is the
most frequently isolated subtype from humans, followed by
either subtype 1 or 6. Other prevalence studies in a wide
range of geographic locations support the observation that
subtype 3, followed by subtype 1, predominates in human
infections [1••]. This finding suggests that subtype distribu-
tion does not vary much between human populations from
different geographic locations. Other genotypes have also
been isolated from humans in surveys but at lesser
frequencies. In decreasing frequency, these are subtypes 2,
4, 6, 7, 8, and 9 [24•]. Most surveys suggest that each
infected individual harbors a particular Blastocystis subtype,
but mixed infections—generally involving subtype 1/3 and
subtype 1/2 combinations—are reported occasionally [1••].
Accumulating studies are shedding light on the possibility
that pathogenesis is subtype-dependent [2–5]. Collectively,
the data suggest that pathogenic strains belong to subtypes 1,
4, and 7 [2–5], whereas subtypes 2 and 3 [3, 5] are likely to
be nonpathogenic (Table 1).
Mode of Transmission
Numerous studies have shown Blastocystis infections are
associated with poor hygiene practices, exposure to
animals, and consumption of contaminated food or water
[1••]. These studies indicate that, like other enteric para-
sites, the mode of transmission is via the fecal-oral route.
Studies implicating water as a source of infection support
the idea that the water-resistant fecal cyst is the transmis-
sible form of the parasite [26].
Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a functional gastrointestinal
disorder in which abdominal pain is associated with a defect
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or a change in bowel habits. Accumulating studies report
higher incidence of Blastocystis infections in IBS patients
compared with healthy controls [2, 27, 28], although others
have shown a lack of association between blastocystosis and
IBS [29]. Stark et al. [28] proposed that low-grade
inflammation through persistent antigenic exposure in a
chronic Blastocystis infection might be a possible mecha-
nism. Current studies do not provide a clear role for
Blastocystis as an etiologic agent of IBS, because the altered
intestinal environment of IBS patients may provide con-
ditions favorable for Blastocystis growth. Studies showing
eradication of infection concomitant with resolution of
symptoms in Blastocystis-infected IBS patients are therefore
necessary to clarify this uncertainty. Because persistent, low-
grade inflammation was suggested to play a role in IBS,
animal infection and in vitro immunologic studies may also
provide clues about the role of Blastocystis in IBS.
Cutaneous Lesions
Several case reports provide compelling evidence that Blasto-
cystis infections give rise to cutaneous disorders, primarily
urticaria [1••]. Recently, a specific association was found
between acute urticaria and the amoeboid forms of Blasto-
cystis sp subtype 3 [11]. The authors suggested several
possible modes through which Blastocystis may give rise to
such cutaneous symptoms, namely by disrupting immune
homeostasis as the host mounts an inflammatory response
against the amoeboid forms of Blastocystis. Possible antigens
might include carbohydrates found on its surface coat, leading
to inflammatory cell recruitment, which release histamine-
activating factors that prime mast cells and basophils. IgE
might also be a possible mediator in urticaria through mast
cell activation and degranulation, and subsequent release of
inflammatory mediators. However, the mechanism by which
a Blastocystis infection gives rise to such symptoms remains
to be elucidated. The identification of Blastocystis-specific
IgE in patients with urticaria would be useful in defining the
mechanism by which the parasite causes these lesions.
High-Risk Populations
Several recent surveys suggest that certain populations may
be more susceptible to Blastocystis infections.
Patients with HIV/AIDS
Patients infected with HIV have a higher incidence of
parasitic infections, and such infections pose a higher risk
of disseminated disease compared with healthy populations.
Studies often report Blastocystis to be the most commonly
isolated protozoan parasite from HIV/AIDS patients [30].
Diarrhea is the most common presenting symptom in such
cases. The authors of a recent study investigating the
prevalence of Blastocystis subtypes in HIV and cancer
patients suggested that subtype 3 was pathogenic because it
was the most frequently isolated subtype in both groups
[31]. However, the subtype distributions were typical of
most surveys in healthy populations. The lack of a control
group and the failure to recognize that subtype 4 was five to
six times overrepresented in their study, compared with the
average of 16 other major studies [24•], indicates that
conclusions reported in this study resulted from misinter-
pretation of data.
Patients with Cancer
Blastocystis is one of the most frequent parasites isolated
from cancer patients [32]. The most common symptoms in
these patients are abdominal pain, diarrhea, and flatulence
[32]. One study reported an overgrowth of Blastocystis after
carcinoma-induced intestinal obstruction [33]. A recent
case study described Blastocystis in abdominal fluid of a
patient with adenocarcinoma and associated bowel perfo-
ration [8].
Children
Children are highly susceptible to Blastocystis infections
[34]. A high incidence of Blastocystis infections was
observed in immunocompetent [34] and immunocompro-
mised [35] minors. Children receiving corticosteroid ther-
apy for nephrotic syndrome are reported to be susceptible to
Blastocystis infections [35].
Exposure to Animals and Animal Products
Blastocystis has a higher prevalence in occupations that
involve exposure to animals (eg, animal handlers and food
handlers), reinforcing the zoonotic nature of the organism
[1••]. A recent epidemiologic survey correlated contact with
pigs and poultry with Blastocystis infections [2].
Pathogenesis
Clinical Studies
Most studies advocating a lack of association between
Blastocystis infections and intestinal disease focus on the
distribution of the parasite between asymptomatic and
symptomatic groups. They indicate either no significant
difference in the prevalence of the parasite between the two
groups or a higher incidence in the asymptomatic group.
Such studies wrongfully assume that Blastocystis infections
are biologically and pathogenically homogeneous. Clinical
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outcomes of parasitic infections are multifactorial and are
influenced by diverse host and parasite factors; therefore,
such studies may not truly reflect the pathogenic potential of
the parasite [1••].
Results of placebo-controlled treatment trials involving
symptomatic patients infected solely with Blastocystis
would better reflect Blastocystis pathogenic potential. Only
two such reports have been published; both concluded that
chemotherapy successfully eradicated the parasite with
concomitant resolution of symptoms [36, 37]. One of these
studies used metronidazole and reported clinical cure in
88% of the patients in the treatment group with parasito-
logic clearance in 80% of cases [36]. Similar outcomes
were observed in studies using nitazoxanide as a chemo-
therapeutic agent [37]. However, symptoms persisted in
patients in whom Blastocystis infection could not be
eradicated, suggesting that these patients were harboring
subtypes that are resistant or less responsive to the
antiprotozoal agents used. Resolution of symptoms with
concomitant parasite clearance in symptomatic patients
with Blastocystis infection provides compelling evidence
for the parasite’s pathogenic potential. However, the out-
comes of such studies are influenced by several factors. The
drugs used in these studies are all broad-spectrum anti-
biotics, and clinical cure thus could be attributed to the
clearance of some unidentified enteric pathogen or to lack
of comprehensive exclusion of other possible enteric
pathogens, especially viruses or bacterial toxins.
Animal Infection Studies
A major obstacle in establishing Blastocystis pathogenic
potential is the absence of an appropriate animal infection
model. Several experimental infection studies involving
rats, mice, guinea pigs, and chickens were reported [1••].
Animal surveys have reported that laboratory mice gener-
ally do not harbor Blastocystis, suggesting that they are not
suitable animal models for Blastocystis infections. Addi-
tionally, experimental infections in mice are generally mild
and self-limiting. Rats and domestic fowl, particularly
chickens, are often infected with the parasite. Therefore,
animal infection studies in recent years have focused
particularly on rats and chickens as potential animal models
for Blastocystis infections. More recently, the infectivity of
various zoonotic Blastocystis genotypes from humans was
tested in rats and chickens [38]. Variability was observed in
the infectivity of rodent subtype 4 and avian subtype 6
isolates. Curiously, isolates of subtype 3—the most com-
mon subtype found in humans—could not infect chickens
and rats, whereas avian subtype 7 isolates could only infect
chickens, suggesting that these subtypes exhibit some level
of host specificity. In another study, Blastocystis isolates
from symptomatic and asymptomatic individuals were used
to experimentally infect rats [39•]. Isolates from symptom-
atic patients induced moderate to severe pathologic changes
in infected rats, whereas parasites from asymptomatic
individuals induced only mild pathology. Authors conclud-
ed that the subtype 1 isolate, which induced mortality in
25% of rats, was pathogenic, and that pathogenic potential
for subtypes 3 and 4 was variable. A recent Blastocystis
animal infection study, using rats as hosts, reported up-
regulation of proinflammatory cytokine interferon-γ, inter-
leukin (IL)-12, and tumor necrosis factor-α 2 to 3 weeks
after infection [40]. Despite significant up-regulation of
proinflammatory cytokines, local tissue pathology was
moderate and the authors suggested that the subtype 4
isolate used in their study was a weak pathogen.
The results of recent animal infection studies are
encouraging. However, the observation that rodents do not
naturally harbor subtypes other than subtype 4, whereas
birds harbor mostly subtypes 6 and 7, may limit the
usefulness of these animals in infection studies [24•]. The
lack of pathology might therefore reflect resistance to
colonization in rats or chickens rather than avirulence of the
parasite. In fact, humans harbor the greatest diversity of
subtypes, and would perhaps make the ideal host for host–
pathogen interaction studies.
Cellular and Molecular Basis for Virulence
Despite a lack of an established Blastocystis-animal infection
model, recently published in vitro studies have increased our
understanding of Blastocystis pathobiology at the cellular
and molecular levels. These studies revealed that the cellular
mechanisms affected by the parasite result in compromise of
the host epithelial barrier function [41•]. Work from our
laboratory showed that Blastocystis subtype 4 induces
apoptosis in rat intestinal epithelium in a caspase-dependent
manner [41•]. The same study also revealed that coincuba-
tion with Blastocystis resulted in an increase in epithelial
permeability and formation of stress fibers in epithelial cells.
Unpublished data from our laboratory suggest a subtype-
dependent variation in Blastocystis-induced host epithelial
pathology. Preliminary findings suggest a possible role for
Blastocystis-induced Rho-associated kinase pathway in tight
junction modulation, resulting in increased intestinal epithe-
lial permeability (Fig 1).
Blastocystis exerts immunologic effects on cultured
colonic epithelial cells. These observations may provide
insights into the roles Blastocystis may play in relation to
host-pathogen interactions and its influence on other
microorganisms present in the intestines. Long et al. [42]
observed that Blastocystis significantly increase IL-8 and
granulocyte-macrophage colony-stimulating factor levels
after 24 h. At 6 h, IL-8 levels did not increase and were
reduced in the presence of the bacteria Escherichia coli and
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the bacterial endotoxin lipopolysaccharide. The authors
suggested that Blastocystis down-regulates the host immune
responses in the early phase of the infection to improve its
survival, which would indirectly facilitate the progress of
infection by other opportunistic pathogens.
It has been suggested that Blastocystis cysteine proteases
are virulence factors. Puthia et al. [43] observed that cell
lysates and secretory products of Blastocystis subtypes 4 and
7 contain IgA-degrading protease, suggesting that Blastocys-
tis proteases may play a role in parasite survival in vivo.
Recently, cysteine proteases from Blastocystis subtype 4
were observed to induce IL-8 production from human
colonic epithelial cells in a nuclear factor-κB-dependent
manner, showing for the first time a specific proinflamma-
tory role for the Blastocystis cysteine proteases [44]. We
recently cloned and characterized legumain, an unusual
cysteine protease found on the surface of Blastocystis spp
subtype 7 [45] and are presently investigating its role as a
virulence factor. Considering emerging evidence for subtype-
dependent virulence in Blastocystis, it is crucial that future
studies focus on the roles of different subtypes in host tissue
inflammation.
Cysteine proteases are known to modulate the activity
protease-activated receptors (PAR) found on epithelial cell
surfaces, resulting in proinflammatory responses. Increased
fecal protease activity and activation of PAR-2 receptors
were reported in several intestinal disorders, including IBS
[46], and the possibility that Blastocystis proteases modu-
late PARs should therefore be investigated. Pathogenic
strains of E. histolytica show higher cysteine protease
activity compared with nonpathogenic strains [47]. We
recently observed that subtype 7 cells exhibit markedly
higher cysteine protease activity when compared with
subtypes 4 cells [15•], suggesting the possibility that subtype
7 parasites are more virulent than subtype 4 parasites.
Interestingly, subtype 7 parasites are also morphologically
larger and grow more slowly than subtype 4 parasites. Two
recent studies reported that cells of Blastocystis parasites
from symptomatic patients were larger than those from
asymptomatic ones [48, 49], and one of the studies [49]
also showed that parasites from symptomatic patients
displayed slower growth rates. Although the pathogenic
mechanisms are unclear, it would be interesting to speculate
that cell size and generation time influence parasite
virulence. Collectively, these results suggest a subtype-
dependent variation in Blastocystis virulence and provide a
tentative explanation that subtypes may influence clinical
outcomes of Blastocystis infections (Table 1). A model for
the pathogenesis of Blastocystis spp is shown in Fig. 1.
Fig. 1 A model for Blastocystis pathogenesis at the cellular level.
Blastocystis infection may result in a variety of pathologic outcomes
such as secretory IgA degradation, barrier function compromise via
alterations to tight junctions, host cell apoptosis, and induction of the
proinflammatory cytokines interleukin (IL)-8, IL-12, interferon (IFN)-
γ, and tumor necrosis factor (TNF)-α. IgA degradation and barrier
disruption may promote the growth and invasion of neighboring
pathogens. Parasite cysteine proteases have been shown to mediate
most of these features. IgA—immunoglobulin A; MLC—myosin
light-chain kinase; MLC-p—phosphorylated MLC; NF-κB—nuclear
factor-κB; PAR-2—protease activated receptor type 2; RhoA—Rho-
GTPase family member A; ROCK—Rho-associated kinase; ZO-1—
zona occludens-1
Table 2 Treatment options and regimens for blastocystosis
Adult dose Pediatric dose
Metronidazole • 750 mg tid for 10 d • 15 mg/kg/d for 7 d
• 500 mg tid for 10 d • 20–30 mg/kg/d for 10 d
• 1.5-g single dose/d for 10 d
TMP-SMX • 320 mg TMP and 1,600 mg SMX daily in two equal
doses for 7 d
• 6 mg/kg TMP and 30 mg/kg SMX daily in two equal doses
for 7 d
Nitazoxanide • 500 mg bid for 3 d • 100 mg bid for 3 d (1–3 y)
• 200 mg bid for 3 d (4–11 y)
bid—twice a day; tid—three times a day; TMP-SMX—trimethoprim-sulfamethoxazole. (Adapted from Tan [1••])
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Treatment
Because the pathogenesis is controversial and symptoms are
self-limited, treatment is generally prescribed for Blastocystis
infections only when other etiologies have been excluded
[50•]. In persistent symptomatic cases, metronidazole is the
drug of choice (Table 2) [50•]. Although several drug trials
and clinical studies advocate the efficacy of metronidazole
against Blastocystis infections, treatment failure was reported
[10]. In vitro drug susceptibility assays for Blastocystis
reported that isolates exhibit varying sensitivities to metro-
nidazole [51]. Although unclear, factors possibly influencing
therapeutic outcome include infection density, presence of
developmental stages intrinsically resistant to metronidazole,
acquisition of drug resistance through genetic mutations, or,
importantly, subtype-dependent variations in drug suscepti-
bility. Co-trimoxazole and paromomycin are often prescribed
as alternatives to metronidazole in nonresponsive Blastocys-
tis cases, although resistance to these drugs was observed in
clinical and during in vitro drug susceptibility studies [1••].
Amid reports of metronidazole resistance in Blastocystis, the
need exists to identify alternative treatment options against
infections. It is pertinent to perform in vitro drug suscepti-
bility studies on a defined panel of Blastocystis subtypes.
Cases of therapeutic clinical cure or treatment failure must
include information on the Blastocystis subtype being
treated. The lack of a proper animal infection model and
the absence of standardized in vitro drug susceptibility
assays are major hindrances to development of alternative
treatment strategies for Blastocystis infections.
Conclusions
Although Blastocystis is one of the most common intestinal
protists found in humans, its pathogenic role is controver-
sial; however, accumulating evidence from recent studies
supports the notion that it is an emerging pathogen. The
primary reasons for the controversies surrounding this
parasite are the lack of a standardized laboratory detection
method, existence of genetic and biologic heterogeneity,
absence of an animal infection model, reports of treatment
failure, and studies with small sample sizes and occasional
misinterpretation of data. Recent studies clearly highlight
the pathogenic potential of this parasite, but more support-
ing data are needed before Blastocystis can be classified as
a human pathogen. Although clinical outcome of the
infection is multifactorial and involves host and parasite
factors, a major research priority is to clearly identify
pathogenic and nonpathogenic Blastocystis subtypes. Cur-
rently, reports suggest that subtypes 1, 4, and 7 are
pathogenic whereas subtypes 2 and 3 represent nonpatho-
genic parasites.
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Abstract Blastocystis is an enteric protistan parasite of
zoonotic potential and poorly understood pathogenesis. We
have previously reported that Blastocystis cysteine pro-
teases can degrade human secretory IgA and are also
responsible for the induction of IL-8 response in colonic
epithelial cells in vitro. Differences in virulence between
Blastocystis subtypes have been reported recently in both
animal models and clinical studies, although cellular
mechanisms for these differences are currently unknown.
Parasites such as Giardia intestinalis and Entamoeba
histolytica have distinct virulent and non-virulent strains
which may be attributable to variations in their cysteine
proteases. In the present study, variations in cysteine
protease activity was observed between avian (subtype 7)
and rodent (subtype 4) isolates of Blastocystis with avian
isolates exhibiting approximately two times higher peak
cysteine protease activity than rodent isolates. Cysteine
protease activity and parasite cell size varied over time
within cultures of the same isolate. An association between
parasite cell size and protease activity was observed.
Introduction
Blastocystis is an anaerobic, protistan parasite of the
intestinal tract (Clark 1997; Tan et al. 2002; Tan 2008).
Various epidemiological surveys have recorded its preva-
lence of up to 10% of the population in developed countries
and as much as 50–60% in developing countries (Tan
2008). Blastocystis shows extensive genetic diversity (Clark
1997; Noël et al. 2005) and humans are host to zoonotic
isolates, including avian and rat isolates (Noël et al. 2005).
Differences in virulence among various Blastocystis sub-
types has been reported in a recent animal infection study
(Hussein et al. 2008).
The parasite is commonly associated with gastrointestinal
symptoms such as watery and mucous diarrhea, vomiting,
abdominal cramps and bloating (Kaya et al. 2007). Epide-
miological studies also suggest its role in irritable bowel
syndrome (Stark et al. 2007; Ustün and Turgay 2006). In
vitro studies show that Blastocystis is capable of altering
the permeability and trans-epithelial resistance of intestinal
epithelial monolayers as well as causing cytoskeletal
rearrangements and apoptosis (Puthia et al. 2006). Despite
recent advances in the understanding of Blastocystis
biology our knowledge about its life cycle is still limited,
and the virulence factors of this parasite remain unknown.
Cysteine proteases play important functional roles in
parasites ranging from cell cycle regulation to host–
pathogen interactions. Enteric parasites such as Giardia
intestinalis and Entamoeba histolytica possess cysteine
proteases that disrupt epithelial integrity and modulate host
immune responses (Buret 2007; Leber 1999; Moncada et al.
2005; Panaro et al. 2007; Que et al. 2003; Zhang et al.
2000). Pathogenic strains of E. histolytica were shown to
have quantitatively higher cysteine protease activity than
non-pathogenic strains (Reed et al. 1989), whereas for G.
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intestinalis, isolates from symptomatic patients exhibited
more proteolytic bands in substrate gels than an isolate
from an asymptomatic carrier (Guimarães et al. 2003).
Qualitative differences in cysteine protease profiles have
also been reported between pathogenic and non-pathogenic
strains of E. histolytica (Davis et al. 2007; Hirata et al.
2007; Reed et al. 1989) and G. intestinalis (DuBois et al.
2006; Guimarães et al. 2003). Blastocystis cysteine pro-
teases cleave human secretory immunoglobulin A (Puthia
et al. 2005) and induce up-regulation of interleukin
8 cytokine transcription and secretion by intestinal epithelial
cells (Puthia et al. 2008).
In the present study, we measured the time-dependent
variation in cysteine protease activity of Blastocystis
isolates belonging to two subtypes, 4 and 7, and compared
their peak protease activity. In addition, cell size and
protease activity variations in relation to culture age were
also investigated. Our results indicate the presence of inter-
and intra-subtype differences in Blastocystis cysteine
protease activity. Our data also suggest a positive correlation
between cell size and protease activity.
Material and methods
Parasite culture and preparation of lysate
Four axenised isolates of Blastocystis were used in this
study. Isolates WR-1 and S-1 belonging to subtype 4 were
isolated during an animal survey of Wistar and Sprague
Dawley rats (Chen et al. 1997). Isolates B and E belonging
to subtype 7 were isolated from patients at the Singapore
General Hospital. All isolates are classified according to a
recently described classification scheme (Stensvold et al.
2007; Wong et al. 2008). The isolates were cultured as
described previously (Sio et al. 2006) with some modifica-
tions. In brief, parasites were maintained in 10 ml of pre-
reduced Iscove’s modified Dulbecco’s medium (IMDM)
containing 10% horse serum in anaerobic jars at 37°C.
Parasites were sub-cultured alternately at 72 and 96 h and
72-h-old cultures were used for the time course experiments.
For azocasein assays, 4×106 parasites were harvested from
the culture in each of the five different time points (0, 24,
48, 72 and 96 h) and washed twice in phosphate-buffered
saline (PBS) (pH 7.4). Lysates were prepared by three
freeze-thaw cycles in liquid nitrogen and 37°C water and
stored at −80°C.
Azocasein assay for cysteine protease activity
Parasite protease activity was determined by azocasein
assay as described previously (Sio et al. 2006). Briefly,
parasite lysates were co-incubated with 2 mM dithiothreitol
(DTT) (Sigma) at 37°C for 10 min to activate protease
activity. Azocasein, 100 μl of 5 mg/ml, (Sigma) solution
was prepared in PBS (pH 7.4) and incubated with 100 μl
parasite lysate for 1 h at 37°C. The reaction was stopped by
adding 300 μl of 10% trichloroacetic acid and samples
were incubated on ice for 30 min. Undigested azocasein
assay was removed by centrifugation (5,000×g for 5 min)
and the resultant supernatant was transferred to a clean tube
containing 500 μl of 525 mM NaOH. Absorbance was
measured with a spectrophotometer at 442 nM (Tecan
Magellan). PBS and lysates boiled at 90°C for 15 min to
inactivate proteases were used as negative controls and
100 μl trypsin (2.5 mg/ml) was used as a positive control.
Cell count and cell size assay
Parasite culture cell size distribution was obtained by
comparing forward scatter profiles of individual cultures
with forward scatter peaks generated using polyvinyl beads
of five different known diameters (3 μm, 6 μm, 8 μm,
10 μm and 15 μm), using a 488 nm laser Epic Altra flow-
cytometer (Beckman Coulter). At each of the five different
time points (0, 24, 48, 72 and 96 h) parasite pellets were re-
suspended and cell counts and diameters were measured
using appropriate dilutions. The generation time of each of
the four isolates was also calculated as described previously
(Zierdt and Swan 1981) using the formula:
GT ¼ t=n ¼ t=3:3 log b=Bð Þ; where
B number of Blastocystis cells at start of time period t
b number of Blastocystis cells at the end of time period t
t time period
n number of generations
log logarithm to base 10 (common log)
GT generation time
Statistical analysis
The Students t test was used to determine statistical
significance. Differences with p-value<0.05 were considered
significant.
Results
Time-dependent variations in protease activity
Lysates of Blastocystis isolates exhibited significant protease
activity with the azocasein substrate (Fig. 1). Protease
activity was measured in azocasein units, defined as the
amount of enzyme producing an increase of 0.01 OD units
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per hour. We have previously reported that the protease
activity of Blastocystis isolate B, changes with culture age
(Sio et al. 2006) but only two time points were investigated.
In the current study it was observed that the protease activity
of 4×106 cells of both avian and rodent isolates fluctuate
over time with a peak at either 24-h post-incubation for
isolates B, WR-1 and S-1 or 48-h post-incubation for isolate
E, indicating that there is a variation in protease activity of
parasite at different culture ages (Figs. 1 and 2).
Intra- and inter-subtype variation in peak protease activity
A difference between peak protease activities among
Blastocystis isolates was observed (Fig. 1). Isolates B, E, S-1
and WR-1 showed peak protease activity of 30.41±3.65,
37.54±1.77, 17.35±1.4 and 16.62±0.8 azocasein units,
respectively. These values were significantly higher than the
negative controls, with isolate E the highest and WR-1 the
lowest. The average peak protease activity of avian isolates
was approximately twofold higher than the rodent isolates. A
significant (p-value=0.034) intra-subtype difference in peak
protease activity was observed for the avian isolates. A subtle
difference in peak protease activity between rodent isolates
was also observed but it was not significant (p-value=0.18).
When iodoacetamide was added to inhibit the cysteine
proteases, abolishment of protease activity of each sample
(p-value<0.01) was observed. Mean baseline protease
activity after iodoacetamide inhibition was found to be
6.59±0.35 and 5.07±0.3 azocasein units for subtype 7 and
subtype 4, respectively (Fig. 2).
Time-dependent variations in parasite culture morphology
Distinct cell size distributions were observed for each
isolate with broadly similar patterns between isolates of the
same subtype (Fig. 3). Subtype 7 (avian) cells (Fig. 3a,b)
were distinctly larger than subtype 4 (rodent) cells (Fig. 3c,d).
Change in cell size distribution was also determined over
time for each isolate. All isolates displayed highest propor-
tion of larger cells at 24 h while cell size distribution tended
towards smaller cells from 48 h to 96 h. Another interesting
observation is that for each isolate, time-dependent fluctua-
tion in cell size profile were observed in replicate experi-
ments performed more than a month apart, indicating that
these fluctuations are consistent for all four isolates assayed.
Parasite generation times
From the growth curves of each isolate (results not shown),
generation times were calculated. Isolate B and E had
generation times of 50.25±1.89 and 83.83±8.96 h, respec-
tively, while WR-1 and S-1 had doubling times of 31.35±
0.49 and 21.44±5.7 h, respectively (Table 1).
Fig. 1 Peak protease activity of Blastocystis isolates E, B, WR-1 and
S-1 determined by azocasein assays. There is a significant inter-subtype
difference between mean peak protease activities of subtype 7 and
subtype 4 (#p-value<0.01) and a significant intra-subtype difference
between the peak protease activity of isolates E and B of subtype 7
(*p-value<0.05). Values are averages of two independent experiments.
Trypsin was used as a positive control. Boiled lysates of the isolates
(BL) showed activity comparable to the PBS negative control. PBS
showed activity that was significantly lower (**p-value<0.01) when
compared to protease activities of the isolates
Fig. 2 Protease activity fluctuations of Blastocystis isolates E, B,
WR-1 and S-1 over time. Protease activity of isolates B, WR-1and S-1
peaked at 24 h while E peaked at 48 h. Peak protease activity of each
isolate was significantly higher (p-value<0.05) than the preceding
time point and falls significantly (p-value<0.05) at the succeeding
time point. An exception is isolate WR-1, of which peak protease
activity at 24-h time point is not significantly higher than the
preceding time point (p-value<0.08). Note that cysteine protease
inhibitor iodoacetamide (IA) abolished protease activity of the isolates
at all time points. Each point represents averages values of two
independent experiments. ST-7, Blastocystis spp. subtype 7 (avian
isolates E and B); ST-4, Blastocystis spp. subtype 4 (rodent isolates
WR-1 and S-1)
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Association between protease activity and cell size
A correlation between protease activity of a particular
isolate with its cell size distribution was observed. Cultures
of subtype 4 isolates have more cells in the lower cell size
ranges (Fig. 3c–d) and have significantly lower protease
activity compared to subtype 7 isolates (Fig. 3a–b) which
have more cells in higher cell size ranges. Furthermore,
from the time course assay, it was evident that the peak
protease activity of all isolates correlated with culture ages
containing the highest proportion of large cells. An
exception was the protease activity of isolate E, which
Fig. 3 Variations in cell size
distribution of Blastocystis isolates
B, E, WR-1 and S-1 over time by
flow cytometry. At 24-h post-
incubation, cell size distribution
within cultures of all four isolates
tended towards higher cell size
ranges compared to other time
points (a–d), with cultures of
isolates belonging to same subtype
showing similar size distribution
profiles over time. Avian isolates
B and E (a, b) comprise larger
percentages of cells in higher cell
size ranges compared to rodent
isolates S-1 and WR-1 (c, d). Line
graph representations (a2, b2, c2,
d2) of histograms (a1, b1, c1, d1)
clearly illustrate variations in size
distributions over time, with
24-h cultures (arrow) comprising
the largest cells. Except for isolate
E, all other isolates show a corre-
lation between cultures comprising
the largest cells (*) and peak
protease activity (#). Each point
represents averages values of two
independent experiments
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peaked 24 h after the parasite culture attained its peak cell
size profile.
Discussion
Observations made from recent studies using in vivo rodent
models as well as clinical reports of Blastocystis infections
suggest that a variation in virulence might exist between
different genotypes of Blastocystis (Hussein et al. 2008;
Kaneda et al. 2001). Blastocystis cysteine proteases have
been reported in in vitro studies to cleave human secretory
IgA (Puthia et al. 2005) as well as induce pro-inflammatory
cytokine IL-8 production (Puthia et al. 2008) suggesting
that these are potential virulence factors, however nothing is
known about relative protease activity between Blastocystis
subtypes and within isolates of the same subtype. In this
study, we report for the first time that there is a quantitative
difference between cysteine proteases activity of isolates
belonging to two different subtypes. We also observed that
in addition to an inter-subtype variation, a quantitative
intra-subtype protease activity difference also exists be-
tween isolate B and E of subtype 7.
Extensive size variations have been reported inBlastocystis
laboratory cultures (Dunn et al. 1989) and stool specimens
(MacPherson and MacQueen 1994). The significance of this
variation is unknown. Cell size variations within microbial
cultures may arise from asymmetrical division of daughter
cells and is a natural phenomenon which becomes pro-
nounced in the presence of stress (Rupeš 2002). As soon as
the insulting agent is removed, order is restored leading to a
reduction of cell size variations. Cell size homeostasis
mechanisms that coordinate between cell growth and
division are responsible for the maintenance of this order
(Jorgensen and Tyers 2004). Studies on yeast suggest that
nutrient deficiency increase cell size variations in a given
colony. New daughter cells in such cultures grow more than
mother cells to acquire the “critical size” before division,
hence prolonging the cell cycle (Rupeš 2002). Cytometric
analysis of Blastocystis cultures in our study suggests that
avian isolate cultures exhibit more pronounced asymmetrical
cell division compared to rodent isolate cultures. Avian
isolates also have significantly prolonged generation time. In
light of our understanding of cell size homeostasis in other
organisms, a simple explanation for extensive cell size
distribution in Blastocystis cultures could be that current in
vitro growth conditions are not optimal for the avian isolates.
Avian subtypes may grow optimally at 40°C instead of 37°C,
as is the case for the avian protozoan flagellate Histomonas
meleagridis (van der Heijden and Landman 2008). However,
when in vitro time course experiments were repeated after
more than 30 days and including multiple subculture cycles
between the replicate experiments, an almost exact pattern of
fluctuation over time in cell size distribution was observed
for each isolate, suggesting that these fluctuations are stable
over time. Hence, an extensive analysis of the Blastocystis
cell cycle is needed to better understand the functional roles
of Blastocystis size variation.
Cysteine proteases play a crucial role in the cell cycle
progression of eukaryotic cells (Concha et al. 2005)
including protozoans (Gantt et al. 1998; Sharma et al.
1996; Ward et al. 1997). Day-to-day variation in protease
activity was reported for E. histolytica (Reed et al. 1989)
and culture age-dependent variation in total protease
activity was also previously observed for Blastocystis
isolate B (Sio et al. 2006). In this study we observed
protease activity variations in cultures of isolates E, WR-1
and S-1. Inhibition of cysteine protease activity by
iodoacetamide revealed that this variation is predominantly
due to fluctuations in cysteine proteases. Interestingly this
fluctuation coincides with age-dependent variation in
culture cell size distribution. Cysteine protease activity
and cell size distribution of Blastocystis isolates peak
simultaneously at 24-h post-incubation. The only exception
was isolate E for which cysteine proteases activity peaked at
48 h but cell size distribution peaked at 24 h. This suggests
that, unlike the other isolates, the production of cellular
proteases is not tightly coupled to the attainment of
maximum cell size, and may be associated with the longer
generation time of this isolate, which in turn might have
influenced the rate at which proteases accumulate in the cell.
Pathogenic strains of E. histolytica show higher cysteine
protease activity per cell compared to non-pathogenic
strains (Reed et al. 1989). We observed that the larger




Time point at which cultures
comprise highest % of large
cells (h)






activity after IA inhibition
(azocasein units)
Subtype 7 (avian) E 83.825±8.96 24 48 37.54±1.77 6.59±0.35
B 50.255±1.89 24 24 30.41±3.65
Subtype 4 (rodent) WR-1 31.38±0.439 24 24 16.62±0.8 5.07±0.3
S-1 21.44±5.68 24 24 17.35±1.4
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avian Blastocystis isolates showed almost twice as much
cysteine protease activity compared to smaller rodent
isolates. Interestingly rodent and not avian subtypes are
considered as potentially pathogenic variants of the parasite.
In vitro (Puthia et al. 2005, 2008) and in vivo experimental
models (Hussein et al. 2008) as well as epidemiological
studies (Kaneda et al. 2001) associate subtype 4 (rodent
isolates) with gastrointestinal symptoms. A possibility for
this apparent discrepancy could be qualitative differences
between cysteine proteases of the two subtypes. Interest-
ingly, a G. intestinalis isolate from a symptomatic patient
was shown to have lower cysteine protease activity than
isolates from asymptomatic carriers (Coradi and Guimarães
2006). It has been reported that G. intestinalis and E.
histolytica possess qualitative inter-strain variations in
cysteine protease activity and that these variations contribute
to differences in pathogenicity (Davis et al. 2007; DuBois
et al. 2006; Guimarães et al. 2003; Hirata et al. 2007). For
Blastocystis, rodent isolates may express specific cysteine
proteases which are potentially injurious to the gastrointes-
tinal epithelium. Future studies should include a qualitative
analysis of cysteine proteases of pathogenic and non-
pathogenic Blastocystis subtypes.
To conclude, Blastocystis spp. subtypes 4 and 7 exhibit
extensive variation in morphology and protease activity.
Considerable variations in cell size distribution were
observed for Blastocystis sp. subtype 7. Cell size distribu-
tion and protease activity of different isolates vary over
time and all isolates exhibit peaks in cysteine protease
activity as well as cell size. The generation time of various
isolates also differ significantly. There appears to be an
association between cell size distribution, protease activity
and generation time of Blastocystis cultures. Future studies
should include a comparison of the cytopathic effects of
these subtypes on colonic epithelial cells and investigate the
role of cysteine proteases in mediating these effects.
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